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Abstract	
The epithelial cell adhesion molecule (EpCAM) is a type I transmembrane protein that 
is expressed on epithelial cells, cancer stem cells, carcinoma cells and embryonic stem 
cells. On epithelial cells, EpCAM is localized to the basolateral membranes, whereas 
on carcinoma cells, it is highly overexpressed and re-distributed all over the cell sur-
face. EpCAM signaling is activated via regulated intramembrane proteolysis (RIP) by 
tumor-necrosis-factor alpha converting enzyme (TACE/ADAM17) and the γ-secretase 
complex. This leads to the release of the extracellular domain (EpEX) and of the intra-
cellular domain (EpICD) into the cellular environment and the cytoplasm, respectively. 
EpICD becomes incorporated in a nuclear complex consisting of Four and a Half LIM 
domains protein-2 (FHL2), β-catenin and lymphoid enhancer-binding factor-1 (Lef-1). 
Translocation into the nucleus leads to activation of EpCAM-target genes, which are 
involved in cell growth and cell proliferation. Due to the expression pattern of EpCAM, it 
is perceived as a valuable target for cancer therapy. Therefore, several immunothera-
peutic approaches have already been launched. However, targeting of the intracellular 
signaling cascade would be a completely new and promising way of interfering with the 
EpCAM signaling cascade. 
The first part of this study served the structural determination of the nuclear complex 
and the design of a potential inhibitor for complex formation. Therefore, several interac-
tion studies were performed with recombinantly produced FHL2, EpICD and β-catenin. 
Unfortunately, none of the performed experiments could confirm an interaction between 
these proteins, which is why a structural determination of the binding was not possible. 
The second part of this project dealt with the establishment and the performance of a 
High-Content Screen (HCS) for the identification of a small inhibitory molecule, which 
inhibits the intracellular EpCAM-signaling cascade. First, the best conditions for this 
screen were identified. Subsequently, a screen with about 26,000 compounds was per-
formed leading to eight high-confidence hits, which potentially inhibit the EpCAM-
signaling cascade. These hits, and later on their analogs, were further characterized 
regarding their mode of action. It could be shown that compounds #4, #9, #10 and #13 
as well as the analogs #13_1 and #10_12 interfere with γ-secretase cleavage of Ep-
CAM. Compound #10 and its analog #10_16 seem to have an EpCAM-specific effect 
on cyclin D1 CCND1 expression. Regarding cytotoxicity and cell proliferation, no Ep-
CAM-dependent effect could be determined. Further analysis is needed to assess the 
compounds’ substrate specificity and how they influence γ-secretase cleavage. 
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Zusammenfassung	
Das epitheliale Zelladhäsionsmolekül (EpCAM) ist ein Typ I Transmembranprotein. 
EpCAM wird in Epithellzellen, Krebsstammzellen, Tumorzellen und embryonalen 
Stammzellen exprimiert. Auf Epithelzellen befindet sich EpCAM hauptsächlich in baso-
lateralen Membranen, wohingegen es auf Krebszellen stark überexprimiert und auf der 
ganzen Zelloberfläche verteilt ist. Die EpCAM-Signalkaskade wird durch eine regulierte 
Intramembranproteolyse (RIP) aktiviert, die durch das Tumornekrosefaktor-alpha kon-
vertierende Enzym (TACE/ADAM17) und den γ-Sekretase Komplex durchgeführt wird. 
Dies führt zu einer Freisetzung der extrazellulären Domäne von EpCAM (EpEX) in die 
Zellumgebung und der intrazellulären Domäne (EpICD) in das Zytoplasma. EpICD wird 
Teil eines Kernkomplexes mit dem Four and a Half LIM domains protein-2 (FHL2), β-
catenin und dem Lymphoid enhancer-binding factor 1 (Lef-1). Nach der Translokation 
dieses Komplexes in den Zellkern aktiviert dieser die Expression von Zielgenen von 
EpCAM, die eine wichtige Rolle beim Zellwachstum und der Proliferation spielen. Auf-
grund des Expressionsmusters ist EpCAM eine interessante Zielstruktur für die Krebs-
therapie. Daher wurden bereits EpCAM-basierte Ansätze für die Krebsimmuntherapie 
entwickelt. Ein komplett neuer Ansatz wäre allerdings die therapeutische Unterbre-
chung der intrazellulären EpCAM-Signalkaskade. 
Der erste Teil dieses Projekts befasste sich mit der Strukturaufklärung des Kernkom-
plexes und dem anschließenden Design eines möglichen Inhibitors dieser Komplexbil-
dung. Dafür wurden verschiedene Interaktionsstudien mit rekombinant hergestelltem 
FHL2, EpICD und β-Catenin durchgeführt. Leider konnte eine Interaktion dieser re-
kombinanten Proteine nicht bestätigt werden, weswegen auch die strukturelle Aufklä-
rung der genauen Bindestelle nicht möglich war. 
Der zweite Teil dieses Projekts befasste sich mit der Etablierung und Durchführung 
eines High-Content Screens (HCS). Dafür wurden zunächst die besten Bedingungen 
identifiziert. Anschließend wurden ca. 26.000 Moleküle getestet. Es wurden acht Ver-
bindungen mit hohem Konfidenzniveau gefunden, welche potentiell die intrazelluläre 
EpCAM-Signalkaskade inhibieren. Anschließend wurde die Wirkungsweise dieser Hits 
und später ihrer Analoga untersucht. Es konnte gezeigt werden, dass die Verbindun-
gen #4, #9, #10 und #13 und auch die Analoga #13_1 und 10_12 die γ-Sekretase 
Spaltung von EpCAM beeinflussen. Außerdem scheinen die Hits #10 and #10_12 ei-
nen EpCAM-spezifischen Effekt auf die Zyklin D1 (CCND1) Expression zu haben. Be-
züglich der Zytotoxizität und der Zellproliferation konnte für keine Verbindung ein 
EpCAM-abhängiger Effekt festgestellt werden. Es sind weitere Untersuchungen not-
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wendig, um die Substratspezifität und den Wirkmechanismus der gefundenen Verbin-
dungen festzustellen. 
  Introduction 
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1 Introduction	
Cancer is one of the major causes of mortality worldwide (World Health Organization, 
2014). In 2012, approximately 14 million new cases were reported, causing 8.2 million 
deaths per year. Cancer is characterized by a malignant transformation of cells leading 
to deregulated cell growth, evasion from cell death and invasion of nearby tissue. Dur-
ing cancer progression, some cancer cells disseminate from the primary tumor and 
spread to other parts of the body, giving rise to metastatic tumors. Metastases are the 
most common cause of cancer-related death (Hanahan and Weinberg, 2011). The 
most frequent cancer types are carcinomas of the lung (1.8 million cases, 13.0 % of the 
total), breast (1.7 million, 11.9 %) and large intestine (1.4 million, 9.7 %; World Cancer 
Report 2014). There are numerous reasons for the development of cancer. Approxi-
mately one third of cancer deaths are related to an unhealthy lifestyle: tobacco use, 
excessive alcohol consumption, lack of physical activity, poor diet and obesity. Other 
reasons might be viral infections such as hepatitis B (HBV), hepatitis C (HCV) or hu-
man papillomavirus (HPV), which lead to genetic changes within the infected cells 
(Cogliano et al., 2011; Wicki and Hagmann, 2011; World Health Organization, 2014; 
World Cancer Report 2014). More than 50 % of hepatocellular carcinomas are caused 
by chronic infections by HBV and HPV is known to be associated with cervical cancer 
and carcinomas of the head and neck (Leemans et al., 2011; Ljubojevic and Skerlev, 
2014, Lafaro et al., 2015, Njei et al., 2015). An example for a carcinogenic bacterium is 
the gram-negative Helicobacter pylori, which is usually found in the stomach and might 
lead to chronic gastritis and ultimately stomach cancer (Correa and Piazuelo, 2011). 
Furthermore, there are some genetic mutations that are associated with an increased 
risk of cancer formation. In 1990, the gene breast cancer 1 (BRCA1) was described to 
play a role in tumor formation (Hall et al., 1990). Mutations in this tumor-suppressor 
gene are associated with an increased risk for breast cancer and ovarian cancer (Weit-
zel et al., 2007). Other known tumor-suppressor proteins are Retinoblastoma protein 
(pRb), p53 or phosphatase and tensin homolog (PTEN), which are known to be dys-
functional in several cancer types (Hollstein et al., 1991; Levine et al., 1991; Sansal 
and Sellers, 2004; Steelman et al., 2004; Dick and Rubin, 2013; Uchida, 2016). Nowa-
days, cancer can be treated through chemotherapy, radiation therapy, hormonal thera-
py, immunotherapy and/or surgery in various combinations depending on the disease 
status. However, all treatment methods have certain limitations: radiation or chemo-
therapy have side effects on healthy cells and surgery will be less efficient or even not 
feasible for metastatic cancer. Therefore, despite current treatment options, cancer 
remains a disease that is in need of more efficacious and compatible therapies. 
  Introduction 
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1.1 The	epithelial	cell	adhesion	molecule	(EpCAM)	
1.1.1 The	EPCAM	gene	
The human EPCAM gene is located on chromosome 2 (location 2p21), consists of nine 
coding exons and has a size of approximately 17.9 kb (Figure 1-1A). Its transcript has 
a size of 1.5 kb (Balzar et al., 1999a; NCBI 2017). Exons 1-6 encode for the proteins´ 
extracellular domain (hEpEX), including the signal peptide. The transmembrane do-
main (TMD) is encoded by exon 7, whereas exon 8 and 9 encode for the intracellular 
part of hEpCAM (hEpICD; Linnenbach et al., 1989; Balzar et al., 1999a). 
 
Figure 1-1 Scheme of the EPCAM gene (A) and protein (B). EPCAM is located on chromosome 2 and 
consists of nine exons, which encode as indicated. hEpCAM consists of 314 aa and can be subdivided in a 
265 aa extracellular domain (EpEX), a 23 aa transmembrane domain (TMD) and a 26 aa intracellular do-
main (hEpICD). SP = signal peptide; TY = thyroglobulin-like domain (modified from Schnell et al., 2013a). 
The 5´-regulatory region of EPCAM does not contain a TATA- or CAAT-box. However, 
consensus transcription factor recognition sequences for the epithelial specific factors 
Initiator (Inr), specificity protein 1* (Sp-1), activator protein-1 (AP-1) and AP-2, Ets, epi-
thelial specific ets-1 (ESE-1) and E-pal-like are present (Behrens et al., 1991; Lee et 
al., 1996; McLaughlin et al., 2004). 177 bp of the 5´-flanking sequence are sufficient in 
order to obtain the maximal promoter activity, whereas 687 bp of the 5´-flanking region 
are necessary for epithelial specificity (McLaughlin et al., 2004). EPCAM expression is 
enhanced by TCF/β-catenin (Yamashita et al., 2007) and diminished by INFγ, NFκB 
and TNFα (Gires et al., 2001; Gires et al., 2003). 
Homozygous mutations of EPCAM have been identified in patients suffering from con-
genital tufting enteropathy (CTE). This is a rare autosomal recessive form of severe 
chronic diarrhea, which occurs in the first few days of life. Several mutations were iden-
tified leading to single amino acid (aa) exchange, truncation, partial deletion or 
frameshifts (Sivagnanam et al., 2008; Al-Mayouf et al., 2009; Ko et al., 2010; Si-
vagnanam et al., 2010; Salomon et al., 2011). All these mutations cause an absence of 
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EpCAM from the plasma membrane, which results in dysplasia and therefore malfunc-
tion of the intestine (Sivagnanam et al., 2008; Schnell et al., 2013b). This dysplasia 
was also shown in EpCAM knock-out mice, which died shortly after birth due to hemor-
rhagic diarrhea. The reason for this intestinal defect might be a dysregulation of β-
catenin and E-cadherin caused by the loss of EpCAM (Guerra et al., 2012). Another 
explanation for the intestinal dysplasia is a morphologically abnormal tight junction due 
to the lack of EpCAM. In healthy tissue, EpCAM together with claudin-7 forms cell-cell 
junctions. In EpCAM knock-out mice however, claudin-7 was down-regulated to unde-
tectable levels causing the abnormal morphology of the tight junctions what eventually 
results in an impaired barrier function of the intestinal epithelium (Lei et al., 2012). 
The EPCAM gene belongs to the tumor-associated antigen gene family GA-733 (Lin-
nenbach et al., 1989; Szala et al., 1990; Alberti et al., 1994). Since EpCAM is overex-
pressed on a variety of carcinomas, it has been discovered numerous times by differ-
ent groups and has been given various names. These names are based on the anti-
body or cDNA that were used for the identification of this antigen (Schnell et al., 2013a; 
Dollé et al., 2015). However, EpCAM is used as its primary name since 2007 (Baeuerle 
and Gires, 2007) 
1.1.2 The	EpCAM	protein	
EpCAM is a calcium-independent homophilic cell adhesion molecule that belongs to 
the family of cellular adhesion molecules (CAM; Litvinov et al., 1994a). It is a 34 to 
42 kDa type I membrane protein consisting of 314 aa, and can be divided in three do-
mains: a large extracellular domain of 242 aa, a TMD of 23 aa and a short intracellular 
domain (ICD) of 26 aa (Figure 1-1B; Strnad et al., 1989; Gires, 2008; Munz et al., 
2009). The extracellular domain contains a signal peptide that is removed by signal 
peptidases in the endoplasmatic reticulum (ER). The primary cleavage site is located 
between Ala23 and Gln24. However, approximately 1 % of EpCAM gets cleaved be-
tween Ala21 and Ala22 (Strnad et al., 1989; Szala et al., 1990; Chong and Speicher, 
2001). The matured protein consists of an epidermal growth factor (EGF)-like domain 
(aa 27-59), a thyroglobulin (TY) type 1A domain (aa 66-135) and a third cysteine-free 
motif that is unrelated to any other known molecule (Molina et al., 1996; Chong and 
Speicher, 2001; Schnell et al., 2013a). EpCAM shows three N-glycosylation sites: 
Asn74, Asn111 and Asn198. Depending of the glycosylation status of these sites, the 
molecular weight of EpCAM ranges between 34 – 42 kDa (Thampoe et al., 1988; 
Schon et al., 1993; Gires, 2008). Glycosylation of Asn198 seems to be important for 
protein stability, since mutation of this site leads to a reduced overall EpCAM protein-
level (Munz et al., 2008). Furthermore, EpCAM has been shown to be hyperglycosylat-
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ed in head and neck carcinoma in comparison to healthy tissue (Pauli et al., 2003). 
This differential glycosylation pattern might cause different EpCAM functions in healthy 
versus malignant tissue (Schnell et al., 2013a). EpEX is followed by TMD, which medi-
ates the interaction with claudin-7 (Nubel et al., 2009). The TMD is followed by the 
26 aa intracellular domain of EpCAM, which contains two potential α-actinin binding 
sites (Arg289 – Lys296 and Glu304 – Ala314; Balzar et al., 1998). Furthermore, the 
three C-terminal amino acids Leu312, Asn313 and Ala314 might be a putative PDZ 
binding site, which plays an important role in binding of signaling proteins (Schnell et 
al., 2013a).  
The EpCAM protein is conserved among different species, including rat, dog, mouse 
and zebrafish. Among higher vertebrates the gene is even more conserved showing an 
amino acid sequence homology of 81 % between human and mouse and even 99 % 
between man and gorilla (Schnell et al., 2013a; Dollé et al., 2015). 
1.1.3 EpCAM	cleavage	and	signaling	
Since the signal peptide is already removed in the ER, it is never part of EpCAM full 
length (FL) protein, which can be found at the plasma membrane. The N-terminus of 
matured EpCAM can be cleaved between Arg80 and Arg81, which are located in the 
TY-domain. Predictably, the cleavage products will stay bound together by the disulfide 
bridge in this domain (Schnell et al., 2013c). This cleavage step occurs in different epi-
thelial cancer types and several proteases have been shown to perform this N-terminal 
cleavage (Thampoe et al., 1988; Schon et al., 1993). Recently it has been shown that 
EpCAM gets cleaved at Arg80 by the cell surface protease matriptase. This cleavage 
step is regulated by hepatocyte growth factor activator inhibitor-2 (HAI-2). Cleaved Ep-
CAM has a reduced ability to associate with claudin-7. Additionally, it gets targeted for 
internalization and lysosomal degradation together with claudin-7 (Wu et al., 2017). 
Furthermore, EpCAM appears to be processed by RIP (Figure 1-2; Maetzel et al., 
2009). RIP is a conserved mechanism for the regulation of transmembrane proteins 
and includes sequential cleavage steps performed by sheddases and the γ-secretase 
complex. Eventually, this leads to the release of a soluble extracellular domain, Aβ-like 
peptides and an ICD. The latter translocates into the nucleus where it activates target 
gene transcription (Brown et al., 2000; Medina and Dotti, 2003; Kopan and Ilagan, 
2004; Lal and Caplan, 2011). RIP of EpCAM is induced by juxtacrine signaling (Denzel 
et al., 2009). Thereby, EpCAM molecules on two different cells interact with each other 
or with an yet unknown ligand, which leads to the activation of RIP. The first step is a 
cleavage by the tumor necrosis factor alpha converting enzyme (TACE, ADAM17), a 
member of the ADAM protein family, in which the extracellular domain (EpEX) is shed-
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ded from the remaining C-terminal fragment (CTF) of EpCAM (Edwards et al., 2008; 
Maetzel et al., 2009). Extracellular shedding of EpCAM occurs at one of the two distinct 
α-cleavage sites Asp243/Pro244 or Pro244/Gly245 (Tsaktanis et al., 2015). Soluble 
EpEX can act as ligand for EpCAM, thereby enhancing the EpCAM signaling cascade 
in a paracrine way. The TACE/ADAM17 cleavage is the prerequisite for the second 
step of RIP, which is conducted by a γ-secretase complex containing presenilin-2 (PS-
2; Maetzel et al., 2009). This subsequent step leads to the release of three distinct Aβ-
like fragments (arising from γ-cleavage) in the surroundings of the cell and two cyto-
plasmatic hEpICD fragments (arising from ε-cleavage). γ-cleavage occurs at 
Val273/Val274, Val274/Val275 or Val275/Val276, ε-cleavage at Val284/Val285 or 
Val285/Leu286. The function of the Aβ-like fragments is still unknown (Tsaktanis et al., 
2015). hEpICD is part of a large nuclear complex together with FHL2 (see section 1.2), 
β-catenin (see section 1.3) and the transcription factor Lef-1. This complex translocates 
into the nucleus and activates the transcription of EpCAM-target genes, which are 
genes involved in cell proliferation and growth, cell death and reprogramming (Munz et 
al., 2004; Barolo et al., 2006; Maaser and Borlak, 2008; Maetzel et al., 2009; Imrich et 
al., 2012; Chavez-Perez, 2013). Via the interaction with FHL2 and its binding to β-
catenin and Lef-1, EpCAM is linked to the Wnt pathway (see section 1.3.2; Imrich et al., 
2012). Additionally, hEpICD as well as its murine counterpart mEpICD are prone to 
rapid degradation by the proteasome, which could represent a regulatory feature 
and/or a means of disposal for EpCAM (Hachmeister et al., 2013; Tsaktanis et al., 
2015). 
  Introduction 
9 
 
 
Figure 1-2 Scheme of EpCAM cleavage and signaling. Human EpCAM (hEpCAM) is cleaved at the 
plasma membrane by ADAM17, which generates soluble EpEX (shEpEX) and hCTF. The resulting CTF 
gets cleaved by γ-secretase to create Aβ-like fragments (γ-cleavage) and intracellular (hEpICD) fragments 
(ε-cleavage). hEpICD is either degraded by the proteasome or it becomes incorporated into a nuclear 
complex together with FHL2, β-catenin and Lef-1, which activates the transcription of EpCAM-target 
genes. Moreover, hEpCAM can be endocytosed and cleaved either by BACE1 in endosomes or by acidic 
hydrolases in lysosomes (modified from Hachmeister et al., 2013). 
Furthermore, it was shown that in carcinoma cell lines hEpCAM is subject to clathrin-
dependent endocytosis and subsequent cleavage at the residues Tyr250/Tyr251 (β-
cleavage) by β-secretase BACE1 (Figure 1-2; Tsaktanis et al., 2015). 
The crystal structure of hEpCAM represented a heart-shaped cis-dimer at the cell sur-
faces (Pavsic et al., 2014). By mapping of the extracellular α- and β-cleavage sites 
onto the protein surface, it could be shown that α-sites are in a groove and β-sites are 
in an even more shielded part of the dimeric protein. Therefore, the dimer most proba-
bly needs to undergo a partial or temporal dissociation or conformational change to 
allow for cleavage of hEpCAM (Tsaktanis et al., 2015). At pH 4.5, the great majority of 
hEpCAM-FL molecules is cleaved, whereas at pH 7 only a minor fraction of the total 
protein is affected (Hachmeister et al., 2013; Tsaktanis et al., 2015). It is likely that the 
acidic milieu of endosomes and lysosomes leads to a destruction of the cis-dimer, 
which provides a readily accessible cleavage site for BACE1 (Pavsic and Lenarcic, 
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2011; Pavsic et al., 2014). Cleavage at α-sites might require a conformational change 
by a yet unknown ligand or by ADAM17 itself or by a certain amount of EpCAM mole-
cules that remained in a monomeric form (Tsaktanis et al., 2015). 
1.1.4 EpCAM	expression	
EpCAM is expressed at the basolateral cell membrane of healthy epithelial cells (Mold-
enhauer et al., 1987; Momburg et al., 1987). In most organs and glands, EpCAM ex-
pression can be found, however, to varying extents. The colon shows a high level of 
EpCAM expression, whereas EpCAM is weakly expressed in the stomach (Molden-
hauer et al., 1987). Other organs displaying a high EpCAM expression are the respira-
tory tract, the gall bladder, certain cells of the kidney and pancreas, the endocrine sys-
tem and the bile duct (Moldenhauer et al., 1987; Cirulli et al., 1998; Pauli et al., 2003; 
Breuhahn et al., 2006; Trzpis et al., 2007). Skin cells vary regarding their expression 
levels of EpCAM ranging from high levels at the proliferative zone and the respiratory 
glands to a lack of expression in melanocytes and keratinocytes (Momburg et al., 1987; 
Tsubura et al., 1992). EpCAM expression is usually high in proliferating cells and low in 
differentiated cells. For example, an expression gradient of EpCAM can be found in the 
intestinal epithelium: the differentiated cells at the top of the villi show low levels of Ep-
CAM, whereas EpCAM is highly expressed in intestinal stem cells of the crypts (Balzar 
et al., 1999; Schnell et al., 2013a). 
Furthermore, EpCAM has been identified as surface marker for pluripotent human and 
murine embryonic stem cells (ESC; Gonzalez et al., 2009; Sundberg et al., 2009; Lu et 
al., 2010; Ng et al., 2010). Additionally, it shows a co-expression with the transcription 
factors required for cellular reprogramming sex-determining Y-Box-2 (SOX2) and Oc-
tamer 4 (OCT4; Lu et al., 2010; Ng et al., 2010). By inducing cell differentiation, a 
down-regulation of EpCAM alongside with other pluripotency markers like SOX2 or 
OCT4 could be observed (Gonzalez et al., 2009). The maintenance of the undifferenti-
ated state of ESCs is strongly connected with EpCAM expression levels (Schnell et al., 
2013a). 
In carcinomas, EpCAM is highly overexpressed and distributed over the whole cell sur-
face, which is frequently associated with cytoplasmatic and nuclear staining (Gosens 
MJ et al., 2007; Yanamoto et al., 2007; Ralhan et al., 2010a; Ralhan et al., 2010b; 
Schnell et al., 2013a). In many cancer types, EpCAM overexpression is associated with 
a poor prognosis for the patient, e.g. lung, ovarian and breast cancer as well as pan-
creatic, gallbladder and prostate carcinoma (Spizzo et al., 2004; Varga et al., 2004; 
Brunner et al., 2008; Fong et al., 2008; Kim et al., 2009; van der Gun et al., 2010; Mas-
soner et al., 2014). Exceptions to this are renal and thyroid carcinomas, in which high 
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EpCAM expression is associated with an increased survival (Went et al., 2005; Ralhan 
et al., 2010). Furthermore, there are cancer types in which EpCAM expression was 
associated with both better and worse outcome for the patient (van der Gun et al., 
2010). Recently, EpCAM was found to also be expressed on tumor cells of acute mye-
loid leukemia (AML), with EpCAM-positive leukemic cells showing a greater resistance 
to chemotherapy (Zheng et al., 2017). 
Regarding EpCAM expression on circulating tumor cells (CTCs) and metastases no 
clear conclusion can be drawn yet. Liver metastases from colorectal cancer and lung 
metastases derived from colon cancer showed a high EpCAM expression comparable 
to that in the primary tumor, whereas metastases derived from head and neck carci-
noma showed a lower EpCAM expression level than the respective primary tumor (Jo-
jovic et al., 1998; Takes et al., 2001; Kuhn et al., 2007). For retrieving CTCs in cancer 
patients, EpCAM is the most used antigen, which indicates an expression in these cells 
(Cohen et al., 2006; Criscitiello et al., 2010). However, there is also data suggesting a 
reduction of EpCAM expression in CTCs from colon and breast carcinomas (Jojovic et 
al., 1998; Rao et al., 2005; Gorges et al., 2012). 
1.1.5 EpCAM	functions	
Already in 1979, EpCAM was identified as tumor-associated antigen (Herlyn et al., 
1979). Up to now, a variety of functions of EpCAM have been described, ranging from 
cell adhesion to cell signaling. Additionally, it is used as prognostic and therapeutic 
marker in carcinomas. 
The name EpCAM was introduced because this molecule was shown to mediate Ca2+-
independent homophilic cell-cell adhesion. However, this interaction can be inhibited by 
treatment with an EpCAM-specific antibody (Litvinov et al., 1994a; Litvinov et al., 
1994b). All motifs in EpCAM´s extracellular domain and also the short ICD are required 
for the homophilic interaction (Balzar et al., 1998; Balzar et al., 2001). Compared to E-
cadherin, EpCAM is a rather weak cell-cell adhesion molecule. In fact, co-expression of 
EpCAM and E-cadherin weakens E-cadherin-mediated cell adhesion, most probably 
due to disruption of E-cadherin association with the cytoskeleton. The mediator of this 
process is phosphatidylinositol-3 kinase (PI3K). Furthermore, in contrast to E-cadherin 
expressing cells, EpCAM expressing cells are only loosely interconnected (Litvinov et 
al., 1994a; Litvinov et al., 1997; Winter et al., 2007). Conditional knock-out of murine 
EpCAM in E-cadherin expressing Langerhans cells led to an attenuated motility and 
migration, which is due to an increased adhesion. This result together with the metas-
tasis-promoting role of EpCAM indicates that EpCAM is rather a negative regulator of 
adhesion (Gaiser et al., 2012). Furthermore, it was shown that neither cleavage inhibi-
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tion nor cellular knockdown or knockout of hEpCAM in cancer cell lines had an effect 
on cell-cell adhesion. It is thus doubtful if hEpCAM acts as homophilic cell-cell adhe-
sion molecule in carcinoma cells (Tsaktanis et al., 2015). In general, the role of EpCAM 
in adhesion has yet to be resolved. 
EpCAM seems to have a promoting role in cell proliferation. Several in vitro and in vivo 
studies demonstrated an induction of cell proliferation due to EpCAM overexpression 
and a decreased cell proliferation after EpCAM down-regulation (Munz et al., 2004; 
Osta et al., 2004; Maetzel et al., 2009; Wenqi et al., 2009; Chaves-Perez et al., 2013). 
Induction of EpCAM expression leads to an upregulation of the oncogenic transcription 
factor c-Myc, which eventually results in upregulation of Cyclin A, D and E (Munz et al., 
2004; Chaves-Pérez et al., 2013). Moreover, matrix metalloproteinase-7 (MMP-7) and 
epidermal fatty acid binding protein (E-FABP) are regulated by EpCAM (Munz et al., 
2005; Denzel et al., 2012). EpICD seems to be necessary and also sufficient for c-Myc 
upregulation (Munz et al., 2004; Munz et al., 2005). The signaling cascade leading to 
these effects is initiated by RIP (see section 1.1.3). 
Tetraspanin-enriched microdomains (TEMs) act as signaling platforms and are orga-
nized macromolecular complexes consisting of integral transmembrane proteins, cer-
tain lipids, tetraspanins and a variety of transmembrane and cytosolic proteins (Hemler, 
2005; Le Naour et al., 2006a; Zoller, 2009). In human colon cancer cells, EpCAM has 
been identified as a TEM-member by interacting with tetraspanin CD9 (Le Naour et al., 
2006b). In rat carcinoma cells, EpCAM has been found in a complex with tetraspanin 
CD9, CO-029 (tetraspanin8) and CD44 isoforms (Figure 1-3; Schmidt et al., 2004). 
Claudin-7 is an essential part of this complex as well, since it is responsible for the re-
cruitment of EpCAM. The different EpCAM mediated processes (apoptosis resistance, 
promotion of cell proliferation and tumorigenicity) are only functional in a complex of 
claudin-7 and EpCAM (Ladewein et al., 2005; Kuhn et al., 2007; Nubel et al., 2009). 
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Figure 1-3 EpCAM in tetraspanin-enriched microdomains (TEMs). EpCAM forms a complex with clau-
din-7 (1) and is afterwards recruited into TEMs (2). There, it forms a complex with tetraspanin 9, CO-029, a 
CD44 isoform and ADAM10. The formation of this complex might play a crucial role in regulation of Ep-
CAM signaling (3; from Schnell et al., 2013a). 
1.1.6 EpCAM	as	target	for	immunotherapy	of	cancer	
Due to its tumor-specific overexpression, EpCAM is a suitable target for cancer therapy 
(Munz et al., 2010; Schnell et al., 2013a). Therefore, this antigen has been used for the 
development of different immunotherapeutic approaches, e.g. monoclonal antibodies, 
vaccination and toxin- or tumor necrosis factor-related apoptosis-inducing ligand 
(TRAIL)-conjugated antibodies, (Riesenberg et al., 2001; Neighbors et al., 2008; Groth 
et al., 2012; Lund et al., 2014; Waldron et al., 2014; Schmohl et al., 2016). The first 
immunotherapeutic anti-EpCAM antibody was Edrecolomab, which was produced in 
ascites of mice (Sears et al., 1982; Sears et al., 2009). However, a clinical activity in 
adjuvant setting could not be confirmed (Fields et al., 2009; Schmoll and Arnold, 2009). 
Another downside of this antibody was the high immunogenicity and short serum half-
life. Therefore, chimeric, humanized, human-engineered and fully human therapeutic 
antibodies were developed (Munz et al., 2010). Examples of these are humanized and 
human-engineered antibodies 3622W94 and ING-1, respectively. Both showed high 
binding affinities, however already low concentrations caused acute pancreatitis (Goel 
et al., 2007; Lewis, 2003; LoBuglio et al., 1997). The fully human antibody Adecatumab 
only led to minor side effects like chill, fatigue, nausea and diarrhea when applied in 
higher doses in a clinical phase II study and no pancreatitis could be observed. Fur-
thermore, this antibody showed a good prognosis in terms of metastasis development 
and overall survival in patients with high EpCAM metastasizing breast cancer (Schmidt 
et al., 2010). In April 2009, the rat-mouse hybrid monoclonal antibody Catumaxomab 
(Removab®) was approved in the European Union for treatment of malignant ascites 
(Linke et al., 2010). However, other EpCAM-directed antibodies are currently under 
development (Schnell et al., 2013a; Liao et al., 2015). 
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1.2 The	Four	and	a	Half	LIM	domains	protein-2	(FHL2)	
The Four and a Half LIM (FHL)-only protein subfamily is a member of the LIM-only pro-
tein family and consists of FHL1, FHL2, FHL3, FHL4 and activator of CREM in testis 
(ACT; Johannessen et al., 2006). The two last-named proteins are expressed only in 
testis (Morgan and Madgwick, 1999). FHL1, FHL2 and FHL3 are mainly expressed in 
muscle, however, FHL1 and FHL2 can also be found in other tissues (see section 
1.2.3; Samson et al., 2004). This family is characterized by having four and a half cys-
teine-rich LIM domains. The half LIM-domain is always located at the N-terminus (Cao 
et al., 2015; Kurakula et al., 2015). The consensus sequence of the LIM domain is 
CX2CX16-23C/HX2/4C/H/EX2CX2CX14-21C/HX1/2/3C/H/D/EX with X depicting any amino 
acid. It contains two zinc fingers, each of which binding one Zn2+ ion (Figure 1-5; 
Schmeichel and Beckerle, 1994; Johannessen et al., 2006). The acronym LIM is de-
duced from the first letters of LIN-11, ISL-1 and MEC-3, the transcription factors in 
which the domain was originally found (Way and Chalfie, 1988). A potential direct in-
teraction of LIM-domains and DNA is not yet fully resolved (Cao et al., 2015). 
1.2.1 The	FHL2	gene	
The FHL2 gene is located on chromosome 2 (location 2q12-q14), consists of seven 
exons (the first three are non-coding exons) and has a size of approximately 78 kb. Its 
transcript has a size of around 1.5 kb (Chan et al., 1998; Johannessen et al., 2006; 
NCBI 2017). So far five transcript variants were reported, which are regulated by two 
alternative promoters. Promoter 1a regulates the transcription of variant 4 and promot-
er 1b regulates transcription of variants 1, 2, 3 and 5. All variants are translated into the 
identical FHL2 protein (see section 1.2.2). Promoter 1b was shown to have a higher 
activity than promoter 1a (Ng et al., 2011; Xu et al., 2014). The transcription of FHL2 is 
regulated by a variety of transcription factors (Figure 1-4). FHL2 expression is associ-
ated with the cellular level of p53. However, there is no direct interaction between these 
proteins (Tanahashi and Tabira, 2000). A p53-dependent FHL2 expression was ob-
served in different cell lines (Scholl et al., 2000; Amaar et al., 2002). It seems very like-
ly that the 1a promoter serves as binding site for p53 (Xu et al., 2014). Another tran-
scription factor that was shown to bind to the FHL2 promoter is the serum response 
factor (SRF). Nkx2.5, an interaction partner of SRF and one of the earliest markers of 
the cardiac lineage is also a regulator of FHL2 expression (Johannessen et al., 2006; 
Philippar et al., 2004). Other transcription factor binding sites found in the FHL2 pro-
moter are the myocyte enhancer factor-2 (MEF-2) and AP-1 (Johannessen et al., 2006; 
Morlon and Sassone-Corsi, 2003). 
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Figure 1-4 Scheme of the FHL2 gene. The seven exons are depicted with green boxes. Lines connecting 
the boxes with each other represent the introns. Exon sizes in bp are given by the number inside the box-
es. Transcription factor binding sites in the respective color (see legend on the bottom right) are depicted 
by smaller boxes in front of exon 1 and in intron 2. Start- and stop-codon are indicated as well (from Jo-
hannessen et al., 2006). 
1.2.2 The	FHL2	protein	
FHL2 is a member of the FHL-only protein subfamily, which belongs to the LIM-only 
protein family (Cao et al., 2015). It is a 32 – 41 kDa protein that consists of 279 aa (Jo-
hannessen et al., 2006). The mass difference is due to post-translational modifications 
since FHL2 contains one O-glycosylation site and several potential phosphorylation 
sites (El Mourabit et al., 2003). Furthermore, a 25 kDa peptide could be detected by 
anti-FHL2 antibodies. This might be a proteolytic fragment, since a potential cleavage 
site was found between LIM2 and LIM3. The resulting destruction of FHL2 might be a 
way of inhibiting interactions with other proteins. The subcellular localization of FHL2 is 
cell-type specific. In HeLa cells, FHL2 was predominantly found in the nucleus whereas 
in HEK293 or HepG2 cells, a distribution all over the cell was detected (Johannessen 
et al., 2006). More than 50 FHL2 interactions partners are known, all of which belong to 
different functional classes: receptors (e.g. integrin), enzymes (e.g. ERK2, TACE), 
transcription factors and cofactors (e.g. β-catenin, androgen receptor), structural pro-
teins (e.g. α-actin ACTA1), splicing factors (e.g. hNP220) or DNA replication and repair 
enzymes (e.g. BRCA1; Muller et al., 2000; Wixler et al., 2000; Martin et al., 2002; Ng et 
al., 2002; Yan et al., 2003; Purcell et al., 2004; Samson et al., 2004; Johannessen et 
al., 2006). These proteins do not show sequence or structure homology. However, for 
most interactions, the functional relevance remains unsolved. The binding of FHL2 to 
its interaction partner occurs via single or multiple LIM domains or sometimes requires 
the FL protein. FHL2 plays a role in several biological processes such as invasion, cell 
adhesion, apoptosis, differentiation and proliferation (Johannessen et al., 2006; Cao et 
al., 2015). 
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Figure 1-5 Structure of Four-and-a-half-LIM-only protein-2 (FHL2). (A) FHL2 consists of four (LIM1-4) 
and a half N-terminal (LIM0) LIM-domain. Every LIM-domain shows two zinc fingers and coordinates two 
Zn2+ ions in total except for the half LIM-domain, which possesses only one zinc finger. The conserved aa 
in the zinc fingers are indicated by single-letter aa code. (B) Structures of LIM-domains as ribbon diagram 
(upper panel), sticks (middle panel) and spheres (lower panel). The coordinated Zn2+ ions are depicted in 
blue, the conserved aa in red. LIM0 & LIM1: 2MIU; LIM2: 1X4K; LIM3: 2D8Z; LIM4: 1X4L (from Tran et al., 
2016). 
1.2.3 FHL2	expression	
The highest FHL2 expression level can be found in the heart. However, this protein 
was also observed in several other tissues, e.g. kidney, lung, ovary, pancreas, liver, 
colon, prostate and cortex. FHL2 could not be detected in tissues related to the im-
mune system such as thymus, spleen and leukocytes (Chan et al., 1998; Zheng and 
Zhao, 2007). In cancer cells, the expression levels display a high variation according to 
the respective cancer type. Lung cancer, breast cancer and colon cancer show high 
FHL2 expression levels, whereas hepatocellular carcinoma or prostate cancer have 
lower FHL2 expression (Tanahashi and Tabira, 2000; Chen et al., 2003; Kinoshita et 
al., 2005; Gabriel et al., 2006; Chen et al., 2012; Xu et al., 2014; Cao et al., 2015). 
1.2.4 FHL2	functions	
As already mentioned, FHL2 is abundantly expressed in the adult heart. Additionally, 
high FHL2 expression levels were also found in the embryonic heart, which suggests a 
role both in the development of the cardiac circulatory system and in cardiac physiolo-
gy (Chu et al., 2000; Kong et al., 2001; Johannessen et al., 2006). There are various 
presumptions about FHL2´s role in heart physiology. FHL2 might antagonize the cardi-
ac hypertrophic response by binding and negatively interfering with the mitogen-
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activated protein (MAP) kinase ERK2, whose signaling pathway is crucial in hyper-
trophic growth response in cardiomyocytes (Purcell et al., 2004). Another FHL2 specific 
response to hypertrophic stimuli might be a modulation of the ventricular functions by 
structural remodeling (Wan et al., 2002). Furthermore, FHL2 might play a role in re-
polarization in cardiac cells via interaction with mink, a subunit of K+ channel. FHL2 
probably connects minK to the cytoskeleton (Krishnamurthy et al., 2004). In patient 
samples obtained after cardiopulmonary bypass, an increase in FHL2 expression was 
detected, implicating a role in myocardial injury (Wan et al., 2002). 
Moreover, high FHL2 expression levels can be found in human osteoblasts. In mouse 
bone marrow cells, a threefold increase of FHL2 could be determined during differen-
tiation into osteoblasts (Chu et al., 200; Amaar et al., 2002). It was shown that in fhl2 
knock-out mice, osteoblasts showed a decreased activity which led to osteopenia. The 
number of osteoblasts however was not affected by the FHL2 deficiency (Kong et al., 
2001). A strong overexpression of FHL2 in osteoblasts led to an increase in bone mass 
in the respective animals, whereas the number of osteoblasts again remained un-
changed (Günther et al., 2005). 
FHL2 might also play a role in muscular processes. Expression of FHL2 in mouse my-
oblasts induced differentiation into myotubes (Martin et al., 2002). Titin is an important 
protein in human muscles since it contributes to muscle contraction (Itoh-Satoh et al., 
2002). FHL2 was shown to interact with titin, thereby acting as an adapter molecule 
that recruits metabolic enzymes, which provide energy needed during muscle contrac-
tion (Lange et al., 2002). An additional interaction was found between FHL2 and integ-
rins in heart muscle cells. However, the biological function of this interaction is not yet 
elucidated (Samson et al., 2004). 
The importance of FHL2 in splicing remains under debate. Although it was shown that 
FHL2 interacts with splicing factors NP220 and pyrimidine tract-binding protein-
associated splicing factor (PSF), the facts that FHL2 deficient mice are viable and that 
the expression of FHL2 is tissue specific are arguments against an essential role in 
splicing (Inagaki et al., 1996; Dye and Patton, 2001; Ng et al., 2002; Johannessen et 
al., 2006). 
It was shown that overexpressed FHL2 is able to induce apoptosis in a plethora of cells 
by an unknown mechanism (Scholl et al., 2000; Johannessen et al., 2006). However, 
FHL2 was also found to suppress apoptosis by eventually negatively regulating the 
activity of the transcription factor Forkhead box protein O1 (FOXO1; Yang et al., 2005). 
FHL2 could possibly be a transducer of apoptotic signals from extracellular matrix to 
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mitochondria, since FHL2 was detected inside these organelles (Li et al., 2001). The 
role of FHL2 in apoptosis is still not understood since this protein can act both as en-
hancer and repressor of apoptosis (Tran et al., 2016). 
FHL2 also affects cell proliferation. It supports β-catenin-induced cyclin D1 promoter 
activity, which leads to an abolishment of the inhibitory effect of FOXO1 on this pro-
moter (Wei et al., 2003; Yang et al., 2005). However, FHL2 also impedes cell prolifera-
tion in differentiating myoblasts by transcriptional inhibition of cyclin A and down-
regulation of cyclin D1 expression (Martin et al., 2002; McLoughlin et al., 2002). 
Moreover, FHL2 might have a function as scaffolding protein in signaling pathways 
(Scholl et al., 2007). This assumption is supported by the localization of FHL2 in vari-
ous intracellular compartments and the binding to different kinds of proteins such as 
receptors, chaperones, molecules involved in ubiquitination, signal transmitter proteins, 
receptor-linked proteins and transcription factors (Wixler et al., 2000; El Mourabit et al., 
2004; Gabriel et al., 2004). 
There were indications that FHL2 might be a transcription factor itself, based on struc-
tural similarities between the half LIM-domain and the DNA-binding domain of the tran-
scription factor GATA-1 (Morgan and Madgwick, 1996). However, a direct FHL2-DNA 
binding was not yet observed, which suggests that FHL2 rather acts as a transcription-
al co-factor. The LIM-domains appear to play different roles depending on the respec-
tive cell line. These specific effects might depend on the cell-specific expression of co-
activators or –repressors (Johannessen et al., 2006). The first transcription factor for 
which a modulating activity of FHL2 was described is the androgen receptor (AR; Mul-
ler et al., 2000). The transcriptional activity of AR was increased by synergistic action of 
FHL2, CBP/P300 and β-catenin (Labalette et al., 2004). In contrast, FHL2 suppresses 
transcriptional activity of FOXO1 and SRF (Philippar et al., 2004; Yang et al., 2005). 
Furthermore, FHL2 interacts with β-catenin (see section 1.3), a modulator of the T-cell 
factor/lymphoid enhancer factor family (TCF/Lef). The effect of this interaction is cell- 
and promoter-specific. An activation of transcription could be observed in HEK293 or 
SE480 cells, whereas this interaction led to a repression in I28 or chinese hamster ova-
ry (CHO) cells (Martin et al., 2002; Wei et al., 2003; Labalette et al., 2004). The speci-
ficity might be explained by the cell- or promoter-specific recruitment of co-activators or 
co-repressors via FHL2. Another hypothesis is that FHL2 blocks or competes for cell-
specific β-catenin binding sites (Johannessen et al., 2006). 
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Figure 1-6 Functional diversity of FHL2. FHL2 (orange) can be found in different subcellular compart-
ments, where it conducts diverse functions. In muscle, FHL2 interacts with titin (see light blue box bottom 
left). In the nucleus, FHL2 might be a modulator of splicing and DNA replication. Additionally, it has the 
ability to affect signal transmission of transcription factors, thereby influencing gene expression (see dark 
blue circle bottom right). At the plasma membrane (green), FHL2 can interact with integrin, presenelin-2 
and voltage-gated K+ channel receptors. Moreover, FHL2 binds to structural proteins, actin filaments or α-
actinin (from Johannessen et al., 2006). 
1.3 Catenin	beta-1	
In the 1980s, Catenin beta-1 (CTNNB1), which is usually referred to as β-catenin, was 
independently discovered twice based on its structure and signaling (Valenta et al., 
2012). β-catenin was isolated together with α-catenin and γ-catenin/plakoglobin as E-
cadherin associated proteins. Therefore, these proteins were termed catenins (Ozawa 
et al., 1989). Its ortholog in Drosophila melanogaster is called Armadillo (Arm) through 
which the role of β-catenin in intracellular signaling was discovered. Further studies of 
this protein showed a structural conservation in adherens junctions (McCrea et al., 
1990; Peifer and Wieschaus, 1990; Orsulic and Pfeifer, 1996). It was shown that arma-
dillo segmentation, which is required for normal patterning within the embryo, is regu-
lated by Wingless (Wg). This was the key observation triggering further characteriza-
tion of the Wg/Arm (Wnt/β-catenin in human) signaling cascade (Riggleman et al., 
1990). Another discovery contributing to an understanding was the pathway leading 
from Wg to an eventual stabilization of Arm by Shaggy/Zeste-white-3 (glycogen syn-
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thase 3 (GSK3)) in vertebrates; Siegfried et al., 1994). Finally, it was shown that the 
signaling function of Arm/β-catenin in the nucleus is mediated via TCF/Lef (Behrens et 
al., 1996; Huber et al., 1996; Molenaar et al., 1996; Brunner et al., 1997; van de Weter-
ing et al., 1997). β-catenin belongs to the armadillo family of proteins and is a multitask-
ing protein, which plays a role in several developmental and homeostatic processes. β-
catenin can be found in different subcellular locations such as junctions, cytoplasm and 
in the nucleus (Valenta et al., 2012; Daugherty et al., 2007; Voronkov and Krauss, 
2013).  
The CTNNB1 gene is located on chromosome 3 (location 3p22.1), consists of 17 exons 
and has a size of approximately 41 kb. The transcript has a size of roughly 3.5 kb 
(NCBI 2017). 
1.3.1 The	CTNNB1	protein	
β-catenin is a highly conserved protein in the Wnt signaling cascade (Valenta et al., 
2012). β-catenin from sponges, ctenophores, and cnidarians show a high sequence 
similarity to mammalian β-catenin, e.g. cnidarian β-catenin has > 60 % aa identity. The 
biggest differences can be found in the C-terminal domain (CTD), which is less con-
served in general (Xing et al., 2008; Zhao et al., 2011). The central region exhibits an 
approximately 80 % structural identity. Furthermore, even the exon/intron structure of 
ctnnb1 is conserved among cnidarians, sponges and later developed metazoans (Hol-
land et al., 2005, Adamska et al., 2010). Also in early metazoans, Wnt/β-catenin signal-
ing has strong impacts on their development. In sponges, the inhibition of β-catenin 
degradation leads to canal openings. In Hydra (cnidarian) a reduction of β-catenin 
leads to a loss of head structures whereas ectopic accumulation of β-catenin results in 
multiple heads and tentacle formation (Broun et al., 2005; Muller et al., 2007; Lapébie 
et al., 2009; Gee et al., 2010). These findings indicate that the Wnt/β-catenin signaling 
cascade is a primeval pathway playing a crucial role in body plan and axis formation 
(Valenta et al., 2012). 
β-catenin belongs to the catenin family, which consists of three subfamilies: p120 (e.g. 
p120 and plakophilin), β- (β-catenin and plakoglobin) and α subfamily (alpha 1-3 caten-
in; Anastasiadis and Reynolds, 2000; Schneider et al., 2003; Kobielak and Fuchs, 
2004; Zhao et al., 2011). The subfamilies differ in the number of their Arm repeats. 
Each of these repeats is comprised of three helices (approximately 42 aa per helix), 
which are arranged in a triangular shape. The p120 subfamily contains nine arm re-
peats and the β subfamily contains even twelve Arm repeats. The α subfamily, howev-
er, contains three vinculin homology domains instead of Arm repeats and therefore 
belongs to the Vinculin superfamily (Zhao et al., 2011). 
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The human β-catenin protein consists of 781 aa and can be subdivided into a 130 aa 
N-terminal domain (NTD), a central region of 523 aa and a CTD consisting of 100 aa 
(Figure 1-7A). The central region, which is the most conserved one, is made up of 
twelve imperfect ARM repeats (R1-12). Altogether, the twelve repeats form a superhe-
lix that features along a positively charged groove (Figure 1-7B). The central region 
forms a rigid scaffold for interactions partners, whereas the NTD and CTD are structur-
ally flexible. A specific conserved helix, which is referred to as Helix-C (residues 667-
683), is located between the center region and the CTD (Huber et al., 1997; Xu and 
Kimelman, 2007; Xing et al., 2008). Via structural and biochemical analysis, it has been 
shown that the binding sites in the charged groove of several β-catenin binding part-
ners are overlapping. This means that the respective proteins cannot bind simultane-
ously. This is the case for instance for E-cadherin, the Adenomatous-polyposis-coli 
protein (APC) and TCF/Lef, which all bind β-catenin at Arm repeats R3-R9 (Figure 
1-7A). All these interacting proteins form salt bridges between Lys435 and Lys312 of β-
catenin and Asp and Glu residues in the binding partners. Other Arm repeats might 
strengthen the interaction (Graham et al., 2000; Eklof et al., 2001; Huber and Weis, 
2001; Poy et al., 2001). Both NTD and CTD are negatively charged and sensitive to 
trypsin digestion (Xu and Kimelman, 2007). They act as an intramolecular chaperone of 
Arm repeat domains and furthermore prevent self-aggregation of the central region 
(Xing et al., 2008). GSK3, α-catenin and β-transducin repeat containing E3 ubiquitin 
protein ligase (β-TrCP) all bind β-catenin at the NTD (Xu and Kimelman, 2007). Addi-
tionally, this part of the protein contains phosphorylation sites. The phosphorylation is 
performed by a large multiprotein complex consisting of GSK3, Axin and APC (Schnei-
der et al., 2003). Moreover, it was suggested that Helix-C is crucial for interactions with 
β-catenin binding proteins, especially those involved in signaling. For β-catenin´s role 
in cell-cell adhesion, this helix does not seem to be required (Xing et al., 2008). 
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Figure 1-7 Structure of hβ-catenin and interaction sites. (A) β-catenin consists of a NTD (aa 1-140), a 
central region consisting of twelve Arm repeats (yellow boxes) and a CTD (aa 665-781). The red stars 
indicate the CK1 phosphorylation sites. The black bars represent the binding sites of the respective inter-
acting protein. Proteins sharing the same regions for binding cannot bind simultaneously. The red dots 
show phosphorylated Ser or Thr residues, which are bound by β-catenin. Helix-C is not depicted in this 
scheme. (B) Structure of the Arm repeats (R1-R12). Each repeat is formed by three helices (yellow, green 
and blue), which are arranged in a triangular shape. The positively charged groove is shown as a red dot-
ted line. Lys312 and Lys435 are depicted as circled Bs (from Xu and Kimelman, 2007). 
1.3.2 The	canonical	Wnt	signaling	pathway	
The Wnt signaling pathway is a crucial cascade, which is involved in cell polarity, cell 
renewal and tissue homeostasis (Logan and Nusse, 2004). The intracellular signaling 
can be divided into three subtypes: the β-catenin dependent canonical pathway, the β-
catenin independent non-canonical pathway and the non-canonical Wnt/Ca2+ pathway 
(Nusse, 2005; Sugimura and Li, 2010; Thrasivoulou et al., 2013). Without Wnt signal-
ing, cytoplasmic β-catenin gets constantly degraded by a multiprotein destruction com-
plex. This complex consists of APC, casein kinase-1 (CK1), the scaffolding protein Axin 
and GSK3. β-catenin is phosphorylated at the NTD by CK1 and GSK3 (see section 
1.3.1), which eventually results in ubiquitination by β-TrCP and finally proteosomal deg-
radation (Figure 1-8; He et al., 2004; Voronkov and Krauss, 2013). The canonical Wnt 
pathway also referred to as Wnt/β-catenin pathway leads to accumulation of β-catenin 
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in the cytoplasm and subsequent translocation into the nucleus where it stimulates 
transcription factors belonging to the TCF/Lef family (Kimelmann and Xu, 2006; Mac-
Donald et al., 2009). This pathway is activated by binding of a Wnt ligand to the Friz-
zled (Fz) receptor and co-receptor lipoprotein receptor related protein 6 (LRP6) or 
LRP5. Thereby, LRP6 gets phosphorylated by CK1 and GSK3 resulting in binding of 
Axin to LRP6. This causes the disruption of the destruction complex (Mao et al., 2001; 
Tamai et al., 2004; Davidson et al., 2005; Zeng et al., 2005). The translocation of the 
complex to the plasma membrane allows for the accumulation of β-catenin in the cyto-
plasm and subsequent translocation in the nucleus, where it activates the transcription 
of Wnt target genes (MacDonald et al., 2009). 
 
Figure 1-8 β-catenin´s life cycle within the cell. Newly synthesized β-catenin (red) can interact both with 
E-cadherin (pink) and α-catenin (light blue), thereby having an influence on the actin cytoskeleton. Either 
by E-cadherin down-regulation or protein kinase activity β-catenin can be released. The released protein is 
immediately bound and phosphorylated by the destruction complex consisting of Axin (dark blue), APC 
(turquoise), CK1 (orange) and GSK3 (yellow). Phosphorylated β-catenin gets degraded by the pro-
teasome. A small amount of β-catenin is retained in the cytoplasm by APC. After activation of Wnt signal-
ing, the destruction complex gets disrupted, which leads to an accumulation of β-catenin in the cytoplasm 
and subsequent translocation into the nucleus. β-catenin interacts with TCF/Lef transcription factors 
(green) and thereby increases Wnt target gene transcription. β-catenin might also bind to other transcrip-
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tion factors and drives transcription of TCF-independent genes. By modulating the nuclear import and 
export, β-catenin´s signaling activity can be regulated. Additionally, β-catenin might interact with the cen-
trosome (CTTA: C-terminal transcriptional activators; NTTA: N-terminal transcriptional activators; from 
Valenta et al., 2012). 
1.4 High-Content	Screening	
High-Content Screening (HCS) is a method which uses living cells to investigate cellu-
lar pathways in healthy and/or diseased cells and the effects of small inhibitory mole-
cules on these pathways. Cells accomplish all functions of life. The tightly regulated 
spatial and temporal interplay of ions, DNA, RNA, proteins, metabolites, and organelles 
is responsible for the performance of life functions. Minor changes in this regulated 
network often make the difference between healthy and diseased. HCS facilitates ob-
taining more information about the spatial or temporal distribution of certain proteins 
within the cell, even at the single-cell level (Giuliano et al., 1997; Gasparri, 2009). Fluo-
rescently labeled antibodies can detect the localization of target proteins. However this 
only allows measurement of one time point. Another possibility is the creation of a cell 
line that expresses a fusion of the target protein with e.g. green fluorescent protein 
(GFP) or yellow fluorescence protein (YFP). This allows for detection at several time 
points. Another possibility is fluorescence resonance energy transfer (FRET), which 
can be used for the investigation of protein-protein interactions (Giuliano et al., 1997; 
Liptrot, 2001). There is a large number of known biochemical pathways that involve 
translocations from the plasma membrane to the nucleus or other organelles. Diseases 
are often the result of a dysfunction or -regulation of these pathways. In order to dis-
cover a new drug candidate, HCS can be used to screen for perturbation of a cellular 
process of interest. Cells are first treated with compounds and afterwards the temporal 
or spatial changes in e.g. target protein distribution are detected and characterized 
using image analysis. Compared to High-Throughput Screening (HTS), HCS consumes 
more time. However, the yielded data contain much more biological information, which 
can provide a deeper insight into drug effects or the function of proteins, genes or sig-
naling pathways in healthy and diseased cells (Giuliano et al., 1997; Abraham et al., 
2004; Zanella et al., 2010). 
1.5 Aim	of	the	project	
EpCAM is a transmembrane molecule that is expressed on epithelial cells, stem cells, 
tumor-initiating cells and cancer cells. On epithelial cells, EpCAM can mainly be found 
in the intercellular space whereas on cancer cells, EpCAM is highly overexpressed and 
distributed all over the cell surface. The EpCAM target genes are involved in cell 
growth and cell proliferation. Due to its cancer-specific overexpression, EpCAM is an 
attractive target for cancer therapy. Compared to existing immunotherapeutic ap-
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proaches, targeting the intracellular EpCAM signaling represents a completely new 
approach.  
The first aim of this study was to obtain the structure of the FHL2/EpICD complex to 
understand the binding mode. This could be used in order to find or design a small in-
hibitory molecule, which disrupts the binding and therefore interrupts the EpCAM sig-
naling cascade. This should be accomplished by biochemical assays and additional 
structural methods. 
The aim of the second part was the establishment and performance of an HCS for find-
ing a small inhibitory molecule that inhibits the EpCAM signaling cascade. The ob-
tained hits should then be further characterized regarding their toxicity and specificity 
towards EpCAM in order to obtain a lead compound for a potential pharmaceutical 
drug. The HCS was performed with a cell line expressing an EpCAM-YFP construct, 
which allows for detection of the localization of EpCAM cleavage products within the 
cell. Further investigation of hits was done by different cellular, biochemical and pro-
tein-biochemical assays. 
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2 Material	and	Methods	
2.1 Chemicals	and	consumables	
All commonly used chemicals were purchased from Roth (Karlsruhe, Germany), Sig-
ma-Aldrich (Taufkirchen, Germany) or Merck (Darmstadt, Germany), unless stated 
otherwise. Enzymes and nucleotides for molecular biology as well as molecular weight 
markers and loading dyes for gel electrophoresis were ordered from New England Bi-
olabs (Frankfurt, Germany) and Invitrogen (Karlsruhe, Germany). DNA oligonucleotides 
were synthesized by Eurofins MWG (Ebersberg, Germany). Bacterial cell culture mate-
rial was obtained from Becton, Dictinson & Co (Heidelberg, Germany) and Sigma-
Aldrich. Media and supplements for mammalian cell culture were purchased from Life 
Technologies (Carlsbad, USA). Cell culture plates were ordered from Eppendorf (Ham-
burg, Germany) and Perkin Elmer (Waltham, USA). Chromatography was performed 
using columns and material from GE Healthcare (Munich, Germany). Transfer mem-
branes for Western blots were ordered from Merck Millipore (Darmstadt, Germany). 
Chemically synthesized peptides were ordered from JPT peptide technologies (Berlin, 
Germany). Sequencing was done by Eurofins MWG. All reactions were performed us-
ing ddH2O. 
2.2 Oligonucleotides	
2.2.1 DNA	oligonucleotides	for	cloning	
Table 2-1 DNA oligonucleotides for cloning 
No. Name Sequence 5´-> 3´ 
1 EpICD_BamHI_for aaaggatccatgtccagaaagaagagaatg 
59 EpICD stop xho rev gaactcgagttatgcattgagttccctatgatctc 
10 FHL2_NcoI_fwd aaaccatgggcatgactgagcgctttgactgccac 
11 FHL2_XhoI_rev aaactcgaggatgtctttcccacagtcggggcacag 
17 FHL2_XhoI_stop aaactcgagttagatgtctttccacagtcggggcacag 
18 pOPINM_FHL2_for aagttctgtttcagggcccgatgactgagcgctttgac 
19 pOPINM_FHL2_rev atggtctagaaagctttagatgtctttcccacagtc 
29 pFastBacI_FHL2f aaaggatccatgaaaatcgaagaaggt 
30 pFastBacI_FHL2r aaaaagctttcagtggtggtggtggtggtg 
15 mut_pETM43_fwd gttccaggggcccatgtccagaaagaagagaatg 
16 mut_pETM43_rev cattctcttctttctggacatgggcccctggaac 
53 LIM1_fwd_BamHI aaaggatcctgccaccattgcaac 
55 LIM2_fwd_BamHI aaaggatcctgccaggaatgcaag 
54 LIM2_rev_XhoI aaactcgagttagcagggcacacagaa 
51 LIM3_BamHI_fwd aaaggatcctgcgttcagtgcaaa 
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52 LIM3_XhoI_rev aaactcgagttagcagttcaggcagta 
49 LIM4_BamHI_fwd aaaggatcctgtgctgggtgcacc 
50 LIM4_XhoI_rev aaactcgagttaacagtcggggcacag 
56 pETM43_LIM1_fwd aaaccatgggctgccaccattgcaac 
57 pETM43_LIM2_fwd aaaccatgggctgccaggaatgcaag 
58 pETM43_LIM3_fwd aaaccatgggctgcgttcagtgcaaa 
33 β-cat_fwd_pOPIN aagttctgtttcagggcccgaacttgattaactatcaagatgat 
34 β-cat_rev_pOPIN atggtctagaaagctttacaggtcagtatcaaaccaggc 
 
2.2.2 DNA	oligonucleotides	for	qPCR	
Table 2-2 DNA oligonucleotides for qPCR 
No. Name Sequence 5´-> 3´ 
35 GAPDH_for tgcaccaccaactgcttagc 
36 GAPDH_rev ggcatggactgtggtcatgag 
37 CycD1_for tattgcgctgctaccgttga 
38 CycD1_rev ccaatagcagcaaacaatgtgaaa 
39 cmyc_qPCR_fwd gtcaagaggcgaacacacaac 
40 cmyc_qPCR_rev ttggacggacaggatgtatgc 
41 qPCR_EpCAM_fwd gctggccgtaaactgctttg 
42 qPCR_EpCAM_rev acatttggcagccagctttg 
43 HSPCB_fwd tctgggtatcggaaagcaagcc 
44 HSPCB_rev gtgcacttcctcaggcatcttg 
45 RPS13_fwd cgaaagcatcttgagaggaaca 
46 RPS13_rev tcgagccaaacggtgaatc 
47 18s_fwd agaaacggctaccacatcca 
48 18s_rev caccagacttgccctcca 
 
2.3 Plasmids	
2.3.1 Commercial	plasmids	
Table 2-3 Commercial plasmids 
Name Applicat ion Tag Antibiot ic Source 
pGEX-6P-1 Protein expression in E. coli GST Amp GE Healthcare 
pETM43 Protein expression in E. coli MBP Kan 
EMBL 
(Heidelberg, Ger-
many) 
pOPINM Protein expression in E. coli His6-MBP Amp 
Addgene 
(Cambridge, USA) 
pOPINS3C Protein expression in E. coli His6-
Sumo 
Amp Addgene 
pFastBac Bac-to-Bac Baculovirus 
expression system 
- Amp/Gen Invitrogen 
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2.3.2 Plasmids	for	recombinant	protein	expression	in	E.	coli	
Table 2-4 Plasmids for recombinant protein expression in E. coli 
No. Name/Insert Vector Primer Restr ict ion 
sites 
Template Note 
8 GST-FHL2 FL pGEX-6P-1 - BamHI/XhoI - a) 
27 FHL2 (288-314) pGEX-6P-1 - BamHI/XhoI - a) 
28 β-catenin (138-781) - - - - b) 
2 MBP-FHL2 FL-His pETM43 10/11 NcoI/XhoI 8  
3 MBP-FHL2 FL pETM43 10/17 NcoI/XhoI 8  
9 pOPINM-FHL2 pOPINM 18/19 KpnI/HindIII 8  
19 GST-LIM1-2 pGEX-6P-1 53/54 BamHI/XhoI 8  
20 GST-LIM2-3 pGEX-6P-1 55/52 BamHI/XhoI 8  
21 GST-LIM3-4 pGEX-6P-1 51/50 BamHI/XhoI 8  
23 MBP-LIM1-2 pETM43 56/54 NcoI/XhoI 8  
24 MBP-LIM2-3 pETM43 57/52 NcoI/XhoI 8  
25 MBP-LIM3-4 pETM43 58/50 NcoI/XhoI 8  
1 GST-EpICD pGEX-6P-1 1/59 BamHI/XhoI 27  
22 β-catenin (138-781) pOPINS3C 33/34 KpnI/HindIII 28  
a) Created by Patrick Schrepfer 
b) Obtained from Prof. Dr. Tobias Madl, Medizinische Universität Graz, Austria 
 
2.3.3 Plasmid	for	recombinant	protein	expression	in	insect	cells	
Table 2-5 Plasmid for recombinant protein expression in insect cells 
No. Name/Insert Vector Primer Restr ict ion 
sites 
Template 
16 FHL2 FL pFastBac 29/30 BamHI/HindIII 2 
 
2.4 Bacterial	strains	
Table 2-6 Bacterial strains 
Name Genotype Source 
XL1-Blue 
recA1 endA1 gyrA96 thi-1 hsdR17 
supE44 relA1 lac [F´proAB lac1q 
ZΔM15Tn10(Tetr)] 
Stratagene (La Jolla, USA) 
BL21 Star (DE3) 
B F- ompT hsdS(rB-mB-) dcm+ Tetr 
galλ (DE3) EndA Hte [argU ile Y 
leu W Camr] 
Stratagene 
DH10Bac 
F- mcrA Δ(mrr-hsdRMS-mcrBC) 
ϕ80lacZΔM15 ΔlacX74 recA1 
endA1 araD139 Δ(ara, leu)7697 
galU galK λ rpsL 
nupG/bMON14272/ pMON7124 
Invitrogen 
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2.5 Insect	cell	lines	
Table 2-7 Insect cell lines 
Name Descript ion Source 
Sf21 
Derived from Spodoptera frugi-
perda ovarian cells. Used for 
isolation and propagation of re-
combinant baculovirus stocks. 
Invitrogen 
High Five 
Derived from Trichoplusia ni ovar-
ian cells. Used for recombinant 
protein expression upon baculovi-
rus infection. 
Invitrogen 
 
2.6 Mammalian	cell	lines	
Table 2-8 Mammalian cell lines 
Name Descript ion Source Note 
HEK293 
Cell line derived from 
human embryonic kidney 
cells 
Obtained from Prof. Dr. 
Olivier Gires, Klinikum 
der LMU München, 
Germany 
 
HEK293 EpCAM FL-
YFP 
HEK293 cells transfect-
ed with 141 
pCAG::EpCAM-YFP 
Created by Karolina 
Bobowski (Labor für 
molekulare Onkologie, 
Klinikum der LMU Mün-
chen, Germany) 
 
HEK293 EpCAM-CTF-
YFP 
HEK293 cells transfect-
ed with 141 
pCAG::EpCAM-CTF-
YFP 
Created by Karolina 
Bobowski 
Construct consists of 
Myc-Tag, EpCAM-CTF 
sequence (251-315), 
FLAG-Tag, TEV-
cleavage site and YFP 
HEK293 EpCAM FL 
HEK293 cells transfect-
ed with 141 
pCAG::EpCAM-FL 
Created by Karolina 
Bobowski 
 
HEK293 ΔEpCAM YFP HEK 293 cells transfect-
ed with 141 pCAG::YFP 
Obtained from Prof. Dr. 
Olivier Gires, Klinikum 
der LMU München, 
Germany 
 
FaDu Human hypopharynx 
carcinoma cell line 
Obtained from Prof. Dr. 
Olivier Gires, Klinikum 
der LMU München, 
Germany 
 
HCT-8 Human colon carcinoma cell line 
Obtained from Prof. Dr. 
Olivier Gires, Klinikum 
der LMU München, 
Germany 
 
HCT-8 KO 
CRISPR-Cas9-mediated 
EpCAM KO clones of 
HCT-8 cells 
Created by Thanos 
Tsaktanis (Labor für 
molekulare Onkologie, 
Klinikum der LMU Mün-
chen, Germany) 
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2.7 Media	and	supplements	for	bacterial	cell	culture	
Table 2-9 Media for bacterial cell culture 
Medium Composit ion 
Luria-Bertani (LB) medium 1 % (w/v) bacto tryphone, 0.5 % (w/v) bacto yeast extract, 0.5 % NaCl, add 
1.5 % (w/v) agar for plates 
SOC 2 % (w/v) bacto tryptone, 0.5 % (w/v) bacto yeast extract, 10 mM NaCl, 2.5 mM KCl, 10 mM MgCl2, 10 mM MgSO4, pH 7.0 
DH10Bac medium 
1 % (w/v) bacto tryptone, 0.5 % (w/v) bacto yeast extract, 0.5 % (w/v) NaCl, 
1 M IPTG, 100 µg/mL bromo-chloro-galactopyranoside (X-Gal), 7 mg/mL 
gentamycin, 10 mg/mL tetracycline, 50 mg/mL kanamycin, pH 7.0 
 
Table 2-10 Supplements for bacterial cell culture 
Supplements Applicat ion Final concentrat ion 
Ampicillin E. coli selection 100 µg/mL 
Kanamycin E. coli selection 50 µg/mL 
Carbenicillin E. coli selection 100 µg/mL 
Gentamycin E. coli DH10Bac selection 7 µg/mL 
Tetracyclin E. coli DH10Bac selection 10 µg/mL 
X-Gal Substrate for blue/white screening on plates 100 µg/mL 
Isopropyl-β-D-
thiogalactosid (IPTG) 
Induction of protein expression in E. coli 0.25 mM 
 
2.8 Media	and	supplements	for	insect	cell	culture	
Table 2-11 Media for insect cell culture 
Medium Composit ion 
SF-900 III SFM Protein-free insect cell culture medium 
HyClone medium 4.13 % (w/v) HyClone, 4.16 mM NaHCO3, 0.15 % (v/v) glycerol, pH 6.1-6.4 
 
Table 2-12 Supplements for insect cell culture 
Supplement Applicat ion Final concentrat ion 
Gentamycin Insect cell selection 10 µg/mL 
 
2.9 Media	and	supplements	for	mammalian	cell	culture	
Table 2-13 Media for mammalian cell culture 
Medium Composit ion Applicat ion 
Complete Medium 90 % (v/v) DMEM, 10 % (v/v) FBS, 100 U/mL penicil-
lin/streptomycin, 2.5 µg/mL fungizone 
Normal cell cul-
ture 
Cryo medium (v/v) 70 % DMEM, (v/v) 20 % FBS, (v/v) 10 % DMSO Freezing of cells 
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Table 2-14 Supplements for mammalian cell culture 
Supplements Applicat ion Final concentrat ion Source 
Gibco® DMEM (4.5 g/L D-
Glucose, L-glutamine, 
phenol red) 
Cell culture 70 or 90 % (v/v) Life Technologies 
FBS (fetal bovine serum) Cell culture 10 or 20 % (v/v) Life Technologies 
Penicillin/streptomycin Antibiotic in cell cul-
ture 
100 U/mL Life Technologies 
Fungizone Antimycotic in cell culture 2.5 µg/mL Life Technologies 
10x Trypsin/EDTA Splitting of cells 1x Life Technologies 
DMSO (dimethylsulfoxid) Cryo medium 10 % (v/v) Carl Roth 
1x PBS (phosphate buff-
ered saline) Washing of cells 1x Life Technologies 
Puromycin Cell selection 1 µg/mL Life Technologies 
 
2.10 Antibodies	
Table 2-15 Primary antibodies 
Primary Antibody Clonali ty/Source Dilut ion/Applicat ion Source 
Anti-β-actin-HRP Monoclonal/mouse 1:1000/ Western blot 
Santa Cruz (Hei-
delberg, Germa-
ny) 
Anti-cyclin D1 Polyclonal/rabbit 1:5000/Western blot Epitomics (Burlin-
game, USA) 
Anti-EpCAM-FITC Monoclonal/mouse 1:200/FACS Life Technologies 
Anti-EpCAM Monoclonal/mouse 1:1000/Western blot Santa Cruz 
Anti-EpICD Polyclonal/guinea pig 1:1000/Western blot 
Peptide Specialty 
Laboratories (Hei-
delberg, Germa-
ny) 
Anti-FLAG Monoclonal/mouse 1:1000/Western blot Sigma-Aldrich 
Anti-GFP Polyclonal/rabbit 1:5000/Western blot Abcam (Cam-
bridge, UK) 
Anti-GAPDH Polyclonal/rabbit 1:5000/Western blot 
Bethyl Laborato-
ries (Montgomery, 
USA) 
Anti-MBP-HRP Monoclonal/mouse 1:1000/Western blot Abcam 
 
Table 2-16 Secondary antibodies 
Secondary Antibody Clonali ty/Source Dilut ion/Application Source 
Anti-guinea-pig-HRP polyclonal/rabbit 1:1000/Western blot 
Thermo Fisher 
Scientific (Wal-
tham, USA) 
Anti-mouse-HRP Polyclonal/goat 1:5000/Western blot Dako (Hamburg, 
Germany) 
Anti-mouse-HRP polyclonal/goat 1:3000/Western blot BioRad (Munich, Germany) 
Anti-rabbit-HRP Polyclonal/goat 1:50007Western blot Dianova (Ham-
burg, Germany) 
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2.11 General	buffers	and	stock	solutions	
Table 2-17 General buffers and stock solutions 
Name Composit ion Applicat ion 
4x stacking gel buffer 0.5 M Tris, 0.4 % (w/v) SDS, pH 6.8 SDS PAGE 
4x separating gel buffer 3 M Tris, 0.4 % (w/v) SDS, pH 8.5 SDS PAGE 
10x TGS 0.25 M Tris, 1 % (w/v) SDS, 1.9 M glycine SDS PAGE 
4x loading dye 
110 mM Tris/HCl pH 6.8, 40 % (v/v) glyc-
erol, 0.5 % (w/v) bromophenol blue, 4 % 
(w/v) SDS, 40 mM DTT 
SDS PAGE 
Coomassie staining solution 50 % (v/v) ethanol, 7 % (v/v) acetic acid, 
0.2 % (w/v) Coomassie Brilliant blue R-250 
SDS PAGE 
50x TAE 2 M Tris-base, 5.71 % (v/v) acetic acid, 50 
mM EDTA (pH 8.0) 
Agarose-gel electro-
phoresis 
10x PBS 80 g NaCl, 2 g KCl, 14.2 g Na2HPO4, 2.4 g 
KH2PO4 in 1 L H2O, pH 7.4 
Western blot 
PBS-T 1x PBS, 1:1000 Tween®20 Western blot 
Lysis buffer 1x PBS, 1 % (v/v) Triton X-100, two tablets 
protease inhibitor cocktail 
Western blot 
Laemmli buffer 
140 mM Tris-HCl, 30 % (w/v) glycerine, 4 
% (w/v) SDS, 16 % (v/v) β-
mercaptoethanol, 0.1 % (w/v) bromophenol 
blue 
Western blot 
Running buffer 250 mM Tris, 2 M glycine, 1 % (w/v) SDS Western blot 
10x Blotting buffer 30 g Tris, 95 g glycine in 1 L H2O Western blot 
Washing buffer 1x PBS, 0.2 % (v/v) Tween®20 Western blot 
Blocking buffer 5 % (w/v) milk powder in washing buffer Western blot 
Primary antibody solution 3% (w/v) BSA in washing buffer Western blot 
Secondary antibody solution 5 % (w/v) milk powder in washing buffer Western blot 
Homogenisation buffer 10 mM MOPS, 10 mM KCl, 1x protease 
inhibitor cocktail 
Membrane Assay 
Assay buffer 120 mM Na3C6H5O7, 10 µM ZnCl2, 1x 
protease inhibitor cocktail 
Membrane Assay 
Lysis buffer_IP 
10 mM Tris/HCl pH 7.5, 150 mM NaCl, 0.5 
mM EDTA, 0.5 % (v/v) NP-40, 1 tablet 
protease inhibitor cocktail 
IP 
Dilution buffer 10 mM Tris/HCl pH 7.5, 150 mM NaCl, 0.5 
mM EDTA 
IP 
Elution buffer_IP 100 mM glycine, pH 2.7 IP 
TEV buffer 25 mM Tris/HCl pH 8.0, 150 mM NaCl, 10 
mM DTT 
TEV cleavage 
 
2.12 Molecular	biology	
2.12.1 Cloning	
Cloning of genes of interest was performed according to Sambrook and Russel, 2001. 
DNA was amplified by polymerase chain reaction (PCR). The resulting PCR products 
were analyzed by agarose-gel electrophoresis (1x TAE buffer, stained with GelRed 
(Biotium, Hayward, USA)) and purified with the NucleoSpin® PCR clean-up kit (Ma-
cherey-Nagel, Düren, Germany) according to manufacturer´s instructions. The insert 
and the vector were digested with restriction enzymes and ligated. Restriction en-
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zymes, buffers and T4 DNA ligase (Thermo Scientific, Waltham, USA) were used ac-
cording to manufacturer´s instructions. Point mutations were introduced using the 
QuickChange II Site-Directed Mutagenesis Kit (Agilent Technologies, Waldbronn, 
Germany). For cloning into pOPIN expression vectors, the purified PCR products were 
ligated with the linearized plasmid by using the In-Fusion Cloning Kit (Clontech, Moun-
tain View, USA) according to manufacturer´s protocol. Concentrations of nucleic acids 
were measured with NanoDrop Spectrophotometer (Thermo Fisher, Ulm, Germany). 
Cloning strategies for all constructs and sequences of the corresponding oligonucleo-
tides are summarized in Table 2-1 and Table 2-4. 
2.12.2 Transformation	of	E.	coli	and	isolation	of	plasmid	DNA	
Preparation of chemically competent E. coli cells was done according to Hanahan, 
1983. Plasmid DNA was transformed as described in Sambrook and Russel, 2001. 
Transformed cells were selected on LB agar plates supplemented with antibiotics. For 
small-scale plasmid preparation, 5 mL LB medium supplemented with respective anti-
biotics were inoculated with a single colony and grown o/n at 37 °C. Plasmid DNA was 
isolated using the NucleoSpin® Plasmid kit (Macherey-Nagel) according to manufac-
turer´s instructions. Cloning was verified by sequencing. 
2.12.3 RNA	isolation	
RNA isolation from mammalian cells was performed with the High Pure RNA Isolation 
Kit (Roche, Mannheim, Germany) according to manufacturer´s protocol. For removal of 
contaminating DNA, isolated RNA was treated twice with Turbo DNAfree kit (Ambion, 
Austin, USA). Concentration was measured with NanoDrop Spectrophotometer. 
2.12.4 Reverse	transcription	of	RNA	
Reverse transcription (RT) of RNA was performed with PrimeScript™ RT Master Mix 
(Takara, Paris, France) according to manufacturer´s instructions. RT was generally 
performed from 1 µg total RNA. cDNA samples were stored at 4 °C until further use. 
2.12.5 Quantitative	Real-Time	PCR	
Quantitative Real-Time- (qRT-) PCR experiments were performed in a LightCycler® 
480 instrument (Roche) using the KAPA SYBR FAST Universal Kit according to the 
manufacturer´s protocol. Reactions were performed in triplicates on FrameStar® 
480/96 (4titude, Wotton, UK) plates. To ensure specific amplification, melting curves 
were analyzed. For normalization, the house-keeping gene GAPDH was included. 
Evaluation was done by using the ΔΔcp method (Pfaffl, 2001). For statistical analysis, 
the paired-sample t-test was applied and statistical significance was determined by a p-
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value where p<0.05 was considered significant. The DNA oligonucleotides used for 
qRT-PCR are summarized in Table 2-2. 
2.13 Bioinformatics	
2.13.1 Protein	parameters	
Protein parameters such as molecular weight (MW), isoelectric point (pI) and the ex-
tinction coefficient (ε) were calculated using the ExPASy Proteomics Server 
(http://web.expasy.org/protparam/). Protein concentration was determined by measur-
ing A280 with NanoDrop Spectrophotometer. 
2.13.2 Sequence	alignment	
DNA and protein sequences for primer design and determination of protein parameters 
were obtained from the NCBI database (https://www.ncbi.nlm.nih.gov/). 
2.13.3 Mammalian	cell	line	properties	
The properties of the cultivated mammalian cell lines such as medium, sub-culturing, 
culture conditions and cryopreservation were obtained from ATCC 
(https://www.lgcstandards-atcc.org/?geo_country=de) and DSMZ 
(https://www.dsmz.de/). 
2.14 Protein	expression	
2.14.1 Recombinant	protein	expression	in	E.	coli	
All cloned constructs (see section 2.12.1) were used to recombinantly express the pro-
teins of interest in E. coli BL21 Star (DE3) cells. Freshly transformed cells were used to 
inoculate 50 mL LB medium supplemented with the respective antibiotic. After cultiva-
tion for 4 h at 37 °C, the preculture was transferred into 3 L prewarmed LB medium 
supplemented with the respective antibiotic. In case of maltose-binding protein (MBP)-
fusion proteins, 2 g/L glucose were added. For zinc binding proteins, 100 µM ZnCl2 
was added. After reaching an OD600 of 0.3-0.4, cell cultures were cooled to 18 °C. Ex-
pression was induced at an OD600 of 0.6 by adding 0.25 mM Isopropyl-β-D-
thiogalactopyranosid (IPTG). The cells were harvested after 12-16 h by centrifugation 
(4,000 rpm, 20 min, 4 °C). Cell pellets were resuspended in the respective lysis buffer, 
flash frozen in liquid nitrogen and stored at -80 °C until further use. 
2.14.2 Recombinant	protein	expression	in	insect	cells	
Recombinant baculovirus was prepared according to the protocol of the Bac-to-Bac 
baculovirus expression system (Invitrogen; Ciccarone et al., 1998). MBP-FHL2 fusion 
protein was cloned into pFastBac1, amplified in XL-1 Blue cells (see section 2.12.1 and 
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2.12.2) and then transformed into DH10Bac E. coli cells. Transformed cells were plated 
on DH10Bac agar plates and grown at 37 °C for 48 h. Positive colonies were detected 
by blue/white screening. 5 mL LB medium supplemented with the corresponding anti-
biotic were inoculated with a white colony and grown o/n at 37 °C. Isolation of bacmid 
DNA was done with the NucleoSpin® Plasmid kit (Macherey-Nagel), however, instead 
of using the provided columns, the DNA was precipitated with isopropanol. For trans-
fection of SF21 cells, 2 µg bacmid DNA and 3 µL FuGeneHD reagent (Roche, Mann-
heim, Germany) were mixed with 300 µL Hyclone SF medium and incubated for 45 min 
at RT. This was added to 2 mL of insect cell suspension (0.4 x 106 cells/mL) and incu-
bated for 4 d at 27.5 °C. Afterwards, the cells were centrifuged (3,000 rpm, 10 min) and 
the supernatant (P0) was used for infection of 10 mL SF21 cells (1.4 x 106 cells/mL). 
After another cultivation for 4 d at 27.5 °C and 95 rpm, the cells were centrifuged 
(3,000 rpm, 10 min) and the supernatant (P1) was used for the infection of 500 mL 
SF21 cells (0.4 x 106 cells/mL). These cells were cultivated for 4 d at 27.5 °C and 
95 rpm and afterwards pelleted (3,000 rpm, 10 min). The supernatant (P2) was sterile 
filtered and stored at 4 °C. 10-30 mL of P2 were used for the infection of 500 mL High 
Five cells (1 x 106 cells/mL). Afterwards, cells were incubated for 60-70 h at 27.5 °C 
and then harvested by centrifugation (2,000 x g, 15 min, 4 °C). Cell pellets were resus-
pended in the respective lysis buffer, flash frozen in liquid nitrogen and stored at -80 °C 
until further use. 
2.15 Protein	purification	
All purification steps were performed at 4 °C or on ice. All buffers used were filtered 
and degased prior to use. Furthermore, all buffers contained 1 mM DTT or 1 mM TCEP 
when the protein was used for ITC. pH of the buffers was adjusted according to the 
protein´s pI. 
2.15.1 Purification	of	GST-tagged	proteins	
After thawing of cell pellets, cells were resuspended in lysis buffer (50 mM HEPES, 
500 mM NaCl, 1 mM EDTA, 20 % (v/v) glycerol, 1 % (v/v) triton X) and one tablet of 
EDTA-free protease inhibitor cocktail (Roche) was added. Cells were disrupted by son-
ication on ice with a Branson Sonifier 250 (Emerson, Danbury, USA). The cell debris 
was removed by centrifugation (16,000 rpm, 30 min, 4 °C). Afterwards, the lysate was 
loaded on a pre-equilibrated 5 mL GSTrap FF column (GE Healthcare). After extensive 
washing with washing buffer (50 mM HEPES, 500 mM NaCl) and high salt buffer 
(50 mM HEPES, 1 M NaCl), the protein was eluted by elution buffer (50 mM HEPES, 
150 mM NaCl, 25 mM glutathione; GSH) using a linear gradient. Fractions containing 
proteins were identified by their A280, analyzed by SDS-PAGE and pooled. If necessary, 
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GST was removed by adding 50 µg PreScission Protease (GE Healthcare), whilst dia-
lysing against dialysis buffer (50 mM Hepes, 100 mM NaCl) o/n at 4 °C. The protein 
was further purified using a HiTrap Q column (GE Healthcare). The eluted fractions 
were analyzed by SDS-PAGE, pooled and concentrated in a centrifugal filter device 
(Amicon Ultra, Millipore Billerica, USA). Prior to purification by size exclusion (SEC) 
with a Superdex 75 10/30 GL column (GE Healthcare) in SEC buffer (20 mM HEPES, 
100 mM NaCl), the protein was centrifuged (16,000 rpm, 20 min, 4 °C). Peak fractions 
were again analyzed on SDS-PAGE, pooled, concentrated, flash frozen in liquid nitro-
gen and stored at -80 °C until further use. 
2.15.2 Purification	of	MBP-tagged	proteins	
MBP-tagged proteins were purified analogously to GST-tagged proteins (see section 
2.15.1). The cleared lysate was loaded onto a pre-equilibrated amylose column. After 
washing steps, the protein was eluted with 75 mL elution buffer (20 mM HEPES, 
150 mM NaCl, 10 mM maltose). The eluted fractions were analyzed by SDS-PAGE. 
After concentration of the protein, the final purification step was carried out on a HiLoad 
16/600 Superdex S75 with SEC buffer. 
2.15.3 Purification	of	His-SUMO	tagged	proteins	
The cell pellet was thawed and resuspended in lysis buffer (20 mM HEPES, 500 mM 
NaCl, 20 % (v/v) glycerol, 1 % (v/v) triton X) and one tablet of EDTA-free protease in-
hibitor cocktail (Roche). Afterwards, the cells were sonified and centrifuged as previ-
ously described (see 2.15.1). The cleared lysate was loaded onto a pre-equilibrated 
5 mL HisTrap column (GE Healthcare). The column was washed with washing buffer 
(20 mM HEPES, 300 mM NaCL, 20 mM imidazole) and afterwards eluted by elution 
buffer (20 mM HEPES, 100 mM NaCl, 500 mM imidazole) in a linear gradient over 
20 column volumes (CV). The protein-containing fractions were identified by their A280 
and analyzed on a SDS-PAGE, pooled and dialyzed o/n at 4 °C against dialysis buffer 
(20 mM HEPES, 100 mM NaCl). For removal of the His-SUMO-Tag, 50 µg PreScission 
protease were added. The protein was further purified analogously to GST-tagged pro-
teins (see section 2.15.1). 
2.16 SDS-PAGE	
For assessing amount and purity of proteins, they were analyzed by sodium dodecyl-
sulfate polyacrylamide gel electrophoresis (SDS-PAGE; Laemmli, 1970). Depending on 
the size of the proteins, 12-19 % polyacrylamide gels were used. Gels were stained 
either with Coomassie blue (Thermo Scientific) or Silver staining solution according to 
standard procedures (Thermo Fisher). 
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2.17 Methods	for	analyzing	protein-protein	interactions	
2.17.1 In	vitro	pull-down	assay	
For pull-down experiments, the respective resin was washed with SEC buffer. The pro-
teins were mixed in a total volume of 100 µL, incubated for 30 min at 4 °C and centri-
fuged (max. speed, 10 min, 4 °C). Afterwards, the resin was resuspended in SEC buff-
er, added to the proteins and incubated for 30 min at 4 °C on the overhead shaker. 
After the incubation, the resin was washed five times (3,000 rpm, 3 min, 4 °C) with SEC 
buffer before eluting the proteins with elution buffer. Samples of every step were ana-
lyzed by SDS-PAGE (see section 2.16). 
2.17.2 Isothermal	titration	calorimetrie	(ITC)	
ITC experiments were performed with SEC buffer in MicroCal iTC200 or MicroCal VP-
ITC (Malvern Instruments, Malvern, UK). Before starting the experiment, all samples 
were centrifuged. The syringe was filled with a 40–110 µM protein solution and was 
titrated into the sample cell, which was filled with a ten times less concentrated putative 
interacting protein solution. ITC experiments were either performed with 20 injections of 
2 µL protein solution every 2 min or with 36 injections of 4 µL protein at 4 min interval. 
The data was analyzed using the MicroCal Origin program. 
2.18 Cell	culture	
2.18.1 Cultivation	of	cells	
All cells were grown in Complete medium. For cultivation of transfected HEK293 cells, 
1 µg/mL puromycin was added to the medium. Upon 90 % cell density, cells were split. 
Therefore, medium was removed and cells were washed with PBS. For the detachment 
of the cells, Trypsin/EDTA was added and incubated for 5 min at 37 °C. Afterwards, 
medium was added to stop the activity of trypsin and the cell suspension was trans-
ferred to Falcon tubes (BD Biosciences, Heidelberg, Germany) and centrifuged 
(1,500 rpm, 5 min). The supernatant was discarded, the pellet was resuspended and 
cells were transferred to a new cell culture flask (Greiner Bio-One, Frickenhausen, 
Germany). For seeding the cells in 6-, 96- or 384-well plates, cells were counted with a 
Luna Cell Counter (Logos Biosystems, Annandale, USA) and the cell number was ad-
justed. All cell lines were cultivated at 37 °C in a humidified incubator with 5 % CO2. 
2.18.2 Cryopreservation	and	thawing	of	cells	
Cells were detached from the flask as previously described (see section 2.18.1), re-
suspended and frozen in cryo-conservation medium (see Table 2-13). 
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Cells were thawed, transferred to 10 mL pre-warmed Complete medium and centri-
fuged (1,500 rpm, 5 min). The supernatant was removed, the cell pellet was resus-
pended and transferred to a new cell culture flask. 
2.18.3 High-Content	Screening	(HCS)	
2.18.3.1 Screening	libraries	
For HCS, four in-house screening libraries of small inhibitory molecules were used. The 
compounds of these libraries were selected according to the following rules: 
• Good solubility 
• Molecular weight less than 600 g/mol 
• Purity > 90 % 
• Non-reactive, unstable and toxic chemical groups 
• Meeting criteria of Lipinski´s rule of five (Lipinski et al., 2001) 
Each library should contain diverse structures and differ from other libraries. The fol-
lowing diversity libraries were used: ChemDiv (10,000 compounds), ChemBridge 
(5,000 compounds), Enamine (10,000 compounds) and ChemDiv Protein-Protein In-
teraction (PPI; 5,000 compounds). Furthermore, an additional library was used that 
consists of FDA approved drugs (Prestwick library, 1,280 compounds; Prestwick 
Chemical, Illkirch, France). Compounds were reordered from the respective company 
as powder stocks and dissolved to a concentration of 10 mM in deuterated DMSO 
(DMSO D6). Aliquots were frozen and stored at -80 °C. 
2.18.3.2 Performance	and	evaluation	of	High-Content	Screening	
Due to the imaging settings, it was not possible to image all of the 31,280 compounds. 
For recording pictures, the high numerical aperture (NA) objective has to come very 
close to the plate, which is not possible on the plate edge. Therefore, in order to identi-
fy small molecules that inhibit the EpCAM signaling cascade, only 26,000 compounds 
were screened. HEK293 EpCAM-CTF-YFP cells were automatically seeded (ELX406 
plate washer and dispenser, BioTek, Winooski, USA; 3,000 cells in 50 µL/well) on 10 % 
(w/v) PDL-coated 384-well plates. In the initial HCS, compounds were tested at a con-
centration of 8 µM (0.8 % DMSO). Compound-treated cells were incubated o/n at 
37 °C. Afterwards, cells were stained with Hoechst33342 (1:1000 in Complete medium) 
and 3.5 µg/mL CellMask™ Deep Red Plasma membrane Stain (Invitrogen) and fixed 
with 2 % (w/v) paraformaldehyde (PFA) solution. Cells were imaged with Operetta 
High-Content-Imaging System (Perkin Elmer) at 40x magnification and confocal imag-
ing method, and results were evaluated with the Harmony High Content Imaging and 
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Analysis Software version 3.5.2. With the help of this software, different cell regions 
were defined: the median of the YFP intensity within these regions was calculated and 
compared to the one of the DMSO treated negative control. If the intensity exceeded a 
predefined threshold, the respective compound was regarded as hit. 128 hits were de-
fined as primary hits and were subsequently tested in a five-point (80-5 µM) and ten-
point (80-0.15 µM) titration. Results were evaluated in the Microsoft Excel program. In 
order to determine the quality of the HCS, the Z-factor was calculated. Thereby, the 
mean and the standard deviation of the positive control are compared to the mean and 
the standard deviation of the negative control. If 0.5 < Z-factor < 1, the assay results 
are considered to be excellent. 
Autofluorescence of the compounds was assessed as described earlier in this chapter. 
However, YFP-negative HEK293 EpCAM-FL cells were used instead. The absence of 
YFP in these cells was confirmed by FACS (see 2.18.4) 
2.18.4 Fluorescence-activated	cell	sorting	(FACS)	experiments	
Cells that were analyzed by FACS in this study were either expressing YFP or stained 
with a FITC-conjugated antibody. Cells were harvested as previously described (see 
section 2.18.1). The cell number was determined, 5x105 cells were transferred to a new 
tube, centrifuged (1,500 rpm, 5 min), resuspended in 1x PBS and measured with a BD 
LSR II Flow Cytometer (BD Biosciences). In case of staining with an antibody, cells 
were washed once with 1x PBS and then incubated with the antibody diluted in 1x PBS 
(1:200) for 30 min at RT in the dark. The cells were washed once again and then re-
suspended in 1x PBS and transferred to FACS measurement. The results were evalu-
ated with the FlowJo program version 10.0.8. 
2.18.5 Viability/toxicity	Assay	
Viability, toxicity and apoptosis of compound-treated cells were assessed using the 
ApoTox-Glo™ Triplex Assay (Promega, Madison, USA). Cells were automatically 
seeded on 384-well plates (5,000 cells in 50 µL/well), treated with compounds and in-
cubated at 37 °C o/n. Viability/Cytotoxicity Reagent and Caspase-Glo® 3/7 Reagent 
were prepared according to manufacturer´s instructions. 5 µL Viability/Cytotoxicity rea-
gent were added per well and plates were again incubated for 30 min at 37 °C. Then, 
fluorescence was measured at 400Ex/505Em (viability) and 484Ex/520Em (cytotoxicity) in 
EnVision plate reader (Perkin Elmer). After adding 25 µL Caspase-Glo® 3/7 Reagent 
per well, plates were incubated for 30 min at RT in the dark and luminescence was 
measured. To evaluate the toxicity of the compounds, the measured intensities were 
related to the DMSO control using the program Microsoft Excel. 
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2.18.6 Proliferation	Assay	
Cells were harvested as previously described (see section 2.18.1) and seeded onto 96-
well plates. After 6 h, one row was stained with 0.25 µL Hoechst33342 and imaged with 
Operetta High-Content-Imaging System (Perkin Elmer). Afterwards, medium was re-
moved and new medium containing the compounds or controls was added. Every 24 h, 
one row was stained with Hoechst33342 and imaged (D0-D7). Results were evaluated 
with the program Microsoft Excel. 
2.19 Biochemical	methods	
2.19.1 Membrane-based	cleavage	assay	
For the analysis of EpCAM cleavage products, membrane-based cleavage assays 
were performed. Cells were grown to confluence in cell culture dishes. Subsequently, 
cells were washed twice with ice cold 1x PBS, harvested by using a cell scraper and 
transferred to a new 15 mL reaction tube. After one more washing step, cells were ho-
mogenized in 1 mL homogenisation buffer by douncing them 10 times with a micro-
lance 3/23G 1.25´´syringe (Becton Dickinson, Franklin Lakes, USA). The homogenized 
cells were centrifuged (1,000 x g, 15 min, 4 °C) and the post nuclear supernatant con-
taining membranes, proteins and small organelles was transferred into a new reaction 
tube. Another centrifugation step was performed (16,000 x g, 20 min, 4 °C) to pellet the 
membranes. The supernatant was discarded and pellets were washed with 500 µL 
homogenisation buffer. Finally, pellets were resuspended in 100 µL assay buffer con-
taining compounds in the desired concentration and incubated o/n at 37 °C. Subse-
quently, samples were further processed as described below in 2.19.2 and 2.19.4. 
2.19.2 Preparation	of	whole	cell	lysates	
Cells were harvested as described in section 2.18.1. Afterwards, lysis buffer was added 
and cells were incubated for 30 min on ice while vortexing every 10 min. After centrifu-
gation (16,000 x g, 20 min, 4 °C), the protein containing supernatant was transferred 
into a new tube and stored at -20 °C until further use. 
2.19.3 Determination	of	protein	concentration	
For the determination of the protein concentration in cell lysates and membrane frac-
tions, respectively, the Pierce™ BCA Protein Assay Kit (Thermo Fisher Scientific) was 
used. The BCA Working Reagent and diluted bovine serum albumin (BSA) standards 
were prepared according to manufacturer´s instructions. 100 µL Working Reagent and 
5 µL sample or BSA standard were mixed and incubated for 15 min at 37 °C. A562 was 
measured for all samples and standards with GeneQuantPro spectrophotometer (GE 
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Healthcare). Background levels of Working Reagent-only samples were subtracted. All 
measurements were performed in triplicates. 
2.19.4 Western	blot	
For whole cell lysates and membrane fractions, 20 µg and 2 µg of protein were loaded 
onto a 12 % SDS-PAGE (see section 2.16) and separated for 15 min at 30 mA and 2 h 
at 30 mA. For protein MW estimation, the Cozy™ Prestained Protein Ladder (highQu, 
Kraichtal, Germany) was used. Afterwards, proteins were transferred onto a methanol-
equilibrated PVDF blotting membrane (Immobilon-P) at 100 V for 50 min. To prevent 
unspecific binding, the membrane was incubated in 5 % (w/v) milk powder/washing 
buffer for 30 min at RT in a rolling device. Subsequently, the blot was incubated with 
the respective primary antibody diluted in Primary antibody solution o/n at 4 °C. For 
removal of unbound antibody, the membrane was washed with washing buffer for 
30 min. The secondary antibody was diluted in the secondary antibody solution and 
was incubated with the blot for 30 min at RT, followed by washing for 30 min. Protein 
bands were detected by incubation with HRP substrate and imaging with ImageLab 
software version 5.2.1 (Biorad). Analysis and quantification of protein bands was also 
done with the ImageLab software. For statistical analysis, the paired-sample t-test was 
applied and statistical significance was determined by a p-value. 
2.19.5 Determination	of	hEpCAM	cleavage	sites	
For the determination of the cleavage sites, HEK293 EpCAM-CTF-YFP cells were 
grown to confluence in T175 cell culture flask. Afterwards, the medium was replaced by 
medium containing compound or DMSO. To have a sufficient amount of protein, two 
T175 cell culture flasks were used and pooled per sample. 
2.19.5.1 Determination	of	γ-cleavage	sites	
24 h after the replacement of the medium, the supernatant was collected for Myc-
immunoprecipitation (IP). 50 mL of supernatant were mixed with 30 µL Myc-beads (Bi-
omol GmbH, Hamburg, Germany) and incubated o/n at 4 °C on a rolling device. Sub-
sequently, the supernatant was centrifuged (2,500 x g, 5 min, 4 °C), washed three 
times with 1x PBS buffer and twice with ddH2O (300 x g, 2 min, 4 °C). After that, pro-
teins were eluted in 10 µL acetonitrile (Sigma) and ddH2O saturated with α-cyano-4-
hydroyl-cinnamic acid (Sigma) and analyzed with MALDI-TOF mass spectrometry on 
an Ultraflex Extreme mass spectrometer (Bruker Daltonics, Bremen, Germany). Pep-
tides were measured in a range of 3,000 – 5,000 m/z, protein fragments in a range of 
10,000 – 100,000 m/z. Single spectra were accumulated for better visualization. Spec-
tra were smoothed and baseline substracted for further evaluation using flexAnalysis 
software version 3.4 (Bruker). 
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2.19.5.2 Determination	of	ε-cleavage	sites	
Cells were harvested in 4 mL lysis buffer_IP (see Table 2-17) by scratching and incu-
bated on ice for 30 min with extensive pipetting every 10 min. Cell lysate was centri-
fuged (20,000 x g, 10 min 4 °C), the supernatant transferred into a new falcon and 
0.6 x vol. of dilution buffer was added. 20 µL pre-equilibrated GFP-Trap®_A beads 
(Chromotek, Planegg, Germany) were added and incubated for 4 h at 4 °C on a rolling 
device. After washing the beads three times with 1x PBS and two times with ddH2O 
(2,500 x g, 2 min, 4 °C), proteins were eluted with 40 µL elution buffer_IP on ice for 
20 min. After centrifugation (280 x g, 5 min, 4 °C), eluted proteins were transferred into 
a new tube and neutralized by 200 µL Tris/HCl (100 mM, pH 8.0). Subsequently, 10 µL 
TEV buffer, 0.75 µL DTT (1 M) and 3 µL TEV protease (2 mg/mL) were added and in-
cubated at 4 °C o/n. Afterwards Flag-beads (Sigma-Aldrich) were added und incubated 
for 4 h at 4 °C. All following steps were performed as described previously (see section 
2.19.5.1). 
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3 Results	
3.1 Structure	determination	of	the	nuclear	complex	
The EpCAM signaling cascade plays an important role since it has a stimulating effect 
on the cell cycle and cell proliferation (Munz et al., 2004). Furthermore, EpCAM-
positive cells have a tumorigenic effect in immunodeficient mouse models (Maetzel et 
al., 2009). Thereby, EpCAM is sequentially cleaved by TACE and γ-secretase, which 
eventually results in the release of EpICD into the cytoplasm. EpICD forms an intracel-
lular complex with FHL2, β-catenin and Lef-1. This complex is translocated into the 
nucleus, where it activates the transcription of EpCAM target genes (Maetzel et al., 
2009). The goal of this part of the project was to confirm the already published interac-
tion between EpICD, FHL2 and β-catenin (Maetzel et al., 2009) and afterwards to solve 
the structure of this complex and identify the key elements responsible for this interac-
tion. After characterization of the binding site, small inhibitory molecules could be de-
signed (structure-based drug design) that prevent the formation of the nuclear complex 
and thereby inhibiting the intracellular EpCAM signaling cascade. 
3.1.1 Expression	and	purification	of	FHL2	and	EpICD	
For all interaction studies, FHL2 derivatives (FHL2 LIM1-2 (17 kDa), FHL2 LIM2-3 (13 
kDa), FHL2 LIM3-4 (13 kDa) and FHL2 FL (32 kDa)) were cloned and expressed as 
described in sections 2.12.1 and 2.14.1. To achieve the best stability and yield of the 
purified proteins, several purification procedures and tags were tested (Figure 3-1). 
Initially, FHL2 FL was purified with a GST-tag (26 kDa). This protein was well ex-
pressed, soluble and could be enriched using a GSTrap column. However, after the 
removal of the GST-tag the protein was degraded leading to a very poor yield after 
SEC (Figure 3-1A). Replacing the GST-tag by an MBP-tag (42 kDa) did not overcome 
this problem. Although the protein was well expressed, soluble and could be enriched 
using an amylose resin, it still became degraded and also partially precipitated after the 
removal of the MBP-tag. The result was again a very poor yield after SEC (Figure 
3-1B). Hence, it was decided to purify FHL2 FL without removal of the tag. Further-
more, the stability of the protein was improved by adding a His-tag to the carboxy-
terminus. By adding ZnCl2 to the growth medium, the expression level and also the 
yield could be substantially improved for both GST-FHL2 FL (58 kDa) and MBP-FHL2 
FL (74 kDa). Both proteins were stable and the achieved purity was ≥ 90 % (Figure 
3-1C). Here, removal of the tag was only possible by the addition of 0.1% (v/v) Triton to 
the dialysis buffer. Yet, the ZnCl2 containing protein still was degraded after the remov-
al of the tag (Figure 3-1D). FHL2 FL for expression in insect cells was cloned and ex-
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pressed as described in 2.14.2. This protein also showed good expression, solubility 
and could be enriched using an amylose resin. During concentrating, the protein al-
ready precipitated at very low concentrations. Therefore, it was not possible to perform 
a SEC, which is why buffer exchange and concentration of the protein was done by 
adding 25 % or 50 % glycerol to the dialysis buffer. The purified protein was stable and 
pure ≥ 85 % (Figure 3-1E). 
 
Figure 3-1 Purification procedures and tags of FHL2 derivatives. (A) Purification of GST-FHL2 FL 
(58 kDa). After the removal of the tag, the protein is degrading. (B) Purification of MBP-FHL2 FL (74 kDa). 
The protein also degrades after removal of the tag. (C) After adding ZnCl2 to the expression, the yield of 
both proteins could be clearly improved. (D) Removal of the tag of ZnCl2 containing proteins was only 
possible after the addition of Triton but still led to degradation of the protein. (E) MBP-FHL2 FL expressed 
in insect cells was concentrated by using glycerol. 
The different LIM-constructs were purified according to the FL protein with the respec-
tive tag. All of the GST-LIM constructs were well expressed and showed good solubili-
ty. After the final purification step by SEC, quality and purity of all proteins were as-
sessed via SDS-PAGE. Purified GST-LIM1-2 was stable and a purity of ≥ 90 % was 
achieved. Purified GST-LIM2-3 showed slight degradation and purity of ≥ 90 %. The 
yield of GST-LIM3-4 was comparatively poor. The protein showed a rather strong deg-
radation and a purity of ≥ 90 % (Figure 3-2A-C). Both MBP-LIM1-2 and MBP-LIM2-3 
showed good expression but were not completely soluble. After enrichment by amylose 
resin and SEC, both purified proteins were stable and pure (≥ 90 %). MBP-LIM3-4 
  Results 
45 
 
showed a very strong expression and solubility. The purified protein was also stable 
and a purity of ≥ 95 % was achieved (Figure 3-2D-F).  
 
Figure 3-2 Purification of LIM-constructs.(A-F) SEC chromatograms (blue) of the final purification step 
with Superdex 75 10/300 GL column (C) or HiLoad 16/600 Superdex S75 (A+B, D-F). Peak fractions were 
analyzed by SDS-PAGE and the best fractions (red dash) were pooled, concentrated and frozen. (A) GST-
LIM1-2 (43 kDa). (B) GST-LIM2-3 (39 kDa). (C) GST-LIM3-4 (39 kDa). (D) MBP-LIM1-2 (59 kDa). (E) 
MBP-LIM2-3 (55 kDa). (F) MBP-LIM3-4 (55 kDa). 
Since EpICD already heavily precipitated in the cell pellet, which could not be improved 
by the addition of arginine to the lysis buffer, it was decided to order a chemically syn-
thesized peptide. Hachmeister et al., 2013 showed that EpCAM-CTF cleavage results 
in different EpICD variants of which the one consisting of 28 AA (starting with V288 
I289) is the most stable one. Therefore, it was decided to order this EpICD fragment N-
terminally fused to a 3x FLAG-tag (6 kDa). 
3.1.2 Expression	and	purification	of	β-catenin	
For interaction studies, β-catenin (138-781; 82 kDa) was cloned and expressed as de-
scribed in sections 2.12 and 2.14.1. The protein was well expressed, soluble and was 
enriched using a nickel-affinity column. After removal of the His6-SUMO tag, the protein 
(70 kDa) remained stable. After SEC, the purified protein was stable and pure (≥ 90 %; 
Figure 3-3). Since purified β-catenin precipitated after freeze and thaw cycles, it had to 
be freshly purified for every interaction study. 
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Figure 3-3 Purification of β-catenin. SEC chromatograms (blue) of the final purification step with HiLoad 
16/600 Superdex S75. Peak fractions were analyzed by SDS-PAGE and the best fractions (red dash) were 
pooled, concentrated and directly used for interaction studies. 
3.1.3 In	vitro	pull-down	experiments	with	FHL2,	EpICD	and	β-catenin	
Yeast two-hybrid screens and immunoprecipitation experiments have already shown 
an interaction between FHL2 and EpICD. β-catenin was identified as member of the 
nuclear complex as well (Maetzel et al., 2009). In order to reconfirm the already pub-
lished interaction between FHL2, EpICD and β-catenin in vitro and to show a direct 
interaction, in vitro pull-down experiments were carried out. Since MBP-tagged FHL2 
FL protein did not bind to the amylose resin (Figure 3-4A), the GST-tagged version was 
used. Pull-down experiments with either FHL2 FL and EpICD or β-catenin were per-
formed. GST-FHL2 FL and either 3x FLAG EpICD or untagged β-catenin were mixed 
with GSH-beads, washed and the bound proteins were eluted with GSH and visualized 
and analyzed via SDS-PAGE. However, none of these experiments showed a direct 
interaction between these proteins (Figure 3-4A+B). To check whether posttranslation-
al modifications are required for an interaction of FHL2 FL and EpICD, pull-down ex-
periments with MBP-tagged FHL2 FL purified from insect cells and 3x FLAG-tagged 
EpICD were carried out. Both proteins were mixed with anti-FLAG beads, washed and 
the bound proteins were eluted by heating in SDS-containing buffer and visualized by 
SDS-PAGE. Small amounts of FHL2 FL could be found in the elution fraction; however, 
the same effect could be seen in the negative control. This indicates that FHL2 FL 
found in the elution fraction is due to unspecific binding of MBP-FHL2 FL to the anti-
FLAG beads. The two additional bands in the elution fraction very likely correspond to 
the heavy chain (50 kDa) and the light chain (23 kDa) of anti-FLAG antibodies (Figure 
3-4C). 
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Figure 3-4 Pull-down experiments with FHL2, β-catenin and EpICD. In vitro pull-down assays were 
performed with MBP-FHL2 and EpICD (A), GST-FHL2 and β-catenin (B), and insect cell MBP-FHL2 and 
EpICD (C). None of these assays showed an interaction. I: input; W: wash; E: elution. 
3.1.4 ITC	experiments	with	FHL2,	EpICD	and	β-catenin	
Since the interaction between FHL2 and EpICD or β-catenin could be transient and 
thus not detectable by pull-down experiments, ITC was used to further investigate this 
possible interaction. By titrating 200 µM EpICD into 20 µM FHL2, no interaction could 
be detected (Figure 3-5A). One potential scenario is that the binding of EpICD and β-
catenin is a prerequisite for the interaction with FHL2. Therefore, 200 µM EpICD was 
titrated into 20 µM β-catenin. However, no interaction could be detected either (Figure 
3-5B). Next, a possible interaction between FHL2 and β-catenin was assessed. 90 µM 
FHL2 was titrated into 7 µM β-catenin. In doing so, an interaction of these two proteins 
could be detected, revealing a Kd≈1.08 µM and a stoichiometry of FHL2 : β-catenin 
=1.06 ± 0.09 (Figure 3-5C). Since β-catenin already starts precipitating at even low 
concentrations, it was not possible to conduct this experiment with higher concentra-
tions. To verify that this result is not due to binding of β-catenin to the MBP-tag, 70 µM 
MBP was titrated in 7 µM β-catenin and no interaction could be detected. Since the 
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FHL2-β-catenin interaction could be a prerequisite for EpICD-binding to the complex, 
FHL2 and β-catenin (11 µM) were pre-incubated before 110 µM EpICD was added. 
However, no interaction could be detected (Figure 3-5D). 
 
Figure 3-5 ITC experiments with β-catenin, FHL2 and EpICD. In order to identify a possible interaction, 
ITC experiments with EpICD and FHL2 (A), EpICD and β-catenin (B), FHL2 and β-catenin (C), and EpICD 
and FHL2-β-catenin (D) were performed. Only for FHL2 and β-catenin, an interaction could be shown, 
revealing a Kd≈1.08 µM and a stoichiometry of 1:1. 
To further analyze the observed FHL2-β-catenin interaction, different FHL2-constructs 
containing diverging sets of LIM-domains (see section 3.1.1) were planned to be test-
ed. Since, on the one hand the GST-tagged constructs precipitated at a comparatively 
low concentration (≈25 µM) and on the other β-catenin showed an interaction with 
GST, it was decided to perform these experiments as MBP-tagged fusion proteins. 
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However, it was not possible to obtain evaluable results. This was probably due to the 
already mentioned precipitation of β-catenin at very low concentrations. Another expla-
nation might be the formation of bubbles induced upon the contact of the cold sample 
(β-catenin) and the warm cell walls. 
3.2 Identification	 of	 a	 small	 inhibitory	 molecule	 of	 the	 EpCAM-
signaling	cascade	
On healthy, polarized epithelial cells, EpCAM is predominantly found at basolateral 
membranes, whereas on tumor (-initiating) cells, EpCAM is highly overexpressed and 
re-distributed all over the cell surface. Therefore, EpCAM is much less accessible on 
normal epithelial cells, which makes it a very attractive target for immunotherapy. How-
ever, the non-tumor specific expression might also cause side effects in EpCAM-
directed immunotherapy (Baeuerle and Gires, 2009; Balzar et al., 1999; Munz et al., 
2010). Therefore, targeting the intracellular EpCAM-signaling might reveal a more spe-
cific way for treatment of EpCAM-positive cancers. Hence, the aim of this part of the 
project was the establishment and performance of a cell-based HCS and a subsequent 
analysis and characterization of the potential hits in order to obtain a possible lead 
compound for the development of a pharmaceutical drug. 
3.2.1 Principle	of	the	High-Content	Screening	
HCS is a phenotypic screen used in drug discovery for the identification of small inhibi-
tory molecules, which change the spatial and temporal distribution of e.g. a target pro-
tein in a desired manner (Giuliano KA and Haskins JR, 2010; Haney, 2008). For the 
here-performed screening, human embryonic kidney 293 (HEK293) wild-type cells 
were stably transfected with hEpCAM-CTF C-terminally fused to YFP. This hEpCAM-
CTF-YFP construct allows for the spatial detection of EpCAM-CTF-YFP and its cleav-
age product EpICD-YFP within the cell (Figure 3-6A). The CTF-fragment was chosen 
to exclude hits, which target the ADAM17 cleavage because inhibition of this step 
would not be specific for EpCAM (Figure 3-6A, centre scheme). Treatment of the cells 
with compounds could have three possible effects: i) the compound does not affect the 
EpCAM-signaling cascade and therefore no accumulation of YFP would be visible 
(Figure 3-6B, left), ii) the compound inhibits hEpCAM-CTF-YFP cleavage and thereby 
leads to accumulation of hEpCAM-CTF, which would be recognizable by cortical cell 
staining (Figure 3-6B, middle) or iii) the compound leads to accumulation of the intra-
cellular fragment hEpICD-YFP, which would cause completely green shining cells 
(Figure 3-6C, right). If the cells are treated with a compound that has an effect on the 
intracellular EpCAM-signaling cascade, there will be accumulation of YFP-fluorescence 
intensity at the cell membrane, in the cytoplasm or in the nucleus. The fluorescence 
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intensity is calculated separately for each cell region by the Harmony High-Content 
Imaging and Analysis Software and is compared with the intensity measured in the 
respective region in the DMSO control (negative control). If the intensity in the com-
pound-treated cells exceeds a certain predefined threshold, then this compound will be 
regarded as a hit. 
 
Figure 3-6 Principle of High-Conten Screen (HCS) and possible effects. (A) HEK293 cells expressing 
hEpCAM-CTF-YFP (middle) were used for the performance of the HCS. Due to the fusion of YFP to the 
carboxy-terminus of EpCAM, it is possible to determine the localization of EpCAM within the cell. (B) 
Treatment of cells with compounds could have no effect at all (left), lead to accumulation of hEpCAM-CTF-
YFP (middle) or to accumulation of hEpICD-YFP (right). 
3.2.2 Image	Analysis	
In order to calculate the YFP intensities in the different cell regions and to compare 
them with the negative control, the images had to be quantitatively analyzed. Due to 
the staining of the cells (see section 3.2.3.1), the analysis software was able to distin-
guish between three different subcellular compartments: nucleus, cytoplasm and mem-
brane. The image analysis comprised several steps. Based on the input image, the 
cells were detected through Hoechst33342 staining. All nuclei that did not meet certain 
criteria regarding roundness and shape were excluded from further analysis (marked 
red on the image). Afterwards, the cytoplasm was determined through CellMask stain-
ing. Based on this now defined cell structure and the selected population, three subcel-
lular compartments were selected: nucleus, cytoplasm, and membrane. Subsequently, 
YFP-intensities were calculated for all three subcellular compartments (Figure 3-7). 
Since not all of the compartments had the same size and not all of the analyzed imag-
es showed the same number of cells, the YFP-intensities were normalized to region 
size and number of cells. Every pixel in a specific region has a given intensity. All these 
intensities in this region were summed and then divided by the number of pixels com-
posing the region. This was done for every object in the image, i.e. for every cell in-
cluded in the population. These values were summed and then divided by the number 
of objects in the image. This calculation procedure provided values that were normal-
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ized to the region size (dividing the value for the region by the number of pixels) and 
the number of cells (dividing the summed values of all regions by the number of cells). 
 
Figure 3-7 Image analysis. According to the nuclear staining by Hoechst33342 (blue) and cytoplasmic 
staining by CellMask (red), the cells were identified, the population was selected and the cytoplasm was 
defined by the analysis software. Subsequently, the nuclear region, membrane region and cytoplasmic 
regions were selected and the fluorescence intensities were calculated for each region (normalized to 
region size and number of cells). Scale bar represents 50 µm. 
Sometimes nuclei are located close to the membrane of the cells. This may result in 
wrongly included parts of the membrane region to the nucleus region, which would lead 
to a higher intensity in the nucleus region. Therefore, it was decided that only the inner 
40 % of the nucleus should be included into the nucleus region. This led to smaller rati-
os compared with the negative control, which rather corresponded to the observations 
on the images. The same process was done for the cytoplasm region. 
3.2.3 Establishment	of	a	High-Content	Screening	
For the identification of small inhibitory molecules targeting the intracellular EpCAM 
signaling cascade, a suitable HCS setting had to be established. Hence, the optimum 
conditions for imaging (magnification and imaging method), staining of the cells and the 
optimal cell number per well had to be determined. For both, the establishment and the 
performance of the HCS, the Operetta High-Content Imaging System and correspond-
ing analysis software provided by Perkin Elmer were used. 
3.2.3.1 Determination	of	optimal	staining	conditions	
To facilitate an automated discrimination between the three different cellular compart-
ments by the software, the cells had to be stained with fluorescent dyes. Cells were 
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plated on 384-well plates and treated with DMSO (negative control) or the γ-secretase 
inhibitor DAPT. DMSO does not have any influence on the EpCAM-signaling cascade, 
whereas DAPT inhibits γ-secretase cleavage and therefore leads to accumulation of 
EpCAM-CTF at the cell membrane (Maetzel et al., 2009). After staining DMSO- or 
DAPT-treated HEK293 EpCAM-CTF-YFP cells with DRAQ5 (DNA stain), the software 
was able to find the nuclei of the cells. However, detection of the cytoplasm was too 
imprecise in order to obtain reliable results (Figure 3-8A, middle and right pictures). 
This problem was solved by staining with Hoechst33342 (DNA stain) and CellMask 
(plasma membrane stain). As a result, the analysis software was able to find both, the 
nuclei and the cytoplasm (Figure 3-8B, middle and right pictures). 
 
Figure 3-8 Determination of optimal staining method. DAPT-treated HEK293 hEpCAM-CTF-YFP cells 
were stained with DRAQ5 (red) (A) or Hoechst33342 (blue) and CellMask (red) (B). Detection of the nuclei 
was possible with both staining methods (middle pictures) whereas detection of the membranes could only 
be accomplished after Hoechst33342 and CellMask staining (pictures on the right). 
Since the staining of the cells requires a number of additional washing steps and 
HEK293 cells are prone to surface detachment, the screening plates were coated with 
poly-D-lysine prior to seeding of the cells. 
3.2.3.2 Determination	of	optimal	magnification	
For image analysis, it was important that the cells were sufficiently large on the images 
in order to enable the analysis software to distinguish between different cellular com-
partments. Additionally, for time limitations it was not possible to image the complete 
wells but only three sections of each well. Therefore, it was crucial to find a magnifica-
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tion, which, on the one hand, would allow for cell analysis and, on the other hand, 
would cover a sufficiently large area to ensure sufficient cell counts. For the determina-
tion of the optimal magnification, HEK293 hEpCAM-CTF-YFP cells were plated on 384-
well plates, incubated for 22 h with DMSO or the γ-secretase inhibitor DAPT, stained, 
imaged at 40x- and 60x magnification and analyzed. DAPT led to accumulation of 
hEpCAM-CTF-YFP at the cell membrane whereas DMSO did not have any effect on 
the EpCAM signaling cascade (Figure 3-9). Evaluation showed that imaging at 40x 
magnification led to bigger DMSO:DAPT ratios for the YFP-intensity in every cell re-
gion, which corresponds to the manual analysis of the pictures (Figure 3-9A + B). Fur-
thermore, by using the lower magnification, a bigger area of the well was covered, 
which reduced the risk of having an image devoid of cells. Comparison of the evalua-
tion of confocal versus non-confocal imaging revealed that non-confocal led to higher 
ratios (Figure 3-9B + D). However, the differences between the subcellular compart-
ments were considerably smaller. 
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Figure 3-9 Determination of optimal magnification. Pictures and evaluation of DMSO (black) or DAPT 
(red) treated hEpCAM-CTF-YFP cells imaged at 40x magnification, confocal (A) and non-confocal imaging 
(B) and at 60x magnification, confocal (C) and non-confocal imaging (D). Shown is the YFP intensity for 
the whole cell (YFP total) and each region after DMSO- and DAPT treatment. Ratio of DMSO:DAPT is 
depicted above the bars. Scale bar represents 50 µm. Pictures are taken with auto-contrast. 
3.2.3.3 Determination	of	optimal	imaging	method	
For the identification of the imaging method allowing for the best analysis, HEK293 
hEpCAM-CTF-YFP cells were plated on 384-well plates, incubated with DMSO or four 
different DAPT concentrations, stained, imaged with confocal and non-confocal imag-
ing and analyzed. It was decided to perform this experiment with several DAPT con-
centrations in order to reveal if our analysis method is sensitive enough for showing a 
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concentration dependent effect. Treatment with 10 nM DAPT did not have any effect on 
the cells. After treatment with 20 nM DAPT, YFP-accumulation could be seen in some 
of the cells. Incubation of cells with 200 nM DAPT showed an even stronger accumula-
tion of YFP when compared to 10 µM DAPT, which is very likely due to the much high-
er DMSO concentration (1:50 instead of 1:1,000), which was mistakenly used. The 
evaluation also showed a concentration-dependent increase in YFP-fluorescence in-
tensity. In images taken with non-confocal imaging, there is no difference in YFP-
intensity between membrane, cytoplasm, and nucleus visible. In images taken with 
confocal imaging, this difference is visible and is also reflected in the evaluation; here, 
a significant difference in YFP-intensity is detected between membrane and nucleus 
region (p<0.01) and between cytoplasm and nucleus region (p<0.05). 
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Figure 3-10 Determination of optimal imaging method. Evaluation and pictures of DMSO and DAPT 
treated HEK293 hEpCAM-CTF-YFP cells at 40x magnification taken with confocal (A) and non-confocal 
imaging (B). Shown is the YFP-intensity in the whole cell (black), in the membrane region (red), in the 
cytoplasm (blue) and in the nucleus (purple). Confocal imaging is the only way to show the significant 
difference in YFP-intensity between membrane and nucleus region and cytoplasm and nucleus region, 
respectively. Shown are mean values and standard deviations of two independent experiments. Scale bar 
represents 50 µm. Images are taken with auto-contrast. Statistical analysis was performed using paired-
sample t-test. P-values are given above the brackets. 
For obtaining bright images, it was necessary to use a high numerical aperture (NA) 
microscope objective. By using a long working distance objective, the images were 
pale and blurred, which makes image analysis impossible. The disadvantage of the 
high NA objective is that the plates´ edges could not be visualized and thus compounds 
in these wells not be evaluated. 
3.2.3.4 Determination	of	optimal	cell	number	
For a proper screening, it was crucial to use cell densities of a sufficient amount of cells 
for analysis, which simultaneously do not form too large cell clusters. The latter would 
hamper single cell detection. In order to find the optimal cell number per well, 3,000 or 
5,000 HEK293 hEpCAM-CTF-YFP cells per well were plated on 384-well plates, treat-
ed with DMSO or DAPT, stained, imaged with confocal imaging and analyzed. Evalua-
tion showed that both cell numbers led to similar results (Figure 3-11A+B). As can be 
seen in the pictures below (Figure 3-11), plating 5,000 cells per well led to comparably 
large cell clusters, which complicate detection of subcellular compartments. Therefore 
it was decided to perform the HCS with 3,000 cells per well. 
 
Figure 3-11 Determination of optimal cell number. Evaluation and pictures of DMSO and DAPT treated 
HEK293 hEpCAM-CTF-YFP cells at 40x magnification taken with confocal imaging. Either 3,000 cells/well 
(A) or 5,000 cells/well (B) were plated. Shown is the YFP-intensity in the whole cell (black), in the mem-
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brane region (red), in the cytoplasm (blue) and in the nucleus (purple). Both cell numbers led to similar 
results. Shown are mean values and standard deviations. 
3.2.4 Performance	of	High-Content	Screening	and	hit	verification	
After establishing the HCS, the following conditions were chosen for the performance 
of the full screening experiment:  
• 40x magnification, confocal imaging 
• Black 384-well plates coated with poly-D-lysine 
• 3,000 cells/well in 50 µL 
• DMSO (1:1000) and DAPT (10 µM) as negative and positive control, respective-
ly 
• Staining with Hoechst33342 and CellMask 
• Incubation for 16 h 
For the identification of small molecules inhibiting the intracellular EpCAM-signaling 
cascade, four in-house libraries (ChemDiv, ChemBridge, Enamine and Protein-Protein 
Interaction) and one commercial library (FDA-approved drugs) were screened. In the 
screening process each compound was tested in a final concentration of 8 µM, which 
corresponds to a final DMSO concentration of 0.8 %. A DMSO killing curve was con-
ducted prior to the screening in order to confirm the nontoxicity of this DMSO concen-
tration (see supplementary data, Figure 6-1). At least 16 plates were imaged at once. 
Since this process takes several hours, the cells were fixed with paraformaldehyde 
solution so that all images of all cells are taken at equal status. Out of the 100 screen-
ing plates, 66 met the criteria for Z´ factor (0.5 ≤ Z´ ≤ 0.9). In total, 128 out of 26,000 
tested compounds showed an effect on the intracellular EpCAM-signaling cascade, 
which corresponds to a primary hit rate of 0.49 %. Afterwards, a hit picking campaign 
was performed for verification of the 128 small molecules. Therefore, these compounds 
were tested in a five-point serial dilution (80 – 5 µM final concentration) under the same 
conditions as in the initial HCS. In doing so, 81 small inhibitory molecules could be con-
firmed. In order to validate the 81 verified hits, all compounds were re-ordered from the 
respective suppliers and tested in a ten-point serial dilution (80 – 0.15 µM final concen-
tration). With this approach, 59 small molecules could be confirmed (Figure 3-12A). 
Since the read-out of the screen was fluorescence, it was important to exclude false-
positive results arising from the autofluorescent compounds. HEK293 cells stably trans-
fected with hEpCAM-FL were subjected to flow cytometry assessment of YFP fluores-
cence (Figure 3-12B). HEK293 wild-type cells (red) served as reference for YFP-
negative cells, HEK293 hEpCAM-CTF-YFP cells (orange) as reference for YFP-
positive cells. HEK293 EpCAM-FL cells (blue) did not show any shift compared to the 
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HEK293 wild-type cells, which confirms that those cells are indeed YFP-negative. 
HEK293 hEpCAM-FL cells were treated with the respective compounds (80 – 0.15 µM 
final concentration) and were analyzed with regard to fluorescence signal. As a result, 
51 additional compounds were excluded due to autofluorescence (Figure 3-12A). An 
example of an autofluorescent hit is given in Figure 3-12C. Both cell lines, YFP-positive 
(upper panel) and YFP-negative (lower panel) show a fluorescent signal, which de-
creased when reducing the compound concentration. This indicates that the fluores-
cence is due to autofluorescence of the compound. Summarizing the HCS campaign, 
out of 26,000 small inhibitory molecules eight hit molecules were obtained which are 
likely to target the intracellular EpCAM-signaling cascade (Figure 3-12A). 
 
Figure 3-12 Hit verification procedure. (A) Scheme for selecting compound including the number of 
compounds left as well as the verification procedure leading to exclusion. (B) YFP-fluorescence was as-
sessed by FACS analysis by comparing HEK293 hEpCAM-CTF-YFP cells (orange) with HEK293 hEp-
CAM-FL cells (blue). HEK293 wild-type cells (red) served as positive control for YFP-negative cells. (C) 
Example for an autofluorescent compound (compound #12). HEK293 hEpCAM-CTF YFP (upper panel) 
and HEK293 hEpCAM-FL cells (lower panel) were treated with a ten-point serial dilution of compounds 
and analyzed with regard to fluorescence. Scale bar represents 50 µm. 
3.2.5 Further	characterization	of	hits	
Of the remaining eight compounds, seven compounds showed EpCAM-accumulation 
at the membrane up to a concentration of 20 µM (40 µM for compound #51), only com-
pound #66 showed accumulation in the cytoplasm at a concentration of 80 µM (Figure 
3-13).  
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Figure 3-13 Effects of eight high confidence hits on HEK293 hEpCAM-CTF-YFP cells. HEK293 hEp-
CAM-CTF-YFP cells were treated with DMSO, DAPT or compounds. Pictures of compounds are taken 
without auto-contrast. Compound used for treatment of the cells is depicted above the respective picture. 
Scale bar represents 50 µm. 
These eight compounds were considered as high-confidence hits and studied further 
with regards to toxicity, effect on the intramembrane cleavage of hEpCAM, effect on 
the transcriptional level of EpCAM target genes and effect on cell proliferation. Unless 
stated otherwise, compounds were tested at 20 µM concentration, since this was the 
lowest concentration at which most of the compounds showed an effect. All com-
pounds were tested at the same concentration for better comparison. 
3.2.5.1 Cytotoxicity	of	compounds	
Since general cytotoxicity of a compound is detrimental to its use as a potential drug, 
the effects of the eight compounds on viability, cytotoxicity and apoptosis were as-
sessed. For this purpose, the ApoToxGlo-Kit was used, which allows to simultaneously 
measure cell viability, cytotoxicity and apoptosis within one well and therefore enables 
the determination of the mechanism of cell death. For the determination of conditions 
that lead to most reproducible results, different cell numbers, cell plates and positive 
controls were tested. Since the drug staurosporine is known to be toxic and a potent 
inducer of apoptosis, it was decided to use it as positive control. After optimization the 
following conditions were chosen for the performance of the assay: 
• Black 384-well plates 
• 5,000 cells/well in 50 µL 
• DMSO (0.8 %) and staurosporine (80 – 0.15 µM final concentration) as negative 
and positive control, respectively 
• Compounds tested in a ten-fold serial dilution (80 – 0.15 µM final concentration) 
For the detection of a potential EpCAM-specific effect, four different EpCAM-positive 
and –negative cell lines were used. These are EpCAM-negative HEK293 wild-type 
cells, HEK293-hEpCAM-FL cells, and two endogenously EpCAM-expressing cell lines, 
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human colon carcinoma cell line HCT-8 and human hypopharyngeal carcinoma cell line 
FaDu. These cell lines were automatically seeded onto 384-well plates, treated with 
compound, the drug staurosporine as positive control or DMSO as negative control, 
and analyzed after 16 h incubation. Results were related to the DMSO control (Table 
3-1). The experiment was performed in technical triplicates and was conducted twice. 
There were no differences in viability, cytotoxicity or apoptosis between the different 
cell lines, which indicates that there is no EpCAM-specific effect of any compound on 
cell death. Staurosporine, expectedly, led to a strongly decreased viability (--) and 
strongly increased cytotoxicity and apoptosis (++). Compound #7 did not show any 
effects on the cells, whereas compounds #13 and #66 very strongly impaired cell viabil-
ity. Compounds #4, #6, #9, #10 and #51 had only minor effects on the cells (for a de-
tailed presentation of the results, see appendix II). 
Table 3-1 Effects of compounds on cell viability, cytotoxicity and apoptosis. Results are depicted in 
comparison to DMSO control. Since there were no differences between the different cell lines, they are not 
indicated individually. ++: strong increase; +: increase; 0: no difference; -: decrease; --: strong decrease. 
Compound No. Viability Cytotoxicity Apoptosis 
DMSO 0 0 0 
Staurosporine -- ++ ++ 
#4 0 0 + 
#6 - + + 
#7 0 0 0 
#9 - 0 0 
#10 - 0 0 
#13 -- ++ + 
#51 0 0 + 
#66 -- + -- 
 
3.2.5.2 Effects	on	target	gene	expression	
For the investigation of a possible effect of compound-treatment on EpCAM-target 
gene transcription, the expression levels of CCND1, MYC and EPCAM were assessed. 
In order to find an EpCAM-specific effect, HCT-8 wild-type and a CRISPR-Cas9-
mediated EpCAM knock-out clone of HCT-8 cells (Tsaktanis et al., 2015; HCT-8 KO) 
were tested and results were compared. The EpCAM-expression level of these two cell 
lines was confirmed by FACS-analysis (see supplementary data, Figure 6-2). Both cell 
lines were manually plated on 6-well plates and incubated with compounds or DMSO 
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(1:500) or DAPT (10 µM) as controls for 18 h. RNA was extracted from cell lysates and 
reversely transcribed into cDNA, which was then used as a template for RT-PCR. Sev-
eral housekeeping-genes were considered as reference genes and therefore their vari-
ations in expression level after compound treatment were assessed. After comparing 
the cp-values, it was decided to use GAPDH as reference gene. The experiment was 
performed in technical triplicates and was carried out five times. Analysis of relative 
expression levels revealed a significant decrease of CCND1 expression after treatment 
with compound #4, #6, #9, #10, #13, #51 and #66 in HCT-8 wild-type cells (Figure 
3-14A, left panel). In HCT-8 KO cells, compound #4 and #6 led to a significant de-
crease of CCND1 expression level, suggesting an EpCAM-independent effect (Figure 
3-14A, right panel). Comparison of expression levels in wild-type cells and in KO cells 
showed that compound #10 led to significant reduction of CCND1 in HCT-8 wild-type 
cells, which indicates an EpCAM-specific effect. For MYC, none of the compounds 
showed a significant down-regulating effect in any cell line upon compound treatment 
(Figure 3-14B). EPCAM expression levels could only be assessed in HCT-8 wild-type 
cells. Treatment with compound #6, #10 or #51 led to a statistically significant reduction 
(Figure 3-14C). 
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Figure 3-14 Effects on target gene expression. Effects on CCND1 (A), MYC (B) and EPCAM (C) ex-
pression were assessed by RT-PCR with EpCAM-positive HCT-8 wild-type cells (left panels) and EpCAM-
negative HCT-8 KO cells (right panels). For CCND1, compounds #4, #6, #9, #10, #13, #51 and #66 
showed an EpCAM-independent effect in wild-type cells (A, left panel), compounds #4 and #6 in KO cells 
(A, right panel). #10 showed an EpCAM-specific effect. No compound had a down-regulating effect on 
MYC (B). Compounds #6, #10 and #51 reduced EPCAM expression levels in wild-type cells (C). Shown is 
the evaluation of five independent experiments. Whiskers span the 10-90 percentiles. Statistical analysis 
was performed using paired-sample t-test. Small letters depict p-values of t-tests within cell lines (a: 
p<0.05; b: p<0.01; c: p<0.005; d: p<0.001), p-values of t-tests between the cell lines are depicted by an 
asterisk (*: p<0.01). 
These results should be confirmed via Western blot by testing the amount of cyclin D1 
(34 kDa) and EpCAM (35 kDa) after compound treatment in the cells. Therefore, HCT-
8 wild-type cells were manually plated on 6-well plates and treated with DMSO, DAPT 
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or compounds for 18 h. Afterwards, cells were harvested, lysed and cell lysates were 
separated in a 10 % SDS-PAGE and analyzed in immunoblot experiments using anti-
cyclin D1 or anti-EpCAM antibodies. β-actin (46 kDa) was used as loading control. The 
experiment was performed in three biological replicates. Unfortunately, the RT-PCR 
results could not be confirmed by Western blots. Neither of the two proteins showed a 
significant down-regulation upon compound treatment (for blots and evaluation, see 
supplementary data, Figure 6-3).  
3.2.5.3 Effects	on	regulated	intramembrane	cleavage	
The effect of compounds on regulated intramembrane cleavage of hEpCAM was ana-
lyzed in membranes isolated from HEK293-hEpCAM-FL-YFP cells. The fused YFP 
increases the size of the cleavage products and therefore facilitates their detection. 
Cells were cultivated for several days and then harvested and lysed. Via several cen-
trifugation steps, isolated membrane fractions were obtained. Either both, cells and 
isolated membrane fractions (Figure 3-15A), or the isolated membrane fractions alone 
(Figure 3-15B) were incubated with DMSO (control), compounds or a combination of 
known cleavage inhibitors. Cleavage products were separated in a 10 % SDS-PAGE 
and analyzed in immunoblot experiments using anti-GFP antibodies. GAPDH (35 kDa) 
was used as loading control (see supplementary data, Figure 6-4). After 22 h incuba-
tion without inhibitor or with DMSO, hEpCAM-FL-YFP (66 kDa) was cleaved into the 
membrane-associated CTF-YFP (35 kDa) and the soluble ICD of EpCAM (hEpICD-
YFP; 31 kDa). Since the given molecular weights refer to the YFP-fusion constructs, 
25 kDa have to be subtracted in order to determine the actual size of the EpCAM 
cleavage products. Incubation with the ADAM protease inhibitor GI254023X (GI) and β-
secretase inhibitor (C3) led to inhibition of cleavage of hEpCAM-FL-YFP. This inhibits 
the formation of hEpCAM-CTF-YFP, but still allows cleavage of already formed frac-
tions of this fragment to hEpICD-YFP (Figure 3-6A). Inhibition with the aforementioned 
inhibitors and additional inhibition with the γ-secretase inhibitor DAPT, which prevents 
the cleavage of hEpCAM-CTF-YFP, abrogates hEpICD-YFP formation and strongly 
reduces hEpCAM-CTF-YFP formation (Figure 3-15). Treatment of cells and isolated 
membrane fractions with compound #4, #9, #10 and #13 led to slightly weaker 
hEpICD-YFP band on the blots (Figure 3-15B). In order to confirm that these effects 
indeed are EpCAM-dependent effects and not due to the fusion to YFP, HEK293 wild-
type cells stably transfected with YFP were treated and analyzed in the same way. Af-
ter all treatments (DMSO, combinations of known inhibitors or compounds), only the 
YFP band could be detected for all samples at the same intensity, which indicates that 
the detected effects on the EpCAM-cleavage products are not influenced by the YFP-
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fusion. Here again, GAPDH was used as loading control (see supplementary data, Fi-
gure 6-5). This test was performed in three independent experiments. 
 
Figure 3-15 Membrane-based EpCAM-cleavage assay. Isolated membrane fractions from HEK293 
hEpCAM-FL-YFP cells (A) or both isolated membrane fractions and cells (B) were treated as indicated and 
cleavage products were separated in a 10 % SDS-PAGE and probed with anti-GFP antibodies. Incubation 
with GI and C3 led to inhibition of hEpCAM-CTF-YFP formation. Additional DAPT treatment inhibited 
hEpICD formation. Incubation of both cells and isolated membrane fractions with compounds #4, #9, #10 
and #13 led to a reduction of hEpICD-YFP (B). 
The effects of the compounds on EpCAM cleavage were quantified from Western blots 
by calculating intensities of different hEpCAM-YFP bands relative to the respective 
band of the DMSO control (Figure 3-16). Since the HCS was conducted with HEK293 
hEpCAM-CTF-YFP cells, the compounds expectedly did not have any influence on 
hEpCAM-FL-YFP cleavage (Figure 3-16A + D). For hEpCAM-CTF-YFP no significant 
accumulation or decrease could be detected as well (Figure 3-16B + E). In contrast, a 
change in the amount of hEpICD-YFP could be detected: Compound #4 (0.88 ± 
0.04 AU), #9 (0.50 ± 0.16 AU), #10 (0.51 ± 0.16 AU) and #13 (0.28 ± 0.12 AU) showed 
a significant decrease of hEpICD-YFP intensity, which indicates that these compounds 
have an influence on γ-secretase cleavage (Figure 3-16F). According to this evalua-
tion, compound #13 has the strongest effect on regulated intramembrane cleavage, 
followed by compounds #9, #10 and #4. The results of the analysis match the observa-
tions on the Western blots. However, this effect was only visible when cells and the 
isolated membrane fractions were incubated with the compounds. In general it seems 
that this set-up is more efficient than inhibition of the membrane fractions alone, since 
GI/C3/DAPT treatment leads to an even more significant hEpICD-YFP decrease after 
in vitro and in vivo inhibition (Figure 3-16C + F). 
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Figure 3-16 Quantitative Western blot analysis from membrane based EpCAM-cleavage assays. 
Intensities of different hEpCAM-YFP bands relative to the respective DMSO 22 h control band were calcu-
lated. Compound treatment was either performed in isolated membrane fractions only (A-C) or in cells and 
in isolated membrane fractions (D-F). Only after double-treatment, significant changes in hEpICD-YFP 
intensities could be detected. Compounds #4, #9, #10 and #13 show significant down-regulation. Shown 
are mean values and standard deviations from three independent experiments. Statistical significance was 
assessed using paired-sample t-test. P-values are given above the brackets. 
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Tsaktanis et al., 2015 showed that γ-secretase cleavage occurs at two distinct sites in 
the hEpCAM TMD, referred to as γ- and ε-cleavage site. Cleavage at the γ-site is lead-
ing to three Aβ-like cleavage products (γ1, γ2, and γ3), which are released into the sur-
roundings of the cell, whereas γ-secretase cleavage at ε-sites is leading to two 
hEpICD-fragments (ε1 and ε2), which are released into the cytoplasm. These cleavage 
products do not occur to the same extent. Treatment of cells with DAPT abrogates all 
of these cleavage fragments. The effect of compounds #4, #10, and #13 on the for-
mation of these cleavage products was assessed in a MS-based approach followed by 
MALDI-TOF read-out. For this experiment, HEK293 hEpCAM-CTF-YFP cells were 
used. The hEpCAM-CTF-YFP construct consists of an N-terminal c-Myc-epitope, 15 aa 
of the extracellular domain, TMD and ICD fused to YFP. Furthermore, FLAG-tag and 
TEV-cleavage site were added between hEpICD and YFP (Figure 3-17A). Those were 
added in order to process the cleavage products into smaller fragments and for detec-
tion. Otherwise a distinction between the cleavage products would not have been pos-
sible, since MALDI has too low resolution at greater masses for such small size differ-
ences. 
 
Figure 3-17 Analysis of intramembrane hEpCAM-cleavage by MS. (A) Scheme of construct used for 
this analysis. A c-Myc-tag was fused N-terminally to CTF-YFP. In order to further process the cleavage 
products, FLAG-tag and TEV-cleavage site were added between hEpICD and YFP. Cleavage products in 
the supernatant (red) or intracellular cleavage products (blue) were enriched by immunoprecipitation be-
fore analyzing them using mass spectrometry. (B) Tabular presentation of expected cleavage fragments 
showing peptide sequence, mark and calculated mass in Dalton (modified from Tsaktanis et al., 2015). 
HEK293-hEpCAM-CTF-YFP cells were treated with DMSO, DAPT or compounds for 
24 h. In order to analyze the cleavage products by mass spectrometry, the superna-
tants were collected and subjected to anti-c-Myc immunoprecipitation (Figure 3-17A, 
red fragment). For analysis of ε-cleavage products, HEK293 hEpCAM-CTF-YFP cells 
were lysed, subjected to anti-YFP immunoprecipitation, followed by TEV-cleavage and 
anti-FLAG immunoprecipitation before the samples were analyzed by mass spectrome-
try (Figure 3-17A, blue fragment). Expected sizes of the cleavage fragments are shown 
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in Figure 3-17B. It was not possible to detect cleavage products after c-Myc immuno-
precipitation in the supernatant. This might be due to a weak binding of the antibody to 
the protein. Another more likely explanation is that the protein in the sample is only 
available in low levels. In a test experiment, γ-cleavage products were detectable in 
very small amounts compared to ε-cleavage products (30-50 AU and 4,000-10,000 AU, 
respectively; see supplementary data, Figure 6-6). While analyzing the cleavage prod-
ucts enriched from cell lysates, only fragments with a molecular weight of approximate-
ly 30 kDa could be detected, which refers to the CTF-FLAG-TEV-YFP fragment. This 
might indicate that TEV-cleavage was not working properly. Since TEV-cleavage and 
the following FLAG-specific immunoprecipitation are sources of error, it was decided to 
not conduct these steps. However, this limited the ability to distinguish between ε1 and 
ε2, since MALDI has too low resolution at 30 kDa for such small size differences 
(212.29 Da). It could be shown that the amount of hEpICD-FLAG-TEV-YFP, which 
arises by cleavage at ε-cleavage sites, was reduced after treatment with compound #4, 
#10 or #13. However, DAPT treatment led to an even more pronounced effect (Figure 
3-18). This experiment was conducted in three biological independent experiments. 
 
Figure 3-18 Representative mass spectrum of ε-cleavage. Shown are peaks of hEpICD-FLAG-TEV-
YFP (≈30 kDa) after treatment of cells with DMSO (blue), DAPT (purple), compound #4 (green), #10 (red) 
and #13 (yellow). Treatment with compounds distinctly reduced the amount of cleavage products com-
pared to DMSO treatment, however, to a lesser extent than DAPT treatment. Shown is one representative 
spectrum out of three independent experiments. 
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3.2.5.4 Effect	on	proliferation	of	cells	
For addressing a potential EpCAM-specific effect of the compounds on cell prolifera-
tion, HCT-8 wild-type (Figure 3-19A) and EpCAM-KO cells (Figure 3-19B) were auto-
matically seeded on a 96-well plate and treated with compounds, DAPT or DMSO. 
Over a period of seven days, the cell numbers were determined on a daily basis using 
Hoechst3342 staining and the automated Operetta Imaging System. The experiment 
was performed in duplicates and conducted two times. None of the compounds 
showed a significant difference between EpCAM-positive and –negative cells. Com-
pound #66 did not have any effect on cell proliferation. Compounds #9, #10 and #7 had 
minor effects on the proliferation of HCT-8 wild-type and KO cells, whereas compounds 
#4, #6, #13 and #51 almost completely inhibited proliferation of both cell lines (Figure 
3-19). 
 
Figure 3-19 Effect on cell proliferation. HCT-8 wild-type (A) and KO-cells (B) were treated with DMSO, 
DAPT or compounds and cell number was assessed on a daily basis. None of the compounds showed an 
EpCAM-specific effect. Compound #66 did not have any influence on cell proliferation, compounds #7, #9 
and #10 had a slight influence and compounds #51, #13, #4 and #6 almost completely inhibited cell prolif-
eration. Shown are mean values and standard deviations from two independent experiments. 
3.2.6 Screening	of	analogs	
Based on the above-described results, analogs of compounds #4, #9, #10 and #13 
were selected. In total, 39 new compounds were assessed: 13 analogs of compound 
#4, four analogs of compound #9, 13 analogs of compound #10 and nine analogs of 
compound #13 were ordered from the respective supplier. All of these compounds, 
including the four original compounds, were tested in a ten-point serial-dilution (80 – 
0.15 µM final concentration) with HEK293 hEpCAM-CTF-YFP cells under the same 
conditions as in the original screening campaign as described in section 3.2.4. The 
effects of the analogs were manually assessed and compared with the results of the 
original hits regarding their efficiency and toxicity. If an analog showed comparable or a 
better effect with simultaneously less toxicity, this compound was used for further stud-
ies. Furthermore, a possible autofluorescence of the analogs was assessed. Therefore, 
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YFP-negative HEK293 hEpCAM-FL cells were also treated with a ten-point serial-
dilution (80 – 0.15 µM final concentration) of the compounds and analyzed with regard 
to fluorescence signal. This confirmed that none of the analogs showed autofluores-
cence. In summary, nine out of 39 analogs were chosen for further studies (Figure 
3-20): one analog of compound #4 (#4_7), none of the analogs of compound #9, five 
analogs of compound #10 (#10_4, #10_6, #10_9, #10_10 and #10_12) and two ana-
logs of compound #13 (#13_1 and #13_7).  
 
 
Figure 3-20 Effects of analogs on cells. HEK293 hEpCAM-CTF-YFP cells were treated with DMSO, 
DAPT or analogs. Pictures of analogs are taken without auto-contrast and show effects after treatment at 
20 µM. Treatment of the cells is depicted above the respective picture. Scale bar represents 50 µm.  
3.2.7 Further	characterization	of	analogs	
As before, the chosen analogs were analyzed regarding their toxicity effects, effects on 
regulated intramembrane cleavage of hEpCAM, effects on the transcriptional level of 
EpCAM target genes and effects on cell proliferation. In order to figure out if there is an 
improvement in any of these characteristics, the results of these analyses were com-
pared with the results of the original compounds. Here again, for ensuring a better 
comparability with the original compounds, all analogs were used at a concentration of 
20 µM if not stated otherwise. 
3.2.7.1 Cytotoxicity	of	analogs	
For identification of analogs with improved cellular toxicity characteristics, their effects 
on the viability of the cells were tested. As before, EpCAM-positive (HEK293 hEpCAM-
FL, HCT-8 wild-type and FaDu wild-type cells) and –negative cells (HEK293 wild-type 
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cells) were automatically plated on 384-well plates, treated with DMSO, staurosporine 
(positive control) or compounds and analyzed with the ApoTox Glo Kit after 16 h incu-
bation. The assay was conducted under the same conditions as already described in 
section 3.2.5.1. The experiment was performed in technical triplicates and was carried 
out two times. Results were related to the DMSO control (Table 3-2). There were no 
observable differences in viability, cytotoxicity or apoptosis between the different cell 
lines, which indicate that there is no EpCAM-specific effect. As expected, staurosporine 
led to a strongly decreased viability (--) and strongly increased cytotoxicity and apopto-
sis (++). Compounds #4_7, #10_4, #10_6, #10_10 and #10_12 had some minor effects 
on the viability of the cells. Compound #9 did not show any influence on cell viability. 
Remarkably, none of the analogs of compound #13 showed any toxic effects on the 
cells, whereas the original compound #13 showed a strong reduction in viability (com-
pare Table 3-1). Thus, analogs of compound #13 have an improved toxicity profile. 
Table 3-2 Effects of analogs on cell viability, cytotoxicity and apoptosis. Results are depicted in 
comparison to DMSO control. Since there were no differences between the different cell lines, they are not 
indicated individually. ++: strong increase; +: increase; 0: no difference; -: decrease; --: strong decrease. 
Compound No. Viability Cytotoxicity Apoptosis 
DMSO 0 0 0 
Staurosporine -- ++ ++ 
#4_7 - + 0 
#9 0 0 0 
#10_4 - 0 0 
#10_6 - 0 0 
#10_9 0 0 0 
#10_10 - 0 0 
#10_12 - 0 0 
#13_1 0 0 0 
#13_7 0 0 0 
 
3.2.7.2 Effects	of	analogs	at	transcriptional	level	
Since CCND1 was the only gene for which an EpCAM-specific effect could be shown 
(see section 3.2.5.2), the effect of the analogs on its expression level was analyzed. 
For the investigation of a possible EpCAM-dependent effect on CCND1 expression, 
HCT-8 wild-type (Figure 3-21, left panel) and EpCAM–KO cells (Figure 3-21, right pan-
el) were treated with DMSO (control) or analogs of compound #10. Since this com-
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pound was the only one with an EpCAM-specific effect (section 3.2.5.2), it was decided 
only to test analogs of compound #10. Both cell lines were manually plated on 6-well 
plates and treated with DMSO (1:500), DAPT or analogs. As template for RT-PCR, 
RNA extracted from cell lysates and reversely transcribed into cDNA was used. Just as 
before, GAPDH was used as reference gene. All experiments were performed in tripli-
cates and were conducted five times. Evaluation was done in boxplots. Analysis of 
relative expression levels revealed a significant decrease of CCND1 expression after 
treatment with compound #10_4 and #10_12 in wild-type cells and for #10_12 in KO 
cells. Comparison of the expression levels between wild-type cells and KO-cells re-
vealed a significant down-regulating effect for compound #10_12, which indicates an 
EpCAM-dependent effect (Figure 3-21). 
 
Figure 3-21 Effects on target gene expression. Effects on CCND1 expression were assessed by RT-
PCR with EpCAM-positive HCT-8 wild-type cells (left panel) and EpCAM-negative HCT-8 KO cells (right 
panel). Compounds #10_4 and #10_12 showed an EpCAM-independent effect in wild-type cells, com-
pounds #10_12 as well in KO cells. #10_12 showed an EpCAM-specific effect. Shown is the evaluation of 
five independent experiments. Whiskers span the 10-90 percentiles. Statistical analysis was performed 
using paired-sample t-test. Small letters depict p-values of t-tests within cell lines (a: p<0.05; b: p<0.01; c: 
p<0.005), p-values of t-tests between the cell lines are depicted by an asterisk (*: p<0.01). 
3.2.7.3 Effects	of	analogs	on	regulated	intramembrane	cleavage	
The effect of the selected nine analogs on regulated intramembrane cleavage of hEp-
CAM was analyzed in isolated membranes of HEK293 hEpCAM-YFP cells. As before, 
cells were cultivated for several days and then harvested, lysed and membrane frac-
tions were obtained via different centrifugation steps. Either the cells and the mem-
brane fractions (Figure 3-22B) or the isolated membrane fractions alone (Figure 3-22A) 
were incubated with DMSO, analogs or a combination of known cleavage inhibitors. 
After 22 h incubation, the cleavage products were separated in a 10 % SDS-PAGE and 
visualized in immunoblot experiments using anti-GFP antibodies. GAPDH (35 kDa) 
was used as loading control (see supplementary data, Figure 6-7). The experiment was 
performed in three biological replicates. For detailed explanation of expected cleavage 
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products after treatment with already known inhibitors, see section 3.2.5.3. After incu-
bation of both cells and isolated membrane fractions with compound #13_1, #13_7, 
#10_6 and #10_12, the hEpICD-YFP band seemed to have a lesser intensity than the 
respective band of the DMSO 22 h control. 
 
Figure 3-22 Membrane based EpCAM-cleavage assay. HEK293 hEpCAM-FL-YFP cells and isolated 
membrane fractions (B) or membrane fractions only (A) were treated as indicated and cleavage products 
were separated in a 10 % SDS-PAGE and probed with anti-GFP antibodies. Incubation of both cells and 
isolated membrane fractions with compounds #13_1, #13_7, and #10_12 led to a reduction of hEpICD-
YFP (B). 
The effects of the analogs on regulated intramembrane cleavage of EpCAM were 
quantified from Western blot analysis. Thereby, intensities of different hEpCAM-YFP 
bands were calculated and normalized to the respective band of the control with 22 h of 
DMSO treatment. As before, none of the analogs showed a significant effect on hEp-
CAM-FL-YFP, which was as expected (Figure 3-23A + D). The results of hEpCAM-
CTF-YFP are difficult to interpret due to the high standard deviations (Figure 3-23B + 
E). However, a significant change in the intensities of hEpICD-YFP could be detected: 
Compound #10_12 (0.42 ± 0.22 AU) and #13_1 (0.34 ± 0.21 AU) led to a significant 
decrease of hEpICD-YFP intensity, which indicates that these compounds have an 
influence on γ-secretase cleavage (Figure 3-23F). For compounds #10_6 and #13_7, 
the EpICD-YFP band seemed to be weaker than the band of the DMSO control (Figure 
3-22B). However, this apparent observation made after Western blot was not reflected 
in the quantitative analysis. The changes in intensity (0.5 ± 0.31 AU and 0.74 ± 0.36 
AU, respectively) were not significant (Figure 3-23F). According to this evaluation, 
compound #13_1 has a stronger effect on regulated intramembrane EpCAM-cleavage 
than compound #10_12. However, compared with the effects of the original com-
pounds #10 and #13, the two analogs showed much weaker effects (compare Figure 
3-16F and Figure 3-23F). Here again, effects were only visible when cells and the iso-
lated membrane fractions were incubated with the compounds. 
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Figure 3-23 Quantitative Western blot analysis from membrane based EpCAM-cleavage assays. 
Intensities of different hEpCAM-YFP bands relative to the respective DMSO control band were calculated. 
Treatment with analogs was either performed in isolated membrane fractions only (A-C) or in cells and in 
isolated membrane fractions (D-F). Only after double-treatment, significant changes in hEpICD-YFP inten-
sities could be detected. Compounds #10_12 and #13_1 show significant down-regulation. Shown are 
mean values and standard deviations from three independent experiments. Statistical significance was 
assessed using paired-sample t-test. P-values are given above the brackets. 
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3.2.7.4 Effects	of	analogs	on	proliferation	
In order to address a potential EpCAM-specific effect of analogs on cell proliferation, 
HCT-8 wild-type and EpCAM-KO cells were treated with analogs of compound #10, 
DAPT or DMSO as control. Both cell lines were automatically plated on 96-well plates 
and treated as indicated. Cell numbers were automatically counted every day for a total 
duration of seven days based on Hoechst3342 staining using the automated Operetta 
Imaging System. The experiments were performed in duplicates and were carried out 
twice. No difference could be detected between EpCAM-positive and –negative cells 
for any compound. Additionally, none of the analogs of compound #10 showed any 
effect on cell proliferation (Figure 3-24A + B). Analogs of compound #4 and #13 were 
only tested regarding their effects on proliferation of HCT-8 wild-type cells. Compound 
#4_7 and compound #13_7 had minor effects on the proliferation of HCT-8 wild-type 
cells (Figure 3-24A). In contrast, compound #13_1 strongly inhibited proliferation of 
these cells. The original compounds #4 and #13 showed a much stronger inhibition of 
proliferation of both cell lines (compare Figure 3-19 and Figure 3-24A). The effects of 
analogs of compounds #4 and #13 on cell proliferation of HCT-8 KO cells were not 
tested, since compound #10 seems to be the only molecule which displayed EpCAM-
specific effects (see section 3.2.5.4).  
 
Figure 3-24 Effect on proliferation. HCT-8 wild-type (A) and KO-cells (B) were treated with DMSO, 
DAPT or compounds and cell number was assessed on a daily basis. None of the compounds showed an 
EpCAM-specific effect. Compound #13_1 strongly inhibited cell proliferation of wild-type cells whereas 
compounds #4_7 and #13_7 only had a minor influence. All the other analogs did not have an influence on 
cell proliferation. Shown are the mean values and standard deviations from two independent experiments. 
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4 Discussion	
4.1 Interaction	of	FHL2	with	EpICD	and	β-catenin	
EpCAM is a transmembrane protein which is highly overexpressed in carcinoma cells. 
After sequential cleavage by TACE/ADAM17 and γ-secretase, EpICD is released into 
the cytoplasm. This fragment is part of a complex furthermore consisting of FHL2 and 
β-catenin. The complex translocates into the nucleus and activates the transcription of 
EpCAM target genes (Maetzel et al., 2009). Due to the cancer-specific overexpression, 
EpCAM is an attractive target for cancer therapy. There have been immunotherapeutic 
approaches. However, targeting of the intracellular EpCAM signaling cascade is a 
completely new and promising approach (Oishi et al., 2014). For instance, inhibition of 
formation of the nuclear complex is one possibility of specifically disrupting the intracel-
lular EpCAM signaling cascade. If the binding sites of the participating proteins were 
known, it could be easier to design/find a small inhibitory molecule. However, in this 
study it was not possible to confirm the interaction between the key players FHL2 and 
EpICD.  
A yeast two-hybrid screen revealed an interaction of EpICD and FHL2, which was later 
reconfirmed in combined immunoprecipitation and blotting experiments (Maetzel et al., 
2009). A serial deletion analysis showed that the fourth LIM domain is required for the 
binding (Maetzel et al., 2009). However, the present study did not demonstrate any 
binding of EpICD and FHL2 FL at all: neither in vitro pull down assays nor ITC experi-
ments could reveal an interaction between these two proteins. This seemingly contra-
dicting result might be caused by the different experimental methods, which led to this 
finding. The rate of false positive and false negative results in yeast two-hybrid screens 
was estimated as high as 70 % (Deane et al., 2002). One reason for this is that pro-
teins, which naturally never occur in the same cell compartment or at the same time 
point, might interact when artificially co-expressed. Furthermore, mammalian proteins 
might not be correctly modified in yeast. The yeast two-hybrid system takes place in 
the nucleus, however, there are some proteins, which are not able to interact in the 
yeast nucleus, e.g. proteins of the secretory compartments (Clark, 2006; Koegl and 
Uetz, 2007). Since the FHL2-EpICD interaction could be confirmed by immunoprecipi-
tation, it is unlikely that this result is a false positive result. The immunoprecipitation 
experiments were performed in HEK293 and HCT-8 cells, whereas the in vitro pull 
down assays and ITC experiments in this study were done with recombinant proteins 
from bacteria and insect cells (Maetzel et al., 2009). Proteins that are expressed in 
bacteria do not contain most of the post-translational modifications (PTMs) found in 
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eukaryotes, which however have a strong impact on protein localization, turnover, ac-
tivity state and its interactions (Schein, 1989; Mann and Jensen, 2003). Expression in 
insect cells provides protein with PTMs, however, not all of the mammalian PTMs occur 
in insect cells and furthermore some of them such as glycosylation differ between the 
cell types (Hoss et al., 1990; O´Reilly et al., 1994). Therefore, mammalian cells are 
most suitable for the expression of mammalian proteins since protein folding and PTMs 
are the way they naturally occur in the endogenous protein (Khan et al., 2013). The 
differences in these expression systems could be the reason for the here presented 
divergent results. The FHL2-EpICD interaction might require a PTM that is neither pro-
vided by insect cells nor bacterial cells. Another reason might be a change in protein 
folding due to the expression system or due to the protein-tag, which could not be re-
moved because of protein stability issues (see section 3.1.1). It would also be conceiv-
able that intact, membranous EpCAM is necessary for FHL2 binding, which would 
mean that this interaction would occur before EpCAM cleavage. 
In immunoprecipitation experiments in HEK293 and FaDu cells, β-catenin was co-
precipitated with FHL2, EpICD (and Lef-1 in nuclear extracts; Maetzel et al., 2009). In 
this study, the already published interaction between β-catenin and FHL2 could be re-
confirmed by ITC (Wei et al., 2003). It is difficult to speculate about the physiological 
relevance of the measured Kd, since the concentrations used for ITC experiments are 
much higher than naturally occurring protein concentrations in cells. It was not possible 
to show this interaction by in vitro pull down-assays, which indicates a transient interac-
tion of FHL2 and β-catenin (see section 3.1.3). However, no interaction between β-
catenin and EpICD or β-catenin, EpICD and FHL2 was observed (see section 3.1.3 
and 3.1.4). The reason might be again a missing or changed PTM due to the expres-
sion system. Another possible explanation would be that this interaction requires an 
additional so far unknown binding partner, which mediates the binding between these 
proteins. Since all constructs are cloned in pOPIN vectors, which contain a mammalian 
expression promoter, the next step would be transfection of these constructs into 
mammalian cells in order to harvest molecules more closely representing endogenous 
proteins. 
Since the ternary FHL2-EpICD-β-catenin interaction was not confirmed in this study, it 
was not possible to solve the structure of the nuclear complex. In general, structural 
determination of the nuclear complex might be problematic. Due to the size of purified 
β-catenin (82 kDa) and tagged FHL2 (58 kDa and 74 kDa with GST- and MBP-tag, 
respectively) it is not possible to perform NMR-studies with these proteins. Structural 
determination by X-ray crystallography is restricted insofar that FHL2 is a flexible pro-
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tein, which makes it inaccessible to this method (Buck, 2003; Kadrmas and Beckerle, 
2004). In a yeast two-hybrid system it was shown that FHL2 FL is required for the in-
teraction with β-catenin. Deletion of one or more LIM-domains drastically reduced the 
binding of these proteins (Wei et al., 2003). Due to the above-mentioned downsides of 
yeast two-hybrid systems, it might be possible that experiments performed with pro-
teins expressed in mammalian cells lead to different results. If the LIM-domains inter-
acting with β-catenin (or EpICD) are known, it would be easier to define the structure of 
the nuclear complex, since the complex size and the flexibility is reduced. 
4.2 Identification	of	a	small	inhibitory	molecule	
Another possibility of finding a small inhibitory molecule is the establishment and per-
formance of a HCS. For the identification of a compound that specifically inhibits the 
intracellular EpCAM signaling cascade, about 26,000 molecules were tested and ana-
lyzed in an HCS campaign. The primary hits were reconfirmed in a five-point and ten-
point dilution series. The eight obtained hits were regarded as high-confidence hits and 
were further characterized in cell based and in vitro assays regarding their toxicity, 
specificity and effects on cell proliferation and regulated intramembrane proteolysis. 
Compound #4 had minor effects on the intramembrane EpCAM cleavage, but showed 
strong inhibition of cell proliferation. Compound #9 and #10 also showed minor effects 
on regulated intramembrane proteolysis. Furthermore, compound #10 seemed to have 
an EpCAM-specific effect on the down-regulation of CCND1. Compound #13 has a 
strong influence on γ-secretase cleavage, however strongly impaired cell viability as 
well as cell proliferation. No compound showed an EpCAM-dependent effect on cell 
proliferation. In order to improve the effects of these inhibitory molecules, a screening 
of compound analogs was performed. These analogs were tested under the very same 
conditions as the initial compounds. Compounds #13_1 and #13_7 have an improved 
toxicity profile. Compound #10_12 showed an EpCAM-specific down-regulating effect 
on CCND1 expression. However, all analogs had a less effective influence on γ-
secretase cleavage. Moreover, none of the analogs seemed to have an EpCAM-
specific effect on cell proliferation. 
The five-point and ten-point serial dilutions were performed with compounds from stock 
aliquots and newly provided by the supplier, respectively. In some cases, the effect 
shown in the initial HCS campaign was not reproducible. Several reasons might ac-
count for this. Since the whole screening campaign took several months, it might be 
possible that the cells themselves changed in cell culture, which influenced their sensi-
tivity towards the compounds. However, this is rather unlikely since cells were freshly 
thawed for every screening set-up from same cell batches. Furthermore, some other 
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compounds continued to show reproducible effects, including DAPT, which was used 
as positive control. The compounds for HCS are stored in compound plates in DMSO 
at -20 °C and underwent several freeze-thaw cycles, which might have led to degrada-
tion of the compounds. Thus, a degradation product might have been the cause of the-
se effects. Moreover, newly provided compound samples might differ in their purity and 
identity of possible contaminants. 
A similar screen has already been performed (Henrich et al., 2013). This identified 
compounds, which inhibited EpCAM-dependent growth of hepatocellular carcinoma 
cells (HCCs) in consequence of reduction of EpCAM expression. EpCAM-positive and 
–negative HCCs were treated with compounds and confirmed differentially active com-
pounds were further characterized regarding their effect on EpCAM expression. In do-
ing so, three compounds that affect EpCAM-dependent growth have been found. The-
se were identified as STAT5 inhibitor, α-adrenoreceptor antagonist and RORγ inhibitor. 
Since this screen was based on changes in cell numbers and expression levels, it was 
not possible to elucidate the molecular mechanism of action for these compounds. A 
clear advantage of the here-performed HCS is that by measuring an increase in YFP-
fluorescence in a specific subcellular compartment, one is able to narrow down the 
possible mode of actions of the hits. Additionally, further characterization of a given 
compound and its effect can be done in a more focused way. 
A downside of the here-performed HCS campaign is that with the employed evaluation 
method, it is not possible to discriminate whether an autofluorescent compound might 
not also have an actual effect on the intracellular EpCAM-signaling cascade. So there 
is a certain possibility that a compound was excluded from further investigation due to 
autofluorescence despite of being effective (false negative result). No compound which 
led to YFP-accumulation at the cell membrane was excluded because of autofluores-
cence. All autofluorescent compounds caused an increase of YFP-fluorescence in the 
cytoplasm and/or nucleus. This effect could be caused by proteasome inhibition, inhibi-
tion of nuclear complex formation or inhibition of nuclear translocation of the complex. 
In order to be able to exclude the possibility of a false negative result, all auto-
fluorescent compounds need to be tested if they inhibit one of the above mentioned 
steps. This could be done by IP experiments or with the aid of special kits e.g. pro-
teasome activity kit or nuclear translocation assay. However, due to the large number 
of autofluorescent compounds (51 molecules), this would be a very time and money 
consuming process. 
After investigating the effects of the eight high-confidence hits on cell viability, prolifera-
tion, target gene expression and regulated intramembrane proteolysis, four compounds 
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showed promising results: Compounds #4, #9, #10 and #13. Therefore, analogs of 
these compounds were chosen and investigated under the same considerations as 
before. By comparing the effects of the analogs with the original compound, it was pos-
sible to analyze the structure-activity relationship (SAR; conducted by Dr. Manfred 
Rösner, Rösner Consulting Group). For the efficacy of compound #4, a 2-
methoxysubstitution on the right-hand aromatic ring seemed to be crucial. If this substi-
tution is in any other position, the compound will lose efficacy (e.g. compounds #4_2 
and #4_5). The fluorine compounds have a very weak effect (#4_3 and #4_4). The only 
alternative is a Cl-substitution instead of a methoxysubstitution; however, this com-
pound #4_6 was more toxic than #4_0 and less effective. Compounds #4_7 and #4_9 
have a Cl and F substitution at the left aromatic ring, respectively. Additionally, they 
show a benzyl-cycloalkylamin at the right aromatic ring. The cycloalkyl seemed to be 
important, since derivatives without this residue do not have any effect (e.g. #4_10 and 
#4_13). The structures of compound #9 and #10 have a very similar scaffold. It seems 
that a secondary amine (R1-NH-R2) has a somewhat better efficacy than N-substitution. 
For analogs of #13_0, it was shown that a benzyl group drastically reduces cytotoxicity 
but shows comparable effectiveness (#13_1). Moreover, compounds substituted at the 
exo-N (#13_5-#13_9) also show similar effects and toxicity as the analogs, which are 
substituted at the N within the aromatic ring. The benzyl group reduces the cytotoxicity 
of these compounds as well. In general, compound #4 and #13 are structurally similar. 
All benzyl-substituted derivatives show the best effects and additionally decrease cellu-
lar toxicity for analogs of compound #13_0. For molecular structures of compounds, 
see appendix II. 
The effects of the compounds and their analogs on regulated intramembrane proteoly-
sis were analyzed in membrane based EpCAM cleavage assays (see sections 3.2.5.3 
and 3.2.7.3). Two different approaches have been applied: incubation of cells and iso-
lated membrane fractions with compounds and incubation of only isolated membrane 
fractions. It was demonstrated, however, that incubation of isolated membrane frac-
tions failed to have any significant effect on intramembrane EpCAM-cleavage. An effect 
was only detectable when the cells were treated with compounds as well. This indi-
cates that the compounds do not directly interfere with EpCAM-cleavage by γ-
secretase e.g. via blocking the cleavage sites of EpCAM but rather have an indirect 
effect e.g. via inhibition of binding of necessary co-factors for cleavage. It would be 
possible that FHL2-EpCAM binding is required for γ-secretase cleavage. If the cells are 
incubated with the compounds and binding is affected, there will not be any cleavage of 
EpCAM neither in the cells nor in the isolated membrane fractions. If, however, only the 
isolated membrane fractions are treated with the compounds, then FHL2-EpCAM bind-
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ing will occur within the cell. The FHL2-EpCAM complex might be still bound together 
after isolation of the membrane fractions, which would then allow for intramembrane 
cleavage of EpCAM despite compound treatment. DAPT, which is a highly specific γ-
secretase inhibitor, leads to a significant effect in both set-ups (Geling et al., 2002). 
Since the compounds identified in the HCS only have an effect after additional incuba-
tion with the cells, it is an indication as well that they are not direct inhibitors of γ-
secretase cleavage. Furthermore, it seems that the effect caused by the compounds 
does not lead to a complete inhibition of intramembrane EpCAM-cleavage, since there 
is still a reasonable amount of detectable EpICD compared to treatment with DAPT 
(Figure 3-16 and Figure 3-23). 
Another important issue is the selectivity of the compounds: do the compounds interact 
with EpCAM or γ-secretase? An interaction with EpCAM is preferable since this would 
be a specific inhibition of the EpCAM signaling cascade. An interference with γ-
secretase would also have an influence on numerous other signaling pathways, which 
would cause unintended side effects when this molecule is used as a drug in cancer 
therapy. If the identified compounds affect γ-secretase, then they should also influence 
the cleavage of other γ-secretase substrates such as β-amyloid precursor protein 
(APP) or Notch (De Strooper et al., 1999; Zhang et al., 2012). This issue should be 
clarified in collaboration with Johannes Trambauer (group of Prof. Dr. Harald Steiner, 
DZNE, München). Therefore, APP-expressing cells were treated with the compounds 
of interest (#4, #10, and #13) and their influence on the amount of cleavage products 
was investigated. Since all compounds influenced APP-cleavage, most likely none of 
the small inhibitory molecules specifically interfere with cleavage of EpCAM, but rather 
generally influence γ-secretase cleavage. However, the degree of influence differs be-
tween the cleavage products. Compound #13 has the strongest impact on EpCAM-
cleavage followed by compound #10 and #4, whereas with respect to APP-cleavage 
compounds #4 and #10 had the strongest. Compound #13 did not have any significant 
effect on APP-cleavage. A next experimental step in the analyses would be to reveal if 
these compounds interfere with Notch-cleavage as well and if so, to what extent. 
A possible explanation for this result might be that the compounds interfere with sub-
strate recognition. It was shown that Nicastrin (Nct) is essential for the binding and 
recognition of the substrate as well as for the maturation of γ-secretase (Chung and 
Struhl, 2001; Shah et al., 2005). After shedding of the substrate, Nct binds the free N-
terminus (Figure 4-1A). Afterwards, the substrate is either translocated into the catalytic 
site or it kinks in order to position the scissile bond within the catalytic site (Figure 
4-1B). Inhibition of this interaction dramatically reduces substrate binding and eventual-
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ly γ-secretase activity (Beel and Sanders, 2008). The compounds could possibly influ-
ence substrate recognition by interacting with the N-terminus of the substrate. This 
would explain the differential activity towards different substrates. If the compounds 
affected substrate recognition via Nct-binding, then one compound should always have 
the same effect regardless of the substrate. An interference of the compounds with γ-
secretase´s catalytic site, which is separated from the substrate-binding site, seems 
also unlikely, since then a compound should have the same effect for every substrate 
as well (Kornilova et al., 2005). 
 
Figure 4-1 Model for substrate recognition and –cleavage of γ-secretase. (A) After ectodomain shed-
ding, the free N-terminus of the substrate (white) is bound by Nicastrin (Nct, black). This leads to position-
ing of the substrate to the substrate-binding site. (B) Subsequently, the substrate either translocates or 
kinks in order to position the scissile bond within the catalytic site (from Beel and Sanders, 2008). 
γ-secretase is a multiprotein complex consisting of Presenilin (PS), Nct, anterior phar-
ynx defective-1 (Aph-1), and presenilin enhancer-2 (Pen2). All of these components 
are necessary for both in vivo and in vitro activity (Edbauer et al., 2003; Kimberly et al., 
2003; Fraering et al., 2004). PS represents the catalytic core of the complex, Nct is 
essential for substrate recognition, Aph-1 plays a crucial role in the assembly and stabi-
lization of the γ-secretase complex and PS-2 causes PS endoproteolysis (Wolfe et al., 
1999; Brunkan et al., 2005; Niimura et al., 2005; Shah et al., 2005). The molecular stoi-
chiometry of the complex was determined to be 1:1:1:1 (for Ps:Nct:Aph-1:Pen-2). It has 
not yet been finally clarified whether there are non-essential co-factors (Sato et al., 
2007; Beel and Sanders, 2008). It seems unlikely that the here-identified compounds 
interfere with the assembly of the γ-secretase complex. This is a fundamental process 
and disruption should have a larger impact on the cleavage than by the compounds 
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seen in this study. Furthermore, all γ-secretase substrates should be affected to the 
same extent if the complex assembly is disturbed.  
Another possibility for identification of compounds´ binding partner is to analyze the 
changes in biophysical properties upon drug binding. The basis of this assay is that the 
thermal stability of a protein changes upon binding to a ligand (Lo et al., 2004). There-
fore, purified proteins are heated at increasing temperatures in the presence or ab-
sence of the small inhibitory molecule of interest. Due to the heat denaturation, the 
protein´s hydrophobic parts are exposed, which can be measured with a fluorescence 
dye. Binding of the protein to the ligand causes differences in denaturation temperature 
(Niesen et al., 2007). This principle can also be used in living cells or whole cell lysates 
and is called cellular thermal shift assay (CETSA). Thereby, cells are treated with com-
pounds or the vehicle control and are heated with increasing temperatures. Afterwards, 
the protein of interest is detected via Western blot (Martinez Molina et al., 2013; Jafari 
et al., 2014). This experiment could be performed either with whole cell lysates or with 
isolated membrane fractions. Protein detection would occur either with anti-EpCAM or 
anti-γ-secretase antibodies. A variant of this assay is the isothermal dose response 
(ITDR): cells or cell lysates are incubated at the same temperature, but treated with 
increasing ligand concentrations. The protein stability increases with increasing con-
centrations and facilitates the determination of affinity values for half maximal stabiliza-
tion (Martinez Molina et al., 2013). Provided that the compounds interfere with FHL2-
EpCAM binding and that this interaction is the prerequisite for γ-secretase cleavage 
(see above), it would be possible to identify the interaction partner by CETSA. The cells 
or cell lysates would be heated and protein detection would be done by either anti-
EpCAM or anti-FHL2 antibodies. 
EpCAM regulates both CMYC and CCND1 expression at the transcriptional level 
(Munz et al., 2004; Chaves-Perez et al., 2013). Therefore, it was investigated if the 
compounds have an effect on the transcription of these EpCAM-target genes. None of 
the compounds had an effect on CMYC (see section 3.2.5.2). Except for compound #7, 
all eight high-confidence hits had a down-regulating effect on CCND1 expression in 
HCT-8 wild-type cells. When comparing these results with the effects in HCT-8 Ep-
CAM-KO cells, it was shown that only compound #10 had an EpCAM-dependent effect. 
This indicates that the other compounds have an influence on CCND1 expression as 
well, however, in an EpCAM-independent manner. In comparison to the already pub-
lished results, the down-regulating effect of compound #10 is very weak. The published 
results, however, were obtained after transfection with small interfering RNA (siRNA), 
which is possibly more effective than compound #10 (Chaves-Perez et al., 2013). Ep-
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CAM siRNA leads to degradation of EpCAM messenger RNA (mRNA), which leads to 
a strong down-regulation of EpCAM (Agrawal et al., 2013). Compound #10, however, 
does not have an influence on EPCAM expression, it solely impairs intramembrane 
cleavage to a certain degree. This might explain the significantly poorer effect of this 
small inhibitory molecule in comparison to the published results. 
The effect shown for CCND1 and EPCAM on the transcriptional level (see section 
3.2.5.2) should be investigated on the protein level as well, since down-regulation also 
led to a reduction of cyclin D1 at the protein level (Chaves-Perez et al., 2013). There-
fore, HCT-8 wild-type cells were treated with compounds and the lysates were ana-
lyzed by Western blot. Neither cyclinD1 nor EpCAM were significantly down-regulated 
after compound treatment (see section 3.2.5.2). A possible explanation is again a 
stronger effectiveness of siRNA-mediated down-regulation (Chaves-Perez et al., 2013). 
Another reason might be the duration of the treatment. Cyclin D1 started to decrease 
after 24 h incubation time and almost completely disappeared after 48 h. In the present 
study, cells were treated with compounds for 18 h. Possibly, an extended incubation 
time could lead to a positive result. Strangely, treatment with the γ-secretase inhibitor 
DAPT did not affect target gene expression at all. After being subjected to RIP, the 
cleaved intracellular EpCAM fragment is thought to be responsible for the activation of 
target genes (Maetzel et al., 2009; Chaves-Perez et al., 2013). Therefore, inhibition of 
formation of this fragment should inhibit target gene expression. It was already shown 
that DAPT treatment, which inhibits cleavage of EpCAM-CTF, eventually results in re-
duced expression of c-Myc and E-FABP (Maetzel et al., 2009). However, this experi-
ment was performed in HEK293 hEpCAM-YFP cells whereas the experiments in the 
present study were conducted with endogenously EpCAM-expressing HCT-8 cells. 
There might be small differences in the EpCAM signaling pathways between these two 
cell lines, which might account for the differing outcomes. 
It was shown that EpCAM directly influences cell cycle regulation and eventually cell 
proliferation via the cyclin-regulated pathway. In general, EpCAM overexpression is 
associated with an increased cell proliferation, whereas EpCAM down-regulation caus-
es a decrease of cell proliferation (Munz et al., 2004; Wenqi et al., 2009; Chaves-Perez 
et al., 2013). Thus, it was decided to examine if an inhibition of the intracellular signal-
ing cascade will lead to a decreased cell proliferation. Therefore, the compounds were 
tested regarding their effect on cell proliferation in HCT-8 wild-type and HCT-8 EpCAM-
KO cells. Thereby, it was shown that compounds #4, #6, #13 and #51 strongly im-
paired cell proliferation for both cell lines. This indicates that these compounds influ-
ence cell proliferation in an EpCAM-independent way. If these compounds adversely 
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affect γ-secretase cleavage in general, it might be possible that several fundamental 
processes are disturbed in these cells, which eventually results in severely restricted 
cell proliferation. Again, DAPT treatment did not influence cell proliferation, which was 
unexpected. 
In summary, the present study describes the discovery of small inhibitory molecules, 
which interfere with the regulated intramembrane proteolysis of EpCAM. However, the 
molecular targets and mechanisms of inhibition still remain elusive. Furthermore, it 
needs to be investigated in more depth if these identified compounds may not actually 
influence EpCAM target gene expression. Neverthelss, targeting the intracellular Ep-
CAM signaling cascade is a very promising and innovative strategy for the identification 
of a specific small inhibitory molecule as a potential pharmaceutical drug for EpCAM-
positive tumors. 
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5 Appendix	I	
5.1 Abbreviations	
Table 5-1 Abbreviations 
% Percent IP Immunoprecipitation 
°C Degree Celsius IPTG Isopropyl-β-D-thiogalactopyranosid 
x g Times standard gravity IDTR Isothermal dose response  
µ Micro k Kilo 
A260, A280, 
A562 
Absorption at wavelength 260 nm/ 
280 nm/ 562 nm 
Kan Kanamycin 
A Alanine (aa), adenine (DNA), 
Ampere 
KCl Potassium chloride 
aa Amino acid L Liter 
ACT Activator of CREM in testis Lef-1 Lymphoid enhancer binding factor-1 
Amp Ampicillin LRP5/6 Lipoprotein receptor related protein 
5/6 
AML Acute myeloid leukemia m Milli, meter 
AP-1/2 Activator protein-1/-2 M Methionine (protein), mol/L 
APC Adenomatous-polyposis-coli pro-
tein 
MALDI Matrix assisted laser desorption ioni-
sation 
Aph-1 Anterior pharynx defective-1 MBP Maltose binding protein 
AR Androgen receptor MEF-2 Myocyte enhancer factor-2 
Arm Armadillo MES Mesenchymal to epithelial transition 
AU Arbitrary unit min Minute 
APP Amyloid precursor protein MAP Mitogen activated protein 
BAC Bacterial artifical chromosome MMP-7 Matrix metalloproteinase-7 
BCA Bicinchonic acid MOPS 3-(N-Morpholino) propanesulfonic acid 
BSA Bovine serum albumin (m/si)RNA (messenger/small interfering) ribonu-
cleic acid 
β-TrCP β-transducin repeats containing 
protein 
MW Molecular weight 
bp Base pair n Nano 
C Cysteine (protein), cytosine (DNA) NaCl Sodiumchloride 
(c)DNA (Complementary) desoxyribonu-
cleic acid 
Nct Nicastrin 
CETSA Cellular Thermal Shift Assay NFκB Nuclear factor kappa-light-chain-
enhancer of activated B-cells 
CHO Chinese hamster ovary NMR Nuclear Magnetic Resonance 
CK1 Casein kinase-1 nt Nucleotide 
CTC Circulating tumor cell NTD N-terminal domain 
CTD C-terminal domain N-term Amino terminus 
CTE Congenital tufting enteropathy OD600 Optical density at 600 nm 
CTF C-terminal fragment o/n Overnight 
CV Column volume PAGE Polyacrylamide gel electrophoresis 
Da Dalton PBS Phosphate buffered saline 
ddH2O Double distilled water PCR Polymerase chain reaction 
DAPT N-[(3,5-Difluorophenyl)acetyl]-L-
alanyl-2-phenyl]glycine-1,1-
dimethylethyl ester 
PDL Poly-D-lysine 
DMEM Dulbecco´s Modified Eagle Medi-
um 
Pen-2 Presenilin enhancer-2 
DMSO Dimethylsulfoxide PFA Paraformaldehyde 
dNTP Deoxyribonucleotide triphosphate pH Potentia hydrogenii 
DTT Dithiothreitol pI Isoelectric point 
E. coli Escherichia coli PI3K Phosphatidylinositol-3 kinase 
EDTA Ethylenediaminetetraaceticacid pRb Retinoblastoma protein 
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E-FABP Epidermal fatty acid binding pro-
tein 
PS Presenilin 
EGF Epidermal growth factor PSF Pyrimidine tract-binding protein-
associated splicing factor 
EpCAM Epithelial cell adhesion molecule PTEN Phosphatase and tensin homolog 
EpEX Extracellular domain of EpCAM PTM Post-translational modification 
(Ep)ICD Intracellular domain (of EpCAM) PVDF Polyvinylidene fluoride 
ESE-1 Ets epithelial specific ets-1 qRT-PCR Quantitative Real Time PCR 
ER Endoplasmatic Reticulum rev Reverse 
FACS Fluorescence activated cell sorter RIP Regulated intramembrane proteolysis 
FBS Fetal bovine serum rpm Rounds per minute 
FDA Food and drug administration RT Room temperature, reverse transcrip-
tase 
FITC Fluorescein isothiocyanate s Second 
FHL2 Four-and-a-half LIM-domains 
protein 2 
SAR Structure-activity relationship 
FL Full length SDS Sodium dodecyl sulfate 
for Forward SEC Size exclusion chromatography 
Fz Frizzled Sp-1 Specificity protein-1 
g Gram, standard gravity SRF Serum response factor 
G Guanine TACE Tumor necrosis factor alpha convert-
ing enzyme 
Gent Gentamycin TCEP Tris-(2-carboxyethyl)-phosphine hy-
drochloride 
GFP Green fluorescent protein TCF Transcription factor 
GSH Glutathione TEM Tetraspanin-enriched microdomains 
GSK3 Glycogen synthase 3 Tet Tetracycline 
GST Glutathione S-transferase TMD Transmembrane domain 
h Hour, human TNFα Tumor-necrosis factor α 
HAI-2 Hepatocyte growth factor activator 
inhibitor-2 
TRIS Tris(hydroxymethyl)aminomethane 
HBV Hepatitis B virus TY Thyroglobulin 
HCC Hepatocellular carcinoma UV Ultraviolet 
HCS High Content Screen V Volt 
HCV Hepatitis C virus v/v Volume per volume 
HEPES (4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid 
Wg Wingless 
HRP Horseradish peroxidase WT Wildtype 
HPV Human Papilloma Virus w/v Weight per volume 
HTS High-Throughput Screening YFP Yellow fluorescent protein 
INFγ Interferon γ ZnCl2 Zinc chloride 
Inr Initiator   
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6 Supplementary	Data	
 
 
Figure 6-1 DMSO killing curve for HEK293 EpCAM-CTF-YFP cells. Cells were plated on a 96-well plate 
and treated with different DMSO concentrations for 18 h. A decrease of viability after DMSO treatment 
could be detected at a concentration of 2.0 % DMSO, which is far beyond the DMSO concentration used in 
the HCS (0.8 %). Cell viability was measured with CellTiter-Blue® Cell Viability Assay. Shown are mean 
values and standard deviations from two independent experiments. 
 
 
Figure 6-2 FACS-analysis of EpCAM-expression on HCT-8 wildtype and EpCAM-KO cells. HCT-8 
wild-type (turquoise) and HCT-8 EPCAM-KO cells (purple) were stained with a GFP-coupled anti-EpCAM 
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antibody. Wild-type cells without antibody (red) were used as negative control. No EpCAM could be de-
tected on the HCT-8 EPCAM-KO cells. 
 
 
Figure 6-3 Western blot analysis of protein expression levels after compound treatment. HCT-8 
wild-type cells were treated as indicated and cyclin D1 (A) and EPCAM (C) protein expression levels were 
analyzed by immunostaining and quantified (B + D). Neither the blots nor the quantification show any 
reduction of protein expression levels after compound treatment. Shown is one representative blot out of 
three independent experiments (A + C). Shown are mean values and standard deviations (B + D). 
 
 
Figure 6-4 GAPDH loading control of membrane-based EpCAM-cleavage assays. HEK293 hEpCAM-
FL-YFP cells and isolated membrane fractions (B) or membrane fractions only (A) were treated as indicat-
ed. Shown is the loading control from blots in Figure 3-15. 
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Figure 6-5 YFP control of membrane-based EpCAM-cleavage assay. Isolated membrane fractions 
from HEK293-YFP cells (A) were treated as indicated and cleavage products were separated in a 10 % 
SDS-PAGE and probed with anti-GFP antibodies. The YFP band was detected at the same intensity for 
every treatment. GAPDH was used as loading control (B). 
 
  Supplementary Data 
92 
 
 
Figure 6-6 Mass spectra of γ-cleavage (A) and ε-cleavage sites (B) of Myc-CTF-Fag-TEV-YFP in 
HEK293. (A) HEK293 cells were treated with DMSO (red) or DAPT (green) to inhibit γ-secretase cleavage. 
Supernatant was collected and subjected to c-Myc IP. Peaks seen after DMSO treatment representing the 
three fragments resulting from γ-cleavage (3919.55 Da, 4018.68 Da, 4117.81 Da) were lacking after DAPT 
treatment. The size difference of approximately 15 Da is very likely due to oxidation of Methionine. (B) 
HEK293 cells were treated with DMSO (blue) or DAPT (red). Cells were lysed and subjected to GFP-IP 
followed by TEV-cleavage and Flag-IP. Peaks seen after DMSO treatment represent the two fragments 
resulting from ε-cleavage (5166.83 Da, 5379.12 Da) were lacking after DAPT treatment. 
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Figure 6-7 GAPDH loading control of membrane-based EpCAM-cleavage assays. HEK293 hEpCAM-
FL-YFP cells and isolated membrane fractions (B) or membrane fractions only (A) were treated as indicat-
ed. Shown is the loading control from blots in Figure 3-22. 
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 1 
A. ApoTox	raw	data	
The tables show the raw data from the ApoTox Assay. Results are shown for FaDu, HCT-8, HEK293 EpCAM-FL and HEK293 wild-type 
cells. The cell type is shown in the top left corner of each table. The compound number is given in the third column. Results for viability are 
shown with orange background, results for cytotoxicity with blue background, and results for apoptosis with green background. Depicted are 
mean values and standard deviations from two independent experiments, each consisting of three replicates. 
 
Table A-1 Raw data for staurosporin treatment. 
FaDu	 		 		 		 		 		 		 		 		 		 		 		
		 Staurosporine	[µM]	 80	 40	 20	 10	 5	 2,50	 1,25	 0,625	 0,313	 0,156	
Viability		 Average	 0,228	 0,209	 0,205	 0,251	 0,317	 0,347	 0,352	 0,376	 0,73	 0,491	
Standard	Deviation	 0,046	 0,036	 0,05	 0,063	 0,066	 0,05	 0,079	 0,063	 0,08	 0,014	
Cytotoxicity		 Average	 3,189	 3,087	 3,098	 3,537	 3,362	 4,07	 3,71	 4,061	 2,559	 2,953	
Standard	Deviation	 1,138	 0,997	 1,204	 1,338	 0,194	 1,072	 0,441	 1,312	 0,502	 0,936	
Apoptosis		
Average	 2,784	 2,652	 2,582	 3,491	 4,924	 4,978	 5,016	 5,605	 3,311	 4,929	
Standard	Deviation	 1,908	 2,053	 2,349	 3,417	 1,03	 0,634	 1,096	 0,581	 0,252	 0,396	
	 	 	 	 	 	 	 	 	 	 	 	HCT-8	 		 		 		 		 		 		 		 		 		 		 		
		 Staurosporine	[µM]	 80	 40	 20	 10	 5	 2,50	 1,25	 0,625	 0,313	 0,156	
Viability		 Average	 0,202	 0,192	 0,182	 0,228	 0,321	 0,355	 0,337	 0,358	 0,703	 0,46	
Standard	Deviation	 0,065	 0,055	 0,057	 0,08	 0,071	 0,107	 0,115	 0,109	 0,192	 0,016	
Cytotoxicity		 Average	 3,653	 3,805	 3,447	 4,009	 5,163	 5,409	 4,954	 5,536	 4,474	 3,523	
Standard	Deviation	 0,093	 0,087	 0,303	 0,164	 2,305	 2,193	 1,915	 2,643	 0,293	 1,584	
Apoptosis		
Average	 2,755	 2,447	 2,357	 2,995	 5,006	 4,804	 4,443	 4,742	 3,564	 4,267	
Standard	Deviation	 1,74	 1,778	 1,94	 2,095	 0,093	 0,485	 0,283	 0,174	 0,65	 0,384	
	 	 	 	 	 	 	 	 	 	 	 	
 2 
HEK293	EpCAM	FL	 		 		 		 		 		 		 		 		 		 		 		
		 Staurosporine	[µM]	 80	 40	 20	 10	 5	 2,50	 1,25	 0,625	 0,313	 0,156	
Viability		
Average	 0,207	 0,19	 0,198	 0,283	 0,353	 0,456	 0,504	 0,553	 0,886	 0,736	
Standard	Deviation	 0,06	 0,057	 0,074	 0,112	 0,123	 0,058	 0,1	 0,139	 0,143	 0,112	
Cytotoxicity		
Average	 3,045	 2,844	 2,687	 2,239	 2,118	 1,823	 1,655	 1,403	 2,303	 1,037	
Standard	Deviation	 1,083	 0,682	 0,666	 0,755	 0,234	 0,757	 0,406	 0,299	 1,991	 0,17	
Apoptosis		
Average	 6,486	 5,835	 3,896	 2,367	 4,723	 4,292	 2,671	 2,384	 1,105	 1,317	
Standard	Deviation	 1,573	 1,418	 1,224	 1,454	 0,581	 1,791	 0,848	 1,031	 0,292	 0,505	
	 	
	 	 	 	 	 	 	 	 	 	
HEK293	wt	 	 		 		 		 		 		 		 		 		 		 		
		 Staurosporine	[µM]	 80	 40	 20	 10	 5	 2,50	 1,25	 0,625	 0,313	 0,156	
Viability		 Average	 0,249	 0,253	 0,247	 0,256	 0,284	 0,376	 0,396	 0,424	 0,798	 0,665	
Standard	Deviation	 0,031	 0,014	 0,011	 0,026	 0,06	 0,107	 0,145	 0,096	 0,085	 0,033	
Cytotoxicity		 Average	 3,479	 3,282	 2,777	 2,247	 2,598	 2,573	 1,893	 1,838	 1,448	 1,441	
Standard	Deviation	 0,037	 0,059	 0,29	 0,002	 0,679	 1,757	 1,169	 1,194	 0,642	 0,537	
Apoptosis		
Average	 3,725	 3,209	 2,765	 2,222	 3,803	 3,02	 2,593	 1,976	 1,216	 1,17	
Standard	Deviation	 2,811	 2,553	 2,019	 1,568	 2,556	 2,745	 2,448	 1,869	 0,418	 0,553	
 
 
Table A-2 Raw data for compound #4_0 
FaDu	 		 		 		 		 		 		 		 		 		 		 		
		 Compound	#4_0	[µM]	 80	 40	 20	 10	 5	 2,50	 1,25	 0,625	 0,313	 0,156	
Viability		 Average	 1,174	 1,13	 1,329	 1,132	 1,26	 1,086	 1,009	 1,061	 1,051	 0,997	
Standard	Deviation	 0,004	 0,111	 0,047	 0,192	 0,056	 0,021	 0,044	 0,001	 0,028	 0,029	
Cytotoxicity		 Average	 1,017	 1,048	 1,061	 0,915	 0,997	 0,897	 0,929	 0,882	 0,97	 0,941	
Standard	Deviation	 0,05	 0,08	 0,187	 0,053	 0,2	 0,115	 0,125	 0,17	 0,111	 0,119	
Apoptosis		
Average	 1,756	 2,033	 1,292	 1,286	 1,194	 1,301	 1,131	 1,177	 1,216	 1,218	
Standard	Deviation	 0,619	 0,599	 0,447	 0,345	 0,369	 0,438	 0,301	 0,3	 0,453	 0,239	
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	 	 	 	 	 	 	 	 	 	 	 	HCT-8	 		 		 		 		 		 		 		 		 		 		 		
		 Compound	#4_0	[µM]	 80	 40	 20	 10	 5	 2,50	 1,25	 0,625	 0,313	 0,156	
Viability		 Average	 1,085	 1,177	 1,276	 1,18	 1,19	 1,084	 1,073	 1,1	 1,007	 1,021	
Standard	Deviation	 0,326	 0,326	 0,326	 0,326	 0,326	 0,326	 0,326	 0,326	 0,326	 0,326	
Cytotoxicity		 Average	 1,084	 1,129	 1,153	 1,063	 0,981	 0,942	 0,931	 0,919	 0,854	 1,089	
Standard	Deviation	 0,098	 0,193	 0,032	 0,058	 0,135	 0,005	 0,037	 0,055	 0,015	 0,396	
Apoptosis		
Average	 1,874	 1,762	 1,266	 1,224	 1,029	 1,127	 1,127	 1,165	 1,172	 1,034	
Standard	Deviation	 0,153	 0,209	 0,057	 0,04	 0,028	 0,025	 0,065	 0,006	 0,088	 0,102	
	 	 	 	 	 	 	 	 	 	 	 	HEK293	EpCAM	FL	 		 		 		 		 		 		 		 		 		 		 		
		 Compound	#4_0	[µM]	 80	 40	 20	 10	 5	 2,50	 1,25	 0,625	 0,313	 0,156	
Viability		 Average	 0,891	 1,039	 1,238	 1,166	 1,255	 1,091	 1,103	 1,168	 1,132	 1,088	
Standard	Deviation	 0,096	 0,333	 0,256	 0,205	 0,181	 0,139	 0,131	 0,071	 0,17	 0,175	
Cytotoxicity		 Average	 1,006	 1,031	 1,589	 0,988	 1,467	 0,975	 0,941	 1,33	 0,988	 0,969	
Standard	Deviation	 0,208	 0,005	 0,922	 0,023	 0,723	 0,031	 0,074	 0,658	 0,043	 0,044	
Apoptosis		
Average	 1,568	 1,46	 1,345	 1,404	 1,325	 1,359	 1,315	 1,15	 1,305	 1,21	
Standard	Deviation	 0,732	 0,49	 0,557	 0,744	 0,694	 0,653	 0,689	 0,49	 0,549	 0,527	
	 	 	 	 	 	 	 	 	 	 	 	HEK293	wt	 	 		 		 		 		 		 		 		 		 		 		
		 Compound	#4_0	[µM]	 80	 40	 20	 10	 5	 2,50	 1,25	 0,625	 0,313	 0,156	
Viability		
Average	 0,847	 0,929	 1,223	 1,052	 1,142	 0,966	 0,942	 1,021	 0,984	 0,787	
Standard	Deviation	 0,002	 0,039	 0,094	 0,05	 0,116	 0,098	 0,044	 0,069	 0,038	 0,274	
Cytotoxicity		
Average	 0,985	 0,979	 0,99	 0,912	 0,874	 0,835	 0,807	 0,828	 0,837	 0,684	
Standard	Deviation	 0,092	 0,131	 0,057	 0,173	 0,177	 0,166	 0,136	 0,16	 0,124	 0,35	
Apoptosis		
Average	 1,409	 1,326	 1,169	 1,146	 1,086	 1,007	 1,002	 1,069	 0,932	 1,105	
Standard	Deviation	 0,144	 0,112	 0,358	 0,163	 0,272	 0,024	 0,141	 0,186	 0,051	 0,159	
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Table A-3 Raw data for compound #6_0. 
FaDu	 		 		 		 		 		 		 		 		 		 		 		
		 Compound	#6_0	[µM]	 80	 40	 20	 10	 5	 2,50	 1,25	 0,625	 0,313	 0,156	
Viability		 Average	 0,532	 1,011	 0,843	 0,814	 0,908	 0,957	 1	 1,064	 1,066	 1,074	
Standard	Deviation	 0,1	 0,105	 0,011	 0,113	 0,21	 0,141	 0,129	 0,082	 0,107	 0,154	
Cytotoxicity		 Average	 1,668	 0,994	 1,197	 1,037	 1,024	 1,065	 0,92	 1,038	 1,013	 1,053	
Standard	Deviation	 0,068	 0,208	 0,19	 0,042	 0,176	 0,126	 0,13	 0,064	 0,255	 0,209	
Apoptosis		
Average	 1,986	 1,604	 3,214	 2,228	 1,497	 1,277	 1,027	 1,131	 1,069	 1,038	
Standard	Deviation	 0,103	 0,152	 1,126	 0,529	 0,057	 0,182	 0,022	 0,086	 0,059	 0,064	
	 	 	 	 	 	 	 	 	 	 	 	HCT-8	 		 		 		 		 		 		 		 		 		 		 		
		 Compound	#6_0	[µM]	 80	 40	 20	 10	 5	 2,50	 1,25	 0,625	 0,313	 0,156	
Viability		 Average	 0,456	 0,963	 0,699	 0,809	 0,849	 0,904	 0,891	 0,956	 0,97	 0,976	
Standard	Deviation	 0,137	 0,117	 0,13	 0,126	 0,104	 0,098	 0,082	 0,027	 0,046	 0,047	
Cytotoxicity		 Average	 1,771	 1,135	 1,175	 1,1	 0,967	 0,988	 0,884	 0,909	 0,919	 0,93	
Standard	Deviation	 0,345	 0,15	 0,126	 0,072	 0,008	 0,014	 0,044	 0,019	 0,04	 0,095	
Apoptosis		
Average	 2,188	 1,637	 3,063	 2,429	 1,487	 1,202	 0,969	 1,045	 1,063	 1,043	
Standard	Deviation	 0,108	 0,503	 1,324	 1,273	 0,403	 0,165	 0,066	 0,249	 0,084	 0,188	
	 	 	 	 	 	 	 	 	 	 	 	HEK293	EpCAM	FL	 		 		 		 		 		 		 		 		 		 		 		
		 Compound	#6_0	[µM]	 80	 40	 20	 10	 5	 2,50	 1,25	 0,625	 0,313	 0,156	
Viability		 Average	 0,475	 0,986	 0,913	 1,019	 1,011	 1,159	 1,13	 1,123	 1,218	 1,316	
Standard	Deviation	 0,145	 0,293	 0,272	 0,299	 0,268	 0,352	 0,212	 0,278	 0,336	 0,434	
Cytotoxicity		 Average	 1,613	 1,478	 1,079	 1,057	 1,057	 1,116	 1,075	 1,045	 1,179	 1,612	
Standard	Deviation	 0,305	 0,626	 0,005	 0,068	 0,064	 0,02	 0,038	 0,023	 0,04	 0,481	
Apoptosis		
Average	 0,895	 0,819	 1,101	 1	 1,092	 1,058	 1,169	 0,959	 1,111	 0,931	
Standard	Deviation	 0,317	 0,046	 0,104	 0,004	 0,181	 0,327	 0,014	 0,271	 0,019	 0,192	
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HEK293	wt	 		 		 		 		 		 		 		 		 		 		 		
		 Compound	#6_0	[µM]	 80	 40	 20	 10	 5	 2,50	 1,25	 0,625	 0,313	 0,156	
Viability		
Average	 0,517	 1,11	 0,901	 0,977	 0,961	 1,056	 1,105	 1,071	 1,134	 1,268	
Standard	Deviation	 0,002	 0,235	 0,161	 0,134	 0,107	 0,194	 0,226	 0,141	 0,138	 0,154	
Cytotoxicity		
Average	 1,909	 1,38	 1,127	 1,147	 1,08	 1,129	 1,149	 1,089	 1,179	 1,258	
Standard	Deviation	 0,27	 0,086	 0,093	 0,05	 0,009	 0,12	 0,138	 0,063	 0,2	 0,033	
Apoptosis		
Average	 1,257	 0,898	 0,846	 0,987	 0,949	 0,972	 0,882	 0,979	 0,986	 1,042	
Standard	Deviation	 0,98	 0,144	 0,121	 0,178	 0,212	 0,03	 0,026	 0,065	 0,144	 0,354	
 
 
Table A-4 Raw data for compound #7_0. 
FaDu	 		 		 		 		 		 		 		 		 		 		 		
		 Compound	#7_0	[µM]	 80	 40	 20	 10	 5	 2,50	 1,25	 0,625	 0,313	 0,156	
Viability		 Average	 0,957	 0,945	 0,882	 1,032	 1,046	 1,03	 0,937	 0,972	 1,041	 1,064	
Standard	Deviation	 0,049	 0,024	 0,301	 0,084	 0,086	 0,009	 0,155	 0,093	 0,003	 0,07	
Cytotoxicity		 Average	 0,907	 0,885	 0,857	 1,009	 1,059	 0,957	 0,955	 0,955	 1,007	 0,966	
Standard	Deviation	 0,038	 0,005	 0,328	 0,127	 0,176	 0,062	 0,206	 0,134	 0,116	 0,156	
Apoptosis		
Average	 1,05	 1,08	 1,042	 1,164	 1,204	 1,179	 1,062	 1,035	 1,086	 1,145	
Standard	Deviation	 0,104	 0,239	 0,037	 0,032	 0,246	 0,238	 0,149	 0,23	 0,053	 0,125	
	 	 	 	 	 	 	 	 	 	 	 	HCT-8	 	 	 	 	 	 	 	 	 	 	 	
		 Compound	#7_0	[µM]	 80	 40	 20	 10	 5	 2,50	 1,25	 0,625	 0,313	 0,156	
Viability		 Average	 0,9	 0,903	 1,013	 0,983	 1,063	 1,074	 1,037	 1,047	 1,021	 1,007	
Standard	Deviation	 0,088	 0,135	 0,044	 0,058	 0	 0,019	 0,002	 0,003	 0,02	 0,001	
Cytotoxicity		 Average	 0,925	 0,861	 0,973	 1,011	 1,006	 1,09	 0,975	 1,068	 0,979	 0,983	
Standard	Deviation	 0,025	 0,024	 0,027	 0,068	 0,061	 0,075	 0,057	 0,079	 0,003	 0,016	
Apoptosis		
Average	 1,083	 1,036	 0,953	 1,064	 1,017	 1,1	 1,092	 1,077	 0,98	 1,063	
Standard	Deviation	 0,097	 0,243	 0,05	 0,006	 0,013	 0,05	 0,025	 0,168	 0,004	 0,057	
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	 	 	 	 	 	 	 	 	 	 	 	HEK293	EpCAM	FL	 		 		 		 		 		 		 		 		 		 		 		
		 Compound	#7_0	[µM]	 80	 40	 20	 10	 5	 2,50	 1,25	 0,625	 0,313	 0,156	
Viability		 Average	 0,834	 0,841	 0,826	 1,083	 1,142	 1,078	 1,075	 1,039	 1,12	 1,15	
Standard	Deviation	 0,113	 0,133	 0,096	 0,211	 0,169	 0,163	 0,148	 0,128	 0,178	 0,145	
Cytotoxicity		 Average	 1,829	 1,019	 0,975	 1,13	 1,413	 1,095	 1,256	 1,034	 1,068	 2,066	
Standard	Deviation	 1,245	 0,183	 0,489	 0,116	 0,483	 0,159	 0,395	 0,199	 0,069	 1,476	
Apoptosis		
Average	 1,531	 1,305	 1,376	 1,208	 1,352	 1,281	 1,257	 1,246	 1,254	 1,205	
Standard	Deviation	 0,191	 0,387	 0,584	 0,182	 0,341	 0,325	 0,274	 0,342	 0,234	 0,258	
	 	 	 	 	 	 	 	 	 	 	 	HEK293	wt	 		 		 		 		 		 		 		 		 		 		 		
		 Compound	#7_0	[µM]	 80	 40	 20	 10	 5	 2,50	 1,25	 0,625	 0,313	 0,156	
Viability		 Average	 0,837	 0,808	 0,957	 0,979	 1,042	 0,854	 0,978	 0,995	 1,03	 1,067	
Standard	Deviation	 0,019	 0,002	 0,005	 0,059	 0,044	 0,287	 0,115	 0,029	 0,047	 0,095	
Cytotoxicity		 Average	 1,076	 0,989	 1,063	 0,97	 0,98	 0,833	 0,869	 0,917	 0,982	 0,868	
Standard	Deviation	 0,152	 0,102	 0,064	 0,15	 0,106	 0,406	 0,148	 0,179	 0,125	 0,165	
Apoptosis		
Average	 0,962	 0,995	 1,006	 0,993	 0,988	 0,872	 0,905	 0,922	 0,971	 0,999	
Standard	Deviation	 0,249	 0,202	 0,116	 0,035	 0,044	 0,051	 0,128	 0,113	 0,152	 0,215	
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Table A-5 Raw data for compound #9_0. 
FaDu	 		 		 		 		 		 		 		 		 		 		 		
		 Compound	#9_0	[µM]	 80	 40	 20	 10	 5	 2,50	 1,25	 0,625	 0,313	 0,156	
Viability		 Average	 0,603	 0,719	 0,974	 0,795	 0,916	 1,034	 1,059	 1,043	 1,008	 1,007	
Standard	Deviation	 0,05	 0,089	 0,066	 0,041	 0,134	 0,14	 0,095	 0,148	 0,189	 0,158	
Cytotoxicity		 Average	 0,636	 0,75	 0,938	 0,904	 1,004	 1,029	 1,014	 1,08	 1,013	 1,011	
Standard	Deviation	 0,04	 0,141	 0,06	 0,014	 0,17	 0,239	 0,133	 0,217	 0,219	 0,191	
Apoptosis		
Average	 0,747	 0,936	 0,902	 0,93	 0,973	 0,979	 1,044	 0,978	 1,006	 1,003	
Standard	Deviation	 0,004	 0,023	 0,013	 0,072	 0,138	 0,03	 0,009	 0,083	 0,139	 0,088	
	 	 	 	 	 	 	 	 	 	 	 	HCT-8	 		 		 		 		 		 		 		 		 		 		 		
		 Compound	#9_0	[µM]	 80	 40	 20	 10	 5	 2,50	 1,25	 0,625	 0,313	 0,156	
Viability		 Average	 0,593	 0,677	 0,872	 0,852	 0,921	 0,992	 0,967	 0,926	 0,999	 0,963	
Standard	Deviation	 0,034	 0,032	 0,052	 0,057	 0,098	 0,081	 0,005	 0,003	 0,034	 0,005	
Cytotoxicity		 Average	 0,819	 0,889	 1,094	 1,089	 1,183	 1,249	 1,213	 1,119	 1,167	 1,15	
Standard	Deviation	 0,032	 0,135	 0,15	 0,038	 0,105	 0,222	 0,204	 0,17	 0,189	 0,127	
Apoptosis		
Average	 0,846	 0,821	 0,825	 0,881	 0,847	 0,916	 0,83	 1,016	 1,073	 1	
Standard	Deviation	 0,053	 0,001	 0,012	 0,086	 0,061	 0,029	 0,006	 0,129	 0,168	 0,147	
	 	 	 	 	 	 	 	 	 	 	 	HEK293	EpCAM	FL	 		 		 		 		 		 		 		 		 		 		 		
		 Compound	#9_0	[µM]	 80	 40	 20	 10	 5	 2,50	 1,25	 0,625	 0,313	 0,156	
Viability		 Average	 0,434	 0,538	 0,932	 0,92	 1,036	 1,167	 1,183	 1,122	 1,202	 1,179	
Standard	Deviation	 0,19	 0,169	 0,331	 0,288	 0,351	 0,302	 0,422	 0,424	 0,372	 0,33	
Cytotoxicity		 Average	 0,66	 0,78	 1,554	 1,026	 1,126	 1,777	 1,889	 1,124	 1,693	 1,147	
Standard	Deviation	 0,039	 0,019	 0,659	 0,005	 0,017	 0,891	 1,101	 0,042	 0,623	 0,091	
Apoptosis		
Average	 2,01	 1,212	 0,823	 0,878	 1,17	 1,066	 0,933	 1,16	 1,002	 1,083	
Standard	Deviation	 0,643	 0,49	 0,015	 0,027	 0,033	 0,07	 0,026	 0,188	 0,079	 0,139	
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HEK293	wt	 		 		 		 		 		 		 		 		 		 		 		
		 Compound	#9_0	[µM]	 80	 40	 20	 10	 5	 2,50	 1,25	 0,625	 0,313	 0,156	
Viability		
Average	 0,445	 0,569	 0,926	 0,882	 0,775	 1,174	 1,175	 1,109	 1,206	 1,17	
Standard	Deviation	 0,113	 0,112	 0,118	 0,031	 0,237	 0,072	 0,14	 0,16	 0,096	 0,223	
Cytotoxicity		
Average	 0,795	 0,984	 1,069	 1,081	 0,91	 1,183	 1,735	 1,102	 1,251	 1,223	
Standard	Deviation	 0,055	 0,177	 0,148	 0,044	 0,203	 0,174	 0,216	 0,095	 0,13	 0,239	
Apoptosis		
Average	 1,177	 0,936	 0,884	 0,98	 1,013	 0,945	 0,929	 0,995	 1,063	 1,005	
Standard	Deviation	 0,411	 0,099	 0,091	 0,001	 0,052	 0,06	 0,038	 0,055	 0,078	 0,015	
 
Table A-6 Raw data for compound #10_0. 
FaDu	 		 		 		 		 		 		 		 		 		 		 		
		
Compound	#10_0	
[µM]	 80	 40	 20	 10	 5	 2,50	 1,25	 0,625	 0,313	 0,156	
Viability		 Average	 0,717	 0,804	 0,838	 0,861	 0,919	 0,924	 0,929	 0,94	 0,966	 0,917	
Standard	Deviation	 0,099	 0,055	 0,051	 0,053	 0,028	 0,018	 0,155	 0,087	 0,058	 0,032	
Cytotoxicity		 Average	 0,753	 0,868	 0,929	 1,011	 0,998	 1,032	 0,97	 0,959	 1,018	 0,937	
Standard	Deviation	 0	 0,053	 0,206	 0,095	 0,138	 0,173	 0,181	 0,167	 0,11	 0,164	
Apoptosis		
Average	 0,893	 0,951	 0,946	 1,17	 1,143	 1,317	 1,131	 1,048	 1,081	 1,105	
Standard	Deviation	 0,253	 0,1	 0,02	 0,073	 0,035	 0,026	 0,035	 0,14	 0,077	 0,024	
	 	 	 	 	 	 	 	 	 	 	 	HCT-8	 		 		 		 		 		 		 		 		 		 		 		
		
Compound	#10_0	
[µM]	 80	 40	 20	 10	 5	 2,50	 1,25	 0,625	 0,313	 0,156	
Viability		
Average	 0,812	 0,923	 1,037	 1,055	 1,065	 1,138	 1,18	 1,133	 1,118	 1,146	
Standard	Deviation	 0,187	 0,142	 0,139	 0,221	 0,25	 0,247	 0,199	 0,258	 0,179	 0,316	
Cytotoxicity		
Average	 0,814	 0,801	 0,953	 1,022	 0,932	 1,079	 0,99	 1,04	 0,951	 0,93	
Standard	Deviation	 0,016	 0,038	 0,056	 0,062	 0,045	 0,031	 0,079	 0,098	 0,078	 0,043	
Apoptosis		
Average	 0,898	 0,98	 0,948	 1,056	 1,028	 1,066	 1,114	 1,047	 1,106	 1,052	
Standard	Deviation	 0,078	 0,039	 0,022	 0,054	 0,013	 0,012	 0,136	 0,1	 0,04	 0,063	
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	 	 	 	 	 	 	 	 	 	 	 	HEK293	EpCAM	FL	 		 		 		 		 		 		 		 		 		 		 		
		
Compound	#10_0	
[µM]	 80	 40	 20	 10	 5	 2,50	 1,25	 0,625	 0,313	 0,156	
Viability		 Average	 0,593	 0,79	 0,851	 0,909	 1,034	 1,026	 1,012	 0,984	 1,081	 1,048	
Standard	Deviation	 0,023	 0,158	 0,098	 0,097	 0,13	 0,121	 0,123	 0,039	 0,116	 0,061	
Cytotoxicity		 Average	 0,664	 0,846	 1,17	 1,786	 1,438	 1,118	 1,224	 1,01	 1,079	 1,067	
Standard	Deviation	 0,092	 0,028	 0,296	 1,053	 0,544	 0,099	 0,399	 0,157	 0,096	 0,137	
Apoptosis		
Average	 0,907	 0,962	 1,085	 1,051	 1,084	 1,064	 0,987	 1,065	 1,153	 0,996	
Standard	Deviation	 0,258	 0,181	 0,394	 0,191	 0,242	 0,218	 0,314	 0,158	 0,247	 0,127	
	 	
	 	 	 	 	 	 	 	 	 	
HEK293	wt	 	 		 		 		 		 		 		 		 		 		 		
		
Compound	#10_0	
[µM]	 80	 40	 20	 10	 5	 2,50	 1,25	 0,625	 0,313	 0,156	
Viability		 Average	 0,666	 0,743	 0,844	 0,86	 0,921	 0,806	 0,932	 0,938	 0,971	 0,955	
Standard	Deviation	 0,005	 0,019	 0,024	 0,035	 0,133	 0,324	 0,096	 0,038	 0,029	 0,06	
Cytotoxicity		 Average	 0,719	 0,851	 1,037	 1,024	 0,969	 0,851	 0,935	 0,921	 0,962	 0,918	
Standard	Deviation	 0,122	 0,202	 0,206	 0,202	 0,236	 0,36	 0,175	 0,195	 0,127	 0,231	
Apoptosis		
Average	 0,777	 0,858	 0,965	 0,932	 0,973	 1,017	 0,895	 0,94	 0,894	 0,974	
Standard	Deviation	 0,019	 0,078	 0,004	 0,128	 0,031	 0,124	 0,068	 0,023	 0,02	 0	
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Table A-7 Raw data for compound #13_0. 
FaDu	 		 		 		 		 		 		 		 		 		 		 		
		
Compound	#13_0	
[µM]	 80	 40	 20	 10	 5	 2,50	 1,25	 0,625	 0,313	 0,156	
Viability		 Average	 0,534	 0,437	 0,723	 0,938	 1,014	 1,048	 0,987	 0,996	 1,043	 1,019	
Standard	Deviation	 0,016	 0,136	 0,126	 0,18	 0,22	 0,039	 0,09	 0,207	 0,152	 0,13	
Cytotoxicity		 Average	 4,068	 1,989	 1,366	 1,233	 1,187	 1,076	 1,027	 1,013	 0,982	 1,048	
Standard	Deviation	 0,872	 0,494	 0,033	 0,208	 0,283	 0,115	 0,141	 0,228	 0,206	 0,173	
Apoptosis		
Average	 1,572	 2,515	 1,08	 1,031	 0,899	 0,947	 1,074	 0,922	 0,916	 1,049	
Standard	Deviation	 0,822	 0,212	 0,075	 0,013	 0,143	 0,054	 0,058	 0,093	 0,074	 0,096	
	 	 	 	 	 	 	 	 	 	 	 	HCT-8	 		 		 		 		 		 		 		 		 		 		 		
		
Compound	#13_0	
[µM]	 80	 40	 20	 10	 5	 2,50	 1,25	 0,625	 0,313	 0,156	
Viability		 Average	 0,436	 0,498	 0,748	 0,961	 1,043	 1,092	 1,047	 0,97	 0,995	 0,966	
Standard	Deviation	 0,03	 0,001	 0,098	 0,168	 0,189	 0,054	 0,001	 0,059	 0,127	 0,003	
Cytotoxicity		 Average	 4,961	 3,259	 1,788	 1,408	 1,263	 1,278	 1,175	 1,049	 1,108	 1,097	
Standard	Deviation	 1,007	 0,09	 0,121	 0,021	 0,194	 0,187	 0,172	 0,116	 0,058	 0,164	
Apoptosis		
Average	 1,623	 2,798	 1,114	 0,973	 0,858	 0,937	 0,952	 0,982	 0,951	 1,087	
Standard	Deviation	 0,638	 0,034	 0,029	 0,035	 0,111	 0,038	 0,048	 0,032	 0,157	 0,036	
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HEK293	EpCAM	FL	 		 		 		 		 		 		 		 		 		 		 		
		
Compound	#13_0	
[µM]	 80	 40	 20	 10	 5	 2,50	 1,25	 0,625	 0,313	 0,156	
Viability		 Average	 0,351	 0,31	 0,66	 0,964	 1,068	 1,032	 1,046	 1,069	 1,213	 1,128	
Standard	Deviation	 0,087	 0,093	 0,155	 0,28	 0,288	 0,138	 0,19	 0,239	 0,349	 0,268	
Cytotoxicity		 Average	 4,982	 3,365	 1,96	 1,332	 1,241	 1,178	 1,095	 1,061	 1,791	 1,091	
Standard	Deviation	 0,887	 1,126	 0,462	 0,006	 0,017	 0,108	 0,013	 0,043	 0,793	 0,116	
Apoptosis		
Average	 2,344	 3,013	 1,526	 1,217	 1,03	 1,281	 1,016	 1,145	 0,874	 1,112	
Standard	Deviation	 0,166	 0,431	 0,205	 0,284	 0,046	 0,066	 0,054	 0,068	 0,038	 0,103	
	 	 	 	 	 	 	 	 	 	 	 	HEK293	wt	 		 		 		 		 		 		 		 		 		 		 		
		
Compound	#13_0	
[µM]	 80	 40	 20	 10	 5	 2,50	 1,25	 0,625	 0,313	 0,156	
Viability		 Average	 0,331	 0,369	 0,609	 0,972	 1,069	 1,121	 1,135	 1,126	 1,183	 1,185	
Standard	Deviation	 0,128	 0,005	 0,004	 0,115	 0,093	 0,171	 0,152	 0,129	 0,082	 0,188	
Cytotoxicity		 Average	 4,184	 4,201	 2,486	 1,662	 1,333	 1,282	 1,263	 1,143	 1,27	 1,223	
Standard	Deviation	 0,684	 0,661	 0,767	 0,139	 0,014	 0,078	 0,029	 0,006	 0,157	 0,124	
Apoptosis		
Average	 2,955	 2,787	 2,169	 1,141	 1,046	 0,972	 0,977	 1,025	 0,903	 0,979	
Standard	Deviation	 2,368	 1,805	 1,794	 0,278	 0,102	 0,004	 0,146	 0,079	 0,252	 0,083	
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Table A-8 Raw data for compound #51_0. 
FaDu	 		 		 		 		 		 		 		 		 		 		 		
		
Compound	#51_0	
[µM]	 80	 40	 20	 10	 5	 2,50	 1,25	 0,625	 0,313	 0,156	
Viability		 Average	 1,084	 1,093	 1,035	 0,891	 0,851	 1,001	 0,987	 0,994	 1,031	 1,013	
Standard	Deviation	 0,152	 0,075	 0,018	 0,128	 0,238	 0,057	 0,015	 0,142	 0,124	 0,098	
Cytotoxicity		 Average	 0,884	 1,094	 1,051	 0,863	 0,884	 0,982	 0,956	 0,978	 1,006	 0,957	
Standard	Deviation	 0,286	 0,041	 0,107	 0,334	 0,445	 0,141	 0,151	 0,109	 0,059	 0,122	
Apoptosis		
Average	 5,746	 1,693	 1,301	 1,205	 1,21	 1,227	 1,152	 1,332	 1,272	 1,29	
Standard	Deviation	 0,619	 0,599	 0,447	 0,345	 0,369	 0,438	 0,301	 0,3	 0,453	 0,239	
	 	 	 	 	 	 	 	 	 	 	 	HCT-8	 		 		 		 		 		 		 		 		 		 		 		
		
Compound	#51_0	
[µM]	 80	 40	 20	 10	 5	 2,50	 1,25	 0,625	 0,313	 0,156	
Viability		 Average	 1,207	 1,184	 1,182	 1,168	 0,947	 1,171	 1,137	 1,146	 1,16	 1,183	
Standard	Deviation	 0,542	 0,38	 0,29	 0,313	 0,028	 0,258	 0,255	 0,326	 0,191	 0,228	
Cytotoxicity		 Average	 1,054	 1,046	 1,159	 1,007	 0,82	 1,007	 0,932	 0,95	 0,901	 0,92	
Standard	Deviation	 0,059	 0,023	 0,087	 0,087	 0,155	 0,036	 0,007	 0,086	 0,041	 0,048	
Apoptosis		
Average	 6,32	 1,939	 1,478	 1,226	 1,143	 1,24	 1,256	 1,244	 1,341	 1,256	
Standard	Deviation	 0,586	 0,169	 0,122	 0,078	 0,007	 0,067	 0,181	 0,03	 0,238	 0,216	
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HEK293	EpCAM	FL	 		 		 		 		 		 		 		 		 		 		 		
		
Compound	#51_0	
[µM]	 80	 40	 20	 10	 5	 2,50	 1,25	 0,625	 0,313	 0,156	
Viability		 Average	 1,012	 1,019	 1,045	 1,112	 0,921	 1,106	 1,03	 0,805	 1,079	 0,873	
Standard	Deviation	 0,052	 0,139	 0,065	 0,062	 0,21	 0,083	 0,017	 0,276	 0,1	 0,317	
Cytotoxicity		 Average	 1,311	 1,09	 1,344	 2,021	 1,134	 1,099	 1,223	 0,787	 1,07	 0,834	
Standard	Deviation	 0,255	 0,063	 0,535	 1,381	 0,674	 0,111	 0,517	 0,407	 0,119	 0,348	
Apoptosis		
Average	 1,924	 1,335	 1,521	 1,293	 1,356	 1,204	 1,161	 1,171	 1,25	 1,254	
Standard	Deviation	 0,099	 0,473	 0,598	 0,507	 0,489	 0,433	 0,275	 0,441	 0,375	 0,505	
	 	 	 	 	 	 	 	 	 	 	 	HEK293	wt	 		 		 		 		 		 		 		 		 		 		 		
		
Compound	#51_0	
[µM]	 80	 40	 20	 10	 5	 2,50	 1,25	 0,625	 0,313	 0,156	
Viability		 Average	 1,097	 0,994	 1,015	 1,076	 1,017	 0,969	 0,865	 1,029	 1,064	 1,013	
Standard	Deviation	 0,191	 0,113	 0,061	 0,001	 0,034	 0,031	 0,268	 0,065	 0,025	 0,023	
Cytotoxicity		 Average	 1,135	 1,007	 1,117	 1,115	 0,908	 0,891	 0,809	 0,926	 0,997	 0,916	
Standard	Deviation	 0,155	 0,153	 0,192	 0,191	 0,145	 0,218	 0,422	 0,208	 0,114	 0,232	
Apoptosis		
Average	 2,369	 0,901	 1,108	 1,067	 1,083	 0,97	 1,037	 1,101	 1,044	 1,036	
Standard	Deviation	 1,793	 0,218	 0,003	 0,001	 0,128	 0,123	 0,121	 0,172	 0,221	 0,162	
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Table A-9 Raw data for compound #66_0. 
FaDu	 		 		 		 		 		 		 		 		 		 		 		
		
Compound	#66_0	
[µM]	 80	 40	 20	 10	 5	 2,50	 1,25	 0,625	 0,313	 0,156	
Viability		 Average	 0,354	 0,531	 0,742	 1,076	 1,015	 1,02	 1,05	 1,028	 1,1	 1,007	
Standard	Deviation	 0,017	 0,139	 0,014	 0,09	 0,089	 0,007	 0,038	 0,046	 0,019	 0,109	
Cytotoxicity		 Average	 1,875	 0,975	 1,072	 0,992	 0,916	 0,952	 0,988	 0,998	 1,007	 0,987	
Standard	Deviation	 0,188	 0,475	 0,086	 0,062	 0,204	 0,151	 0,013	 0,098	 0,145	 0,123	
Apoptosis		
Average	 0,334	 0,371	 0,256	 0,495	 0,614	 0,845	 0,978	 1,024	 1,077	 1,062	
Standard	Deviation	 0,14	 0,208	 0,031	 0,115	 0,048	 0,188	 0,204	 0,263	 0,359	 0,307	
	 	 	 	 	 	 	 	 	 	 	 	HCT-8	 		 		 		 		 		 		 		 		 		 		 		
		
Compound	#66_0	
[µM]	 80	 40	 20	 10	 5	 2,50	 1,25	 0,625	 0,313	 0,156	
Viability		 Average	 0,32	 0,554	 0,751	 0,876	 0,983	 1,073	 1,02	 0,97	 0,979	 1,019	
Standard	Deviation	 0,012	 0,09	 0,03	 0,33	 0,051	 0,022	 0,033	 0,014	 0,17	 0,025	
Cytotoxicity		 Average	 2,135	 1,458	 1,515	 0,89	 1,051	 1,259	 1,118	 1,089	 1,034	 1,129	
Standard	Deviation	 0,245	 0,324	 0,03	 0,157	 0,232	 0,259	 0,132	 0,11	 0,091	 0,172	
Apoptosis		
Average	 0,356	 0,291	 0,32	 0,494	 0,641	 0,86	 0,952	 1,087	 1,104	 1,186	
Standard	Deviation	 0,054	 0,125	 0,067	 0,071	 0,055	 0,065	 0,191	 0,274	 0,344	 0,278	
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HEK293	EpCAM	FL	 		 		 		 		 		 		 		 		 		 		 		
		
Compound	#66_0	
[µM]	 80	 40	 20	 10	 5	 2,50	 1,25	 0,625	 0,313	 0,156	
Viability		 Average	 0,312	 0,584	 0,874	 1,11	 1,179	 1,125	 1,031	 1,098	 1,055	 1,163	
Standard	Deviation	 0,128	 0,216	 0,289	 0,095	 0,23	 0,164	 0,045	 0,259	 0,114	 0,401	
Cytotoxicity		 Average	 1,274	 1,168	 1,172	 1,021	 1,08	 1,104	 0,967	 1,043	 1,818	 1,049	
Standard	Deviation	 0,096	 0	 0,084	 0,012	 0,067	 0,102	 0,058	 0,034	 1,392	 0,113	
Apoptosis		
Average	 0,471	 0,603	 0,574	 0,539	 0,93	 0,968	 1,116	 1,107	 1,063	 1,055	
Standard	Deviation	 0,136	 0,122	 0,105	 0,045	 0,181	 0,319	 0,115	 0,198	 0,32	 0,298	
	 	 	 	 	 	 	 	 	 	 	 	HEK293	wt	 		 		 		 		 		 		 		 		 		 		 		
		
Compound	#66_0	
[µM]	 80	 40	 20	 10	 5	 2,50	 1,25	 0,625	 0,313	 0,156	
Viability		 Average	 0,365	 0,624	 0,91	 1,223	 1,151	 0,802	 1,195	 1,045	 1,302	 1,211	
Standard	Deviation	 0,091	 0,034	 0,086	 0,04	 0,177	 0,501	 0,132	 0,164	 0,228	 0,13	
Cytotoxicity		 Average	 2,417	 1,714	 1,497	 1,198	 1,09	 0,781	 1,162	 1,002	 1,422	 1,165	
Standard	Deviation	 1,091	 0,603	 0,315	 0,006	 0,06	 0,472	 0,069	 0,077	 0,075	 0,125	
Apoptosis		
Average	 0,386	 0,664	 0,589	 0,683	 0,874	 1,074	 1,171	 1,661	 0,996	 1,702	
Standard	Deviation	 0,049	 0,096	 0,343	 0,378	 0,521	 0,556	 0,525	 1,145	 0,394	 1,245	
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Table A-10 Raw data for compound #4_7. 
FaDu	 		 		 		 		 		 		 		 		 		 		 		
		 Compound	#4_7	[µM]	 80	 40	 20	 10	 5	 2,50	 1,25	 0,625	 0,313	 0,156	
Viability		 Average	 0,562	 0,806	 0,88	 0,726	 0,91	 0,901	 0,874	 0,933	 0,972	 0,952	
Standard	Deviation	 0,055	 0,129	 0,142	 0,14	 0,056	 0,058	 0,053	 0,069	 0,056	 0,154	
Cytotoxicity		 Average	 1,494	 1,391	 1,14	 0,822	 0,968	 0,938	 0,853	 0,902	 0,92	 0,911	
Standard	Deviation	 0,232	 0,235	 0,256	 0,178	 0,081	 0,006	 0,056	 0,018	 0,004	 0,041	
Apoptosis		
Average	 0,849	 1,096	 0,971	 0,874	 0,936	 1,009	 0,929	 1,054	 1,02	 1,071	
Standard	Deviation	 0,089	 0,06	 0,144	 0,07	 0,095	 0,158	 0,013	 0,025	 0,065	 0,183	
	 	 	 	 	 	 	 	 	 	 	 	HCT-8	 		 		 		 		 		 		 		 		 		 		 		
		 Compound	#4_7	[µM]	 80	 40	 20	 10	 5	 2,50	 1,25	 0,625	 0,313	 0,156	
Viability		 Average	 0,662	 0,931	 0,989	 1,107	 1,096	 1,045	 1,047	 1,11	 1,078	 1,078	
Standard	Deviation	 0,03	 0,233	 0,302	 0,212	 0,309	 0,273	 0,239	 0,23	 0,269	 0,295	
Cytotoxicity		 Average	 1,342	 1,392	 1,21	 1,301	 1,258	 1,131	 1,166	 1,22	 1,166	 1,195	
Standard	Deviation	 0,401	 0,634	 0,572	 0,528	 0,448	 0,312	 0,311	 0,42	 0,317	 0,374	
Apoptosis		
Average	 1,03	 1,163	 1,139	 1,205	 1,157	 1,104	 1,096	 1,136	 1,051	 1,072	
Standard	Deviation	 0,282	 0,434	 0,269	 0,386	 0,238	 0,326	 0,207	 0,295	 0,2	 0,242	
	 	 	 	 	 	 	 	 	 	 	 	HEK293	EpCAM	FL	 		 		 		 		 		 		 		 		 		 		 		
		 Compound	#4_7	[µM]	 80	 40	 20	 10	 5	 2,50	 1,25	 0,625	 0,313	 0,156	
Viability		 Average	 1,047	 1,088	 1,001	 1,097	 1,154	 1,117	 1,135	 1,223	 1,18	 1,173	
Standard	Deviation	 0,643	 0,348	 0,286	 0,258	 0,222	 0,221	 0,216	 0,168	 0,165	 0,142	
Cytotoxicity		 Average	 0,999	 1,107	 0,934	 0,891	 0,892	 0,845	 0,891	 1,034	 1,096	 1,091	
Standard	Deviation	 0,365	 0,307	 0,358	 0,338	 0,336	 0,251	 0,231	 0,122	 0,008	 0,026	
Apoptosis		
Average	 1,581	 1,384	 1,428	 1,366	 1,327	 1,37	 1,197	 1,196	 1,189	 1,159	
Standard	Deviation	 1,388	 0,818	 0,743	 0,489	 0,571	 0,422	 0,424	 0,459	 0,384	 0,457	
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HEK293	wt	 		 		 		 		 		 		 		 		 		 		 		
		 Compound	#4_7	[µM]	 80	 40	 20	 10	 5	 2,50	 1,25	 0,625	 0,313	 0,156	
Viability		
Average	 0,532	 0,729	 0,842	 0,785	 0,893	 0,894	 0,946	 0,945	 0,951	 0,939	
Standard	Deviation	 0,038	 0,009	 0,031	 0,048	 0,102	 0,127	 0,109	 0,109	 0,093	 0,073	
Cytotoxicity		
Average	 1,536	 1,383	 1,181	 1,008	 0,991	 0,983	 1,016	 1,023	 0,965	 0,948	
Standard	Deviation	 0,267	 0,212	 0,125	 0,016	 0,134	 0,095	 0,085	 0,059	 0,087	 0,055	
Apoptosis		
Average	 0,717	 0,97	 1,208	 1,199	 1,088	 1,153	 0,871	 1,112	 1,062	 0,903	
Standard	Deviation	 0,009	 0,091	 0,045	 0,066	 0,194	 0,186	 0,116	 0,195	 0,155	 0,189	
 
 
Table A-11 Raw data for compound #9_0. 
FaDu	 		 		 		 		 		 		 		 		 		 		 		
		 Compound	#9_0	[µM]	 80	 40	 20	 10	 5	 2,50	 1,25	 0,625	 0,313	 0,156	
Viability		 Average	 0,708	 0,845	 0,674	 0,735	 0,772	 0,826	 0,827	 0,856	 0,849	 0,844	
Standard	Deviation	 0,026	 0,074	 0,036	 0,053	 0,069	 0,035	 0,034	 0,084	 0,064	 0,075	
Cytotoxicity		 Average	 0,798	 0,869	 0,867	 0,91	 0,969	 1,002	 1,027	 0,955	 0,98	 0,968	
Standard	Deviation	 0,109	 0,106	 0,076	 0,035	 0,054	 0,03	 0,092	 0,094	 0,037	 0,058	
Apoptosis		
Average	 0,803	 0,793	 0,868	 0,933	 0,931	 0,917	 1,06	 1,01	 1,053	 1,009	
Standard	Deviation	 0,01	 0,053	 0,053	 0,047	 0,054	 0,008	 0,045	 0,096	 0,128	 0,022	
	 	 	 	 	 	 	 	 	 	 	 	HCT-8	 	 	 	 	 	 	 	 	 	 	 	
		 Compound	#9_0	[µM]	 80	 40	 20	 10	 5	 2,50	 1,25	 0,625	 0,313	 0,156	
Viability		 Average	 0,839	 0,853	 0,788	 0,78	 0,781	 0,815	 0,837	 0,85	 0,84	 0,826	
Standard	Deviation	 0,195	 0,402	 0,186	 0,062	 0,095	 0,08	 0,071	 0,08	 0,108	 0,131	
Cytotoxicity		 Average	 0,851	 0,988	 0,936	 1,083	 1,072	 1,098	 1,061	 1,059	 1,068	 1,059	
Standard	Deviation	 0,087	 0,04	 0,071	 0,07	 0,034	 0,033	 0,044	 0,067	 0,052	 0,009	
Apoptosis		
Average	 0,819	 0,97	 0,98	 1,115	 0,993	 1,076	 1,014	 1,022	 0,972	 1,028	
Standard	Deviation	 0,255	 0,348	 0,249	 0,157	 0,249	 0,026	 0,127	 0,044	 0,131	 0,096	
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	 	 	 	 	 	 	 	 	 	 	 	HEK293	EpCAM	FL	 		 		 		 		 		 		 		 		 		 		 		
		 Compound	#9_0	[µM]	 80	 40	 20	 10	 5	 2,50	 1,25	 0,625	 0,313	 0,156	
Viability		 Average	 1,169	 0,984	 1,078	 0,932	 0,993	 1,015	 0,941	 0,995	 0,992	 0,852	
Standard	Deviation	 0,429	 0,527	 0,552	 0,182	 0,197	 0,329	 0,12	 0,012	 0,028	 0,229	
Cytotoxicity		 Average	 1,583	 0,884	 1,104	 0,794	 0,891	 0,761	 0,809	 0,838	 0,799	 0,719	
Standard	Deviation	 0,972	 0,708	 0,905	 0,406	 0,558	 0,446	 0,408	 0,395	 0,385	 0,464	
Apoptosis		
Average	 0,716	 0,888	 0,912	 1,07	 1,053	 0,969	 0,918	 0,978	 0,916	 0,909	
Standard	Deviation	 0,071	 0,035	 0,127	 0,105	 0,156	 0,08	 0,107	 0,042	 0,129	 0,162	
	 	 	 	 	 	 	 	 	 	 	 	HEK293	wt	 		 		 		 		 		 		 		 		 		 		 		
		 Compound	#9_0	[µM]	 80	 40	 20	 10	 5	 2,50	 1,25	 0,625	 0,313	 0,156	
Viability		 Average	 0,862	 0,863	 0,867	 0,833	 0,864	 0,926	 0,895	 0,949	 0,969	 0,95	
Standard	Deviation	 0,175	 0,398	 0,265	 0,043	 0,056	 0,028	 0,039	 0,047	 0,08	 0,063	
Cytotoxicity		 Average	 1,125	 1,073	 0,962	 0,929	 0,991	 1,025	 1,011	 1,005	 1,046	 1,033	
Standard	Deviation	 0,144	 0,512	 0,205	 0,044	 0,016	 0,056	 0,088	 0,047	 0,086	 0,006	
Apoptosis		
Average	 0,777	 0,798	 0,949	 0,981	 0,968	 0,989	 1,114	 1,018	 1,169	 1,026	
Standard	Deviation	 0,002	 0,084	 0,033	 0,033	 0,096	 0,111	 0,288	 0,04	 0,075	 0,016	
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Table A-12 Raw data for compound #10_4. 
FaDu	 		 		 		 		 		 		 		 		 		 		 		
		
Compound	#10_4	
[µM]	 80	 40	 20	 10	 5	 2,50	 1,25	 0,625	 0,313	 0,156	
Viability		 Average	 0,499	 0,608	 0,684	 0,74	 0,754	 0,751	 0,815	 0,847	 0,936	 0,863	
Standard	Deviation	 0,038	 0,052	 0,005	 0,013	 0,005	 0,045	 0,005	 0,025	 0,064	 0,083	
Cytotoxicity		 Average	 0,641	 0,793	 0,966	 0,995	 0,976	 0,973	 0,984	 1,001	 1,034	 0,957	
Standard	Deviation	 0,099	 0,113	 0,206	 0,123	 0,087	 0,058	 0,051	 0,068	 0,029	 0,043	
Apoptosis		
Average	 0,791	 0,924	 1,003	 0,974	 0,976	 0,995	 1,047	 1,011	 1,013	 0,928	
Standard	Deviation	 0,156	 0,123	 0,078	 0,149	 0,138	 0,075	 0,067	 0,159	 0,105	 0,003	
	 	 	 	 	 	 	 	 	 	 	 	HCT-8	 		 		 		 		 		 		 		 		 		 		 		
		
Compound	#10_4	
[µM]	 80	 40	 20	 10	 5	 2,50	 1,25	 0,625	 0,313	 0,156	
Viability		 Average	 0,672	 0,788	 0,835	 0,963	 0,99	 1,012	 1,039	 1,079	 1,057	 1,073	
Standard	Deviation	 0,032	 0,073	 0,175	 0,2	 0,227	 0,146	 0,196	 0,175	 0,158	 0,17	
Cytotoxicity		 Average	 0,911	 1,06	 1,159	 1,229	 1,296	 1,303	 1,319	 1,324	 1,259	 1,345	
Standard	Deviation	 0,271	 0,3	 0,392	 0,407	 0,351	 0,331	 0,358	 0,322	 0,415	 0,369	
Apoptosis		
Average	 1,073	 1,164	 1,187	 1,104	 1,197	 1,16	 1,171	 1,156	 1,118	 1,166	
Standard	Deviation	 0,274	 0,147	 0,261	 0,294	 0,156	 0,098	 0,145	 0,13	 0,157	 0,257	
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HEK293	EpCAM	FL	 		 		 		 		 		 		 		 		 		 		 		
		
Compound	#10_4	
[µM]	 80	 40	 20	 10	 5	 2,50	 1,25	 0,625	 0,313	 0,156	
Viability		 Average	 0,799	 0,831	 0,867	 0,954	 0,904	 0,982	 0,95	 1,038	 1,082	 1,001	
Standard	Deviation	 0,142	 0,081	 0,111	 0,042	 0,101	 0,041	 0,037	 0,117	 0,03	 0,032	
Cytotoxicity		 Average	 0,594	 0,712	 0,762	 0,824	 0,841	 0,844	 0,801	 0,823	 0,825	 0,84	
Standard	Deviation	 0,302	 0,368	 0,426	 0,398	 0,344	 0,397	 0,334	 0,327	 0,333	 0,349	
Apoptosis		
Average	 0,986	 1,074	 1,16	 1,158	 1,044	 1,103	 1,147	 1,083	 1,063	 1,027	
Standard	Deviation	 0,429	 0,489	 0,43	 0,499	 0,114	 0,436	 0,216	 0,306	 0,387	 0,408	
	 	 	 	 	 	 	 	 	 	 	 	HEK293	wt	 		 		 		 		 		 		 		 		 		 		 		
		
Compound	#10_4	
[µM]	 80	 40	 20	 10	 5	 2,50	 1,25	 0,625	 0,313	 0,156	
Viability		 Average	 0,633	 0,718	 0,8	 0,875	 0,927	 0,937	 0,969	 0,984	 1,009	 0,985	
Standard	Deviation	 0,009	 0,044	 0,024	 0,006	 0,032	 0,048	 0,024	 0,055	 0,006	 0,005	
Cytotoxicity		 Average	 0,649	 0,797	 0,889	 0,942	 1,022	 1,042	 1,024	 1,045	 1,101	 1,009	
Standard	Deviation	 0,087	 0,025	 0,031	 0,013	 0,05	 0,046	 0,043	 0,028	 0,027	 0,001	
Apoptosis		
Average	 0,767	 0,835	 0,873	 0,908	 0,941	 0,808	 0,89	 1,083	 1,049	 0,925	
Standard	Deviation	 0,079	 0,189	 0,076	 0,085	 0,201	 0,027	 0,038	 0,147	 0,187	 0,025	
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Table A-13 Raw data for compound #10_6. 
FaDu	 		 		 		 		 		 		 		 		 		 		 		
		
Compound	#10_6	
[µM]	 80	 40	 20	 10	 5	 2,50	 1,25	 0,625	 0,313	 0,156	
Viability		 Average	 0,558	 0,662	 0,739	 0,79	 0,855	 0,869	 0,904	 0,935	 0,996	 1,039	
Standard	Deviation	 0,055	 0,002	 0,004	 0,033	 0,039	 0,067	 0,025	 0,053	 0,028	 0	
Cytotoxicity		 Average	 0,655	 0,823	 0,92	 1,022	 1,045	 1,036	 1,041	 1,066	 1,072	 1,112	
Standard	Deviation	 0,114	 0,147	 0,129	 0,113	 0,026	 0,034	 0,089	 0,017	 0,051	 0,065	
Apoptosis		
Average	 0,709	 0,86	 0,901	 0,951	 0,969	 0,971	 0,954	 1,014	 0,932	 1,086	
Standard	Deviation	 0,065	 0	 0,034	 0,036	 0,134	 0,099	 0,016	 0,164	 0,034	 0,022	
	 	 	 	 	 	 	 	 	 	 	 	HCT-8	 		 		 		 		 		 		 		 		 		 		 		
		
Compound	#10_6	
[µM]	 80	 40	 20	 10	 5	 2,50	 1,25	 0,625	 0,313	 0,156	
Viability		 Average	 0,539	 0,643	 0,71	 0,765	 0,785	 0,867	 0,908	 0,93	 0,903	 0,91	
Standard	Deviation	 0,173	 0,15	 0,142	 0,163	 0,139	 0,117	 0,147	 0,18	 0,149	 0,149	
Cytotoxicity		 Average	 0,763	 0,843	 1,001	 1,002	 1,027	 1,101	 1,161	 1,145	 1,144	 1,162	
Standard	Deviation	 0,019	 0,102	 0,062	 0,019	 0,017	 0,129	 0,073	 0,027	 0,047	 0,065	
Apoptosis		
Average	 0,992	 1,024	 1,093	 1,091	 1,083	 1,086	 1,073	 1,092	 1,117	 1,098	
Standard	Deviation	 0,07	 0,09	 0,043	 0,029	 0,016	 0,084	 0,015	 0,061	 0,027	 0,064	
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HEK293	EpCAM	FL	 		 		 		 		 		 		 		 		 		 		 		
		
Compound	#10_6	
[µM]	 80	 40	 20	 10	 5	 2,50	 1,25	 0,625	 0,313	 0,156	
Viability		 Average	 0,721	 0,746	 0,887	 0,873	 0,903	 0,902	 0,989	 0,988	 1,001	 1,033	
Standard	Deviation	 0,15	 0,302	 0,167	 0,168	 0,111	 0,065	 0,19	 0,083	 0,046	 0,032	
Cytotoxicity		 Average	 0,555	 0,666	 0,763	 0,791	 0,768	 0,757	 0,787	 0,795	 0,821	 0,824	
Standard	Deviation	 0,241	 0,457	 0,419	 0,399	 0,395	 0,37	 0,412	 0,337	 0,353	 0,345	
Apoptosis		
Average	 0,872	 1,043	 1,022	 1,204	 1,127	 1,053	 1,027	 0,978	 0,977	 0,967	
Standard	Deviation	 0,075	 0,042	 0,046	 0,044	 0,17	 0,031	 0,087	 0,009	 0,191	 0,024	
	 	 	 	 	 	 	 	 	 	 	 	HEK293	wt	 		 		 		 		 		 		 		 		 		 		 		
		
Compound	#10_6	
[µM]	 80	 40	 20	 10	 5	 2,50	 1,25	 0,625	 0,313	 0,156	
Viability		 Average	 0,538	 0,636	 0,724	 0,809	 0,833	 0,875	 0,955	 0,946	 0,951	 0,949	
Standard	Deviation	 0,051	 0,115	 0,076	 0,055	 0,046	 0,056	 0,076	 0,096	 0,147	 0,09	
Cytotoxicity		 Average	 0,647	 0,767	 0,885	 0,957	 1,005	 1,017	 1,067	 1,02	 1,04	 1,051	
Standard	Deviation	 0,012	 0,087	 0,048	 0,075	 0,024	 0,012	 0,047	 0,032	 0,052	 0,081	
Apoptosis		
Average	 0,75	 0,909	 0,981	 0,991	 1,076	 0,978	 0,946	 1,063	 0,976	 1,037	
Standard	Deviation	 0,043	 0,001	 0,087	 0,012	 0,087	 0,014	 0,009	 0,113	 0,108	 0,044	
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Table A-14 Raw data for compound #10_9. 
FaDu	 		 		 		 		 		 		 		 		 		 		 		
		
Compound	#10_9	
[µM]	 80	 40	 20	 10	 5	 2,50	 1,25	 0,625	 0,313	 0,156	
Viability		 Average	 0,743	 0,92	 0,999	 1,058	 1,038	 1,053	 1,075	 1,163	 1,161	 1,123	
Standard	Deviation	 0,154	 0,142	 0,15	 0,117	 0,1	 0,075	 0,094	 0,154	 0,064	 0,049	
Cytotoxicity		 Average	 0,596	 0,782	 0,887	 0,973	 0,924	 0,971	 1,008	 1,073	 1,062	 1,014	
Standard	Deviation	 0,117	 0,133	 0,176	 0,138	 0,055	 0,09	 0,056	 0,081	 0,092	 0,011	
Apoptosis		
Average	 0,79	 0,953	 0,911	 0,964	 0,821	 0,94	 1,003	 1,081	 0,958	 1,127	
Standard	Deviation	 0,019	 0,123	 0,038	 0,18	 0,022	 0,029	 0,004	 0,133	 0,023	 0,222	
	 	 	 	 	 	 	 	 	 	 	 	HCT-8	 		 		 		 		 		 		 		 		 		 		 		
		
Compound	#10_9	
[µM]	 80	 40	 20	 10	 5	 2,50	 1,25	 0,625	 0,313	 0,156	
Viability		 Average	 0,81	 0,821	 1,042	 1,067	 1,101	 1,179	 1,12	 1,171	 1,142	 1,163	
Standard	Deviation	 0,151	 0,079	 0,275	 0,253	 0,254	 0,327	 0,234	 0,213	 0,291	 0,208	
Cytotoxicity		 Average	 0,882	 1,025	 1,266	 1,274	 1,301	 1,373	 1,356	 1,382	 1,411	 1,373	
Standard	Deviation	 0,427	 0,521	 0,635	 0,602	 0,568	 0,619	 0,548	 0,574	 0,663	 0,522	
Apoptosis		
Average	 1,206	 1,243	 1,234	 1,267	 1,233	 1,2	 1,215	 1,155	 1,193	 1,279	
Standard	Deviation	 0,232	 0,347	 0,315	 0,262	 0,289	 0,279	 0,201	 0,191	 0,139	 0,192	
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HEK293	EpCAM	FL	 		 		 		 		 		 		 		 		 		 		 		
		
Compound	#10_9	
[µM]	 80	 40	 20	 10	 5	 2,50	 1,25	 0,625	 0,313	 0,156	
Viability		 Average	 0,934	 1,002	 1,08	 1,13	 1,16	 1,097	 1,11	 1,122	 1,194	 1,095	
Standard	Deviation	 0,225	 0,309	 0,261	 0,217	 0,116	 0,009	 0,11	 0,068	 0,069	 0,054	
Cytotoxicity		 Average	 0,631	 0,737	 0,822	 0,816	 0,821	 0,779	 0,836	 0,91	 1,047	 0,944	
Standard	Deviation	 0,328	 0,377	 0,453	 0,373	 0,271	 0,212	 0,307	 0,222	 0,057	 0,117	
Apoptosis		
Average	 1,005	 1,011	 1,085	 1,121	 1,04	 0,932	 0,902	 0,938	 0,937	 0,844	
Standard	Deviation	 0,26	 0,276	 0,171	 0,07	 0,049	 0,122	 0,109	 0,043	 0,017	 0,041	
	 	 	 	 	 	 	 	 	 	 	 	HEK293	wt	 		 		 		 		 		 		 		 		 		 		 		
		
Compound	#10_9	
[µM]	 80	 40	 20	 10	 5	 2,50	 1,25	 0,625	 0,313	 0,156	
Viability		 Average	 0,633	 0,808	 0,891	 0,963	 1,022	 1,011	 0,987	 1,01	 1,027	 1,026	
Standard	Deviation	 0,046	 0	 0,032	 0,012	 0,049	 0,023	 0,025	 0,026	 0,048	 0,04	
Cytotoxicity		 Average	 0,639	 0,824	 0,89	 0,998	 1,055	 1,047	 1,049	 1,027	 1,068	 1,04	
Standard	Deviation	 0,122	 0,015	 0,011	 0,012	 0,087	 0,078	 0,114	 0,122	 0,11	 0,047	
Apoptosis		
Average	 1,097	 1,205	 1,076	 1,097	 0,931	 0,874	 0,925	 0,891	 0,791	 0,946	
Standard	Deviation	 0,055	 0,131	 0,025	 0,04	 0,068	 0,009	 0,018	 0,006	 0,044	 0,027	
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Table A-15 Raw data for compound #10_10. 
FaDu	 		 		 		 		 		 		 		 		 		 		 		
		
Compound	#10_10	
[µM]	 80	 40	 20	 10	 5	 2,50	 1,25	 0,625	 0,313	 0,156	
Viability		 Average	 0,635	 0,754	 0,929	 0,918	 0,827	 1,015	 1,027	 1,002	 1,09	 1,122	
Standard	Deviation	 0,132	 0,093	 0,16	 0,206	 0,069	 0,19	 0,232	 0,232	 0,107	 0,175	
Cytotoxicity		 Average	 0,521	 0,62	 0,75	 0,786	 0,75	 0,823	 0,836	 0,82	 0,895	 0,924	
Standard	Deviation	 0,064	 0,048	 0,043	 0,057	 0,004	 0,089	 0,16	 0,126	 0,004	 0,023	
Apoptosis		
Average	 0,7	 0,78	 0,832	 0,898	 0,824	 0,909	 0,912	 0,849	 0,879	 0,898	
Standard	Deviation	 0,013	 0,02	 0,016	 0,207	 0,069	 0,009	 0,013	 0,026	 0,013	 0,072	
	 	 	 	 	 	 	 	 	 	 	 	HCT-8	 		 		 		 		 		 		 		 		 		 		 		
		
Compound	#10_10	
[µM]	 80	 40	 20	 10	 5	 2,50	 1,25	 0,625	 0,313	 0,156	
Viability		 Average	 0,508	 0,637	 0,723	 0,721	 0,749	 0,824	 0,811	 0,865	 0,838	 0,849	
Standard	Deviation	 0,019	 0,049	 0,041	 0,015	 0,076	 0,004	 0,094	 0,075	 0,016	 0,029	
Cytotoxicity		 Average	 0,721	 0,835	 0,914	 0,882	 0,893	 0,965	 0,989	 1,006	 0,963	 1,048	
Standard	Deviation	 0,265	 0,223	 0,265	 0,182	 0,058	 0,229	 0,376	 0,223	 0,246	 0,214	
Apoptosis		
Average	 0,984	 0,976	 1,009	 0,986	 0,977	 1	 0,945	 0,961	 0,914	 0,997	
Standard	Deviation	 0,21	 0,048	 0,151	 0,049	 0,005	 0,031	 0,194	 0,21	 0,144	 0,039	
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HEK293	EpCAM	FL	 		 		 		 		 		 		 		 		 		 		 		
		
Compound	#10_10	
[µM]	 80	 40	 20	 10	 5	 2,50	 1,25	 0,625	 0,313	 0,156	
Viability		 Average	 0,631	 0,722	 0,882	 0,904	 0,851	 1,053	 1,088	 1,22	 0,996	 1,169	
Standard	Deviation	 0,06	 0,22	 0,259	 0,177	 0,048	 0,279	 0,362	 0,361	 0,083	 0,29	
Cytotoxicity		 Average	 0,46	 0,488	 0,624	 0,642	 0,56	 0,708	 0,677	 0,708	 0,652	 0,745	
Standard	Deviation	 0,107	 0,198	 0,248	 0,211	 0,073	 0,32	 0,282	 0,26	 0,212	 0,354	
Apoptosis		
Average	 0,873	 0,847	 0,93	 0,951	 1,043	 0,868	 1,014	 0,981	 0,853	 0,907	
Standard	Deviation	 0,069	 0,041	 0,018	 0,012	 0,033	 0,031	 0,083	 0,054	 0,032	 0,041	
	 	 	 	 	 	 	 	 	 	 	 	HEK293	wt	 		 		 		 		 		 		 		 		 		 		 		
		
Compound	#10_10	
[µM]	 80	 40	 20	 10	 5	 2,50	 1,25	 0,625	 0,313	 0,156	
Viability		 Average	 0,521	 0,578	 0,686	 0,761	 0,793	 0,822	 0,835	 0,908	 0,884	 0,91	
Standard	Deviation	 0,011	 0,022	 0,008	 0,04	 0,06	 0,007	 0,036	 0,028	 0,007	 0,021	
Cytotoxicity		 Average	 0,626	 0,675	 0,779	 0,824	 0,872	 0,893	 0,916	 0,927	 0,893	 0,915	
Standard	Deviation	 0,069	 0,06	 0,095	 0,114	 0,146	 0,09	 0,132	 0,122	 0,104	 0,119	
Apoptosis		
Average	 0,912	 0,758	 0,952	 0,872	 0,877	 0,909	 0,925	 0,946	 0,891	 0,896	
Standard	Deviation	 0,04	 0,058	 0,031	 0,121	 0,166	 0,024	 0,114	 0,009	 0,012	 0,003	
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Table A-16 Raw data for compound #10_12. 
FaDu	 		 		 		 		 		 		 		 		 		 		 		
		
Compound	#10_12	
[µM]	 80	 40	 20	 10	 5	 2,50	 1,25	 0,625	 0,313	 0,156	
Viability		 Average	 0,479	 0,593	 0,663	 0,71	 0,73	 0,819	 0,842	 0,837	 0,886	 0,905	
Standard	Deviation	 0,027	 0,024	 0,024	 0,047	 0,033	 0,006	 0,069	 0,034	 0,089	 0,072	
Cytotoxicity		 Average	 0,555	 0,651	 0,783	 0,843	 0,898	 0,958	 0,962	 0,912	 1	 1,034	
Standard	Deviation	 0,015	 0,011	 0,066	 0,037	 0,042	 0,037	 0,007	 0,038	 0,044	 0,05	
Apoptosis		
Average	 0,828	 0,846	 0,922	 0,923	 0,92	 1,065	 0,923	 0,926	 1,01	 0,965	
Standard	Deviation	 0,037	 0,009	 0,012	 0,004	 0,057	 0,012	 0,037	 0,027	 0,002	 0,003	
	 	 	 	 	 	 	 	 	 	 	 	HCT-8	 		 		 		 		 		 		 		 		 		 		 		
		
Compound	#10_12	
[µM]	 80	 40	 20	 10	 5	 2,50	 1,25	 0,625	 0,313	 0,156	
Viability		 Average	 0,555	 0,818	 0,92	 1,008	 1,086	 1,104	 0,98	 1,098	 1,241	 1,24	
Standard	Deviation	 0,132	 0,312	 0,345	 0,324	 0,35	 0,401	 0,25	 0,326	 0,506	 0,415	
Cytotoxicity		 Average	 0,757	 1,001	 1,151	 1,296	 1,357	 1,346	 1,138	 1,356	 1,339	 1,386	
Standard	Deviation	 0,248	 0,442	 0,505	 0,536	 0,56	 0,569	 0,411	 0,553	 0,645	 0,666	
Apoptosis		
Average	 1,014	 1,073	 1,04	 1,1	 1,077	 1,057	 1,082	 1,163	 1,099	 1,162	
Standard	Deviation	 0,179	 0,125	 0,204	 0,231	 0,281	 0,209	 0,212	 0,283	 0,199	 0,325	
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HEK293	EpCAM	FL	 		 		 		 		 		 		 		 		 		 		 		
		
Compound	#10_12	
[µM]	 80	 40	 20	 10	 5	 2,50	 1,25	 0,625	 0,313	 0,156	
Viability		 Average	 0,559	 0,759	 0,773	 0,878	 0,914	 0,975	 1,001	 0,935	 0,967	 0,9	
Standard	Deviation	 0,093	 0,162	 0,03	 0,029	 0,011	 0,039	 0,035	 0,131	 0,247	 0,211	
Cytotoxicity		 Average	 0,4	 0,605	 0,636	 0,702	 0,735	 0,787	 0,746	 0,647	 0,857	 0,657	
Standard	Deviation	 0,133	 0,052	 0,229	 0,257	 0,239	 0,313	 0,26	 0,102	 0,055	 0,053	
Apoptosis		
Average	 1,009	 0,974	 1,037	 1,102	 1,046	 1,116	 1,053	 1,166	 1,029	 1,069	
Standard	Deviation	 0,397	 0,42	 0,444	 0,311	 0,282	 0,295	 0,3	 0,278	 0,389	 0,178	
	 	 	 	 	 	 	 	 	 	 	 	HEK293	wt	 		 		 		 		 		 		 		 		 		 		 		
		
Compound	#10_12	
[µM]	 80	 40	 20	 10	 5	 2,50	 1,25	 0,625	 0,313	 0,156	
Viability		 Average	 0,511	 0,732	 0,738	 0,852	 0,885	 0,927	 0,976	 0,952	 0,989	 0,957	
Standard	Deviation	 0,045	 0,188	 0,048	 0,116	 0,097	 0,099	 0,147	 0,094	 0,152	 0,052	
Cytotoxicity		 Average	 0,543	 0,77	 0,803	 0,895	 0,956	 0,993	 1,048	 0,981	 0,985	 0,971	
Standard	Deviation	 0,001	 0,116	 0,045	 0,065	 0,096	 0,075	 0,1	 0,079	 0,073	 0,044	
Apoptosis		
Average	 0,786	 0,846	 0,888	 0,976	 0,913	 0,895	 0,951	 0,912	 0,891	 0,864	
Standard	Deviation	 0,074	 0,032	 0,034	 0,062	 0,033	 0,037	 0,034	 0,125	 0,192	 0,103	
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Table A-17 Raw data for compound #13_1. 
FaDu	 		 		 		 		 		 		 		 		 		 		 		
		
Compound	#13_1	
[µM]	 80	 40	 20	 10	 5	 2,50	 1,25	 0,625	 0,313	 0,156	
Viability		 Average	 0,781	 0,811	 0,828	 0,909	 0,842	 0,909	 0,91	 0,918	 0,891	 0,91	
Standard	Deviation	 0,096	 0,054	 0,028	 0,001	 0,067	 0,004	 0,014	 0,025	 0,029	 0,006	
Cytotoxicity		 Average	 0,98	 0,987	 1,057	 1,039	 0,919	 1,014	 1,017	 0,956	 0,997	 1,009	
Standard	Deviation	 0,149	 0,058	 0,013	 0,02	 0,085	 0,017	 0,058	 0,001	 0,029	 0,007	
Apoptosis		
Average	 0,883	 0,882	 1,014	 1,04	 1,017	 0,945	 1,016	 0,992	 1,004	 0,975	
Standard	Deviation	 0,051	 0,036	 0,125	 0,045	 0,062	 0,024	 0,049	 0,004	 0,011	 0,06	
	 	 	 	 	 	 	 	 	 	 	 	HCT-8	 		 		 		 		 		 		 		 		 		 		 		
		
Compound	#13_1	
[µM]	 80	 40	 20	 10	 5	 2,50	 1,25	 0,625	 0,313	 0,156	
Viability		 Average	 0,802	 0,888	 0,925	 1,022	 0,957	 0,943	 0,934	 0,924	 0,965	 0,926	
Standard	Deviation	 0,183	 0,124	 0,046	 0,111	 0,16	 0,051	 0,073	 0,076	 0,011	 0,057	
Cytotoxicity		 Average	 0,973	 1,028	 1,096	 1,168	 1,088	 1,114	 1,103	 1,099	 0,967	 1,035	
Standard	Deviation	 0,017	 0,021	 0,11	 0,144	 0,002	 0,131	 0,063	 0,079	 0,061	 0,175	
Apoptosis		
Average	 1,25	 1,294	 1,269	 1,164	 1,054	 1,047	 1,084	 1,104	 0,944	 0,999	
Standard	Deviation	 0,265	 0,126	 0,109	 0,144	 0,114	 0,224	 0,019	 0,033	 0,116	 0,137	
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HEK293	EpCAM	FL	 		 		 		 		 		 		 		 		 		 		 		
		
Compound	#13_1	
[µM]	 80	 40	 20	 10	 5	 2,50	 1,25	 0,625	 0,313	 0,156	
Viability		 Average	 0,863	 0,782	 0,791	 0,955	 0,961	 0,957	 0,937	 0,816	 0,718	 0,683	
Standard	Deviation	 0,009	 0,104	 0,081	 0,049	 0,073	 0,047	 0,021	 0,195	 0,371	 0,422	
Cytotoxicity		 Average	 0,808	 0,779	 0,798	 0,841	 0,796	 0,813	 0,846	 0,768	 0,764	 0,768	
Standard	Deviation	 0,348	 0,399	 0,346	 0,362	 0,309	 0,335	 0,269	 0,035	 0,074	 0,244	
Apoptosis		
Average	 1,354	 1,314	 1,316	 1,232	 1,144	 1,053	 1,048	 1,065	 1,067	 0,987	
Standard	Deviation	 0,432	 0,317	 0,006	 0,158	 0,009	 0,039	 0,057	 0,057	 0,142	 0,155	
	
	
	
	 	 	 	 	 	 	 	 	 	
HEK293	wt	 	 		 		 		 		 		 		 		 		 		 		
		
Compound	#13_1	
[µM]	 80	 40	 20	 10	 5	 2,50	 1,25	 0,625	 0,313	 0,156	
Viability		 Average	 0,704	 0,734	 0,775	 0,881	 0,911	 0,916	 0,912	 0,92	 0,93	 0,902	
Standard	Deviation	 0,005	 0,027	 0,068	 0,041	 0,064	 0,041	 0,047	 0,006	 0,02	 0,104	
Cytotoxicity		 Average	 0,916	 0,938	 0,936	 0,957	 0,989	 1,022	 1,013	 1,022	 0,986	 0,998	
Standard	Deviation	 0,066	 0,087	 0,022	 0,059	 0,059	 0,034	 0,001	 0,028	 0,032	 0,009	
Apoptosis		
Average	 1,066	 1,052	 1,023	 1,121	 1,002	 0,978	 1,039	 0,933	 1,073	 0,899	
Standard	Deviation	 0,033	 0,007	 0,033	 0,097	 0,042	 0,014	 0,048	 0,018	 0,158	 0,216	
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Table A-18 Raw data for compound #13-7. 
FaDu	 		 		 		 		 		 		 		 		 		 		 		
		
Compound	#13_7	
[µM]	 80	 40	 20	 10	 5	 2,50	 1,25	 0,625	 0,313	 0,156	
Viability		 Average	 0,881	 1,005	 0,977	 0,986	 0,917	 0,969	 0,969	 0,974	 0,968	 0,986	
Standard	Deviation	 0,077	 0,051	 0,073	 0,02	 0,098	 0,067	 0,017	 0	 0,036	 0,057	
Cytotoxicity		 Average	 0,987	 1,042	 1,054	 1,031	 0,991	 1,026	 1,042	 1,002	 1,008	 1,015	
Standard	Deviation	 0,101	 0,003	 0,013	 0,041	 0,12	 0,04	 0,013	 0,008	 0,045	 0,044	
Apoptosis		
Average	 1,045	 1,092	 1,058	 1,101	 1,015	 1,061	 0,981	 1,086	 1,051	 0,989	
Standard	Deviation	 0,034	 0,048	 0,258	 0,14	 0,139	 0,069	 0,109	 0,172	 0,02	 0,108	
	
	
	 	 	 	 	 	 	 	 	 	 	HCT-8	 	 	 	 	 	 	 	 	 	 	 	
		
Compound	#13_7	
[µM]	 80	 40	 20	 10	 5	 2,50	 1,25	 0,625	 0,313	 0,156	
Viability		 Average	 1,055	 1,2	 0,96	 1,197	 1,099	 1,13	 1,072	 1,153	 1,111	 1,121	
Standard	Deviation	 0,031	 0,096	 0,096	 0,167	 0,054	 0,165	 0,209	 0,219	 0,209	 0,185	
Cytotoxicity		 Average	 1,238	 1,407	 1,141	 1,431	 1,291	 1,257	 1,243	 1,172	 1,264	 1,224	
Standard	Deviation	 0,342	 0,508	 0,174	 0,485	 0,326	 0,3	 0,392	 0,314	 0,55	 0,438	
Apoptosis		
Average	 1,453	 1,288	 1,381	 1,285	 1,161	 1,049	 1,135	 0,985	 1,166	 1,09	
Standard	Deviation	 0,282	 0,354	 0,361	 0,237	 0,175	 0,06	 0,207	 0,095	 0,262	 0,119	
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HEK293	EpCAM	FL	 		 		 		 		 		 		 		 		 		 		 		
		
Compound	#13_7	
[µM]	 80	 40	 20	 10	 5	 2,50	 1,25	 0,625	 0,313	 0,156	
Viability		 Average	 0,866	 1,014	 0,963	 1,033	 0,953	 0,986	 0,955	 1,029	 0,748	 0,809	
Standard	Deviation	 0,123	 0,156	 0,115	 0,122	 0,005	 0,041	 0,088	 0,2	 0,367	 0,297	
Cytotoxicity		 Average	 0,789	 0,792	 0,835	 0,874	 0,839	 0,892	 0,875	 0,981	 0,719	 0,855	
Standard	Deviation	 0,137	 0,241	 0,24	 0,239	 0,265	 0,192	 0,105	 0,087	 0,163	 0,093	
Apoptosis		
Average	 1,02	 0,997	 0,955	 0,98	 0,922	 0,871	 0,875	 0,828	 0,808	 0,928	
Standard	Deviation	 0,064	 0,003	 0,117	 0,044	 0,035	 0,078	 0,07	 0,091	 0,091	 0,022	
	 	 	 	 	 	 	 	 	 	 	 	HEK293	wt	 		 		 		 		 		 		 		 		 		 		 		
		
Compound	#13_7	
[µM]	 80	 40	 20	 10	 5	 2,50	 1,25	 0,625	 0,313	 0,156	
Viability		 Average	 0,854	 0,977	 0,992	 1,035	 1,01	 1,011	 0,974	 1,023	 1,003	 1,004	
Standard	Deviation	 0,056	 0,057	 0,062	 0,052	 0,06	 0,057	 0,054	 0,149	 0,027	 0,072	
Cytotoxicity		 Average	 0,977	 1,032	 1,047	 1,056	 1,057	 1,07	 1,088	 1,079	 1,072	 1,012	
Standard	Deviation	 0,031	 0,056	 0,066	 0,031	 0,106	 0,096	 0,079	 0,14	 0,081	 0,056	
Apoptosis		
Average	 1,088	 1,061	 1,129	 0,99	 0,932	 1,177	 0,892	 1,011	 0,884	 0,915	
Standard	Deviation	 0,068	 0,017	 0,128	 0,008	 0,007	 0,346	 0,145	 0,075	 0,149	 0,025	
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B. ApoTox	Evaluation	
The graphs show the evaluation of ApoTox Assay. Results are depicted for FaDu (black), HCT-8 (dark grey), HEK293 EpCAM-FL (light grey) 
and HEK293 wild-type cells (white) as fold change from DMSO treated control. The drug staurosporine was used as positive control. The first 
graph shows the results for viability, the middle one for cytotoxicity and the last for apoptosis. Depicted are mean values and standard 
deviations from two independent experiments, each consisting of three replicates. 
 
Figure B-1 Results from staurosporine treated cells.	
 34 
 
Figure B-2 Results from compound #4_0 (upper panel) and compound #6_0 (lower panel) treated cells. 
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Figure B-3 Results from compound #7_0 (upper panel) and compound #9_0 (lower panel) treated cells. 
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Figure B-4 Results from compound #10_0 (upper panel) and compound #13_0 (lower panel) treated cells. 
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Figure B-5 Results from compound #51_0 (upper panel) and compound #66_0 (lower panel) treated cells. 
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Figure B-6 Results from compound #4_7 (upper panel) and compound #9_0 (lower panel) treated cells. 
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Figure B-7 Results from compound #10_4 (upper panel) and compound #10_6 (lower panel) treated cells. 
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Figure B-8 Results from compound #10_9 (upper panel) and compound #10_10 (lower panel) treated cells. 
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Figure B-9 Results from compound #10_12 (upper panel) and compound #13_1 (lower panel) treated cells. 
 42 
 
Figure B-10 Results from compound #13_7 treated cells. 
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C. Compound	structures	
 
Table C-1 Structures of high-confidence hits and their analogs. Shown are the compound ID, the 
chemical structure, the molecular formula and the molecular weight 
Compound ID Structure Formula Mol Weight 
[g/mol] 
4_0 
 
C21H19N3O3S 393.46 
4_1 
 
C19H15N3OS 333.41 
4_2 
 
C19H13N3O2S 347.4 
4_3 
 
C20H16FN3OS 365.43 
 44 
4_4 
 
C19H13F2N3OS 369.4 
4_5 
 
C21H19N3O3S 393.47 
4_6 
 
C18H11Cl2N3S 372.28 
4_7 
 
C24H22ClFN4OS 468.98 
4_8 
 
C19H22N4OS 354.48 
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4_9 
 
C24H22FN3S 403.53 
4_10 
 
C22H20FN3O2S 409.49 
4_11 
 
C19H19FN4OS 370.45 
4_12 
 
C17H17N3OS 311.41 
4_13 
 
C21H19N3O2S 377.47 
 46 
6_0 
 
C21H26N4O3 382.46 
7_0 
 
C23H25FN2O3S 428.52 
9_0 
 
C21H23NO4S3 449.61 
9_1 
 
C30H31NO6S3 597.78 
9_2 
 
C21H21NO6S3 479.5 
 47 
9_3 
 
C26H24N2O6S3 556.68 
9_4 
 
C19H19NO5S3 437.56 
10_0 
 
C23H21NO2S3 439.61 
10_1 
 
C25H23NO2S3 465.66 
10_2 
 
C31H27NO2S3 541.76 
 48 
10_3 
 
C29H31NO3S3 537.77 
10_4 
 
C24H23NOS3 437.65 
10_5 
 
C24H23NO2S3 453.65 
10_6 
 
C23H21NOS3 423.62 
10_7 
 
C31H27NO4S3 573.76 
 49 
10_8 
 
C25H25NO3S3 483.67 
10_9 
 
C26H25NO3S3 495.69 
10_10 
 
C25H25NO3S3 483.67 
10_11 
 
C26H25NO4S3 511.69 
10_12 
 
C23H21NO2S3 439.62 
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10_13 
 
C25H25NO2S3 467.68 
13_0 
 
C24H25N3O3 403.47 
13_1 
 
C27H23N3O3 437.5 
13_2 
 
C25H21N3O4 427.46 
13_3 
 
C22H21N3O 343.43 
 51 
13_4 
 
C28H25N3O3 451.53 
13_5 
 
C26H19N3O2 405.46 
13_6 
 
C24H25N3O3 403.49 
13_7 
 
C27H23N3O3 437.5 
13_8 
 
C26H25N5O3 455.52 
 52 
13_9 
 
C28H25N3O3 451.53 
51_0 
 
C25H22N2O3 398.45 
66_0 
 
C15H12N2O 236.27 
 
 
